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O P E N I N G

1
I N T R O D U C T I O N
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L. van Bon, M. Cossu, T.R.D.J. Radstake, An update on an immune system that goes awry in
systemic sclerosis. 2011 Curr Opinion Rheum
T.W. van Hal, L. van Bon, T.R.D.J. Radstake, A system out of breath; how hypoxia possibly
contributes the pathogenesis of Systemic Sclerosis. 2011 Int J Rheum
K.C.M. Santegoets, L. van Bon, W. van den Berg, M. Waenink, T.R.D.J. Radstake, Toll-like recep-
tors in rheumatic diseases: are we paying a high price for our defense against bugs? 2011 FEBBS
lett
3
4 introduction
First, this general introduction will give an insight into the clinical picture
of patients with systemic sclerosis (SSc) and highlight the key challenges in
clinical care. The diagnosis of SSc is still mainly based on clinical symptoms
reflecting the advanced stages of the disease instead of – ideally – early
biomarkers. Very sensitive and specific biomarkers would enable treating
the disease and stopping the process as early as possible. Early treatment
is expected to increase patients’ prognosis regarding survival and quality
of life. Moreover, it could give more insight into the etiology of SSc, which
is still largely unknown. More knowledge on the etiology will eventually
lead to targeted treatments, which will mean a strong improvement in the
care for SSc patients. Next, the general introduction will highlight basic re-
search into the molecular mechanisms involved in SSc, which has provided
a clearer picture of the role played by an aberrant immune system. The
general introduction presents an overview of the knowledge gained in that
area. The last part of the introduction describes how biomarkers support-
ing daily clinical care have evolved from these developments. This thesis
addresses several key questions that emerge from the general introduction.
When answering these questions, we will follow the fruitful path from in-
spiration distilled from the bedside to gathering basic knowledge on the
immune system . . . and go back to the bedside again.
1.1 from the bedside . . .
“It seems as if my skin stiffens and it is so itchy.” “Doctor, since recently
I have had a burning pain underneath my breast and sometimes the food
just comes back into my mouth when lying down.” “I am so tired that I
can hardly get up the stairs or do the groceries.” “What are those strange
red-blue spiderlike marks recently showing on my face?” “Doctor, what’s
wrong with my hands, they turn white, red and blue whenever I go out-
side.“
Systemic sclerosis patients visit medical doctors with complaints so wide-
ranging that they pose a challenge to providing good clinical care. To make
things even more difficult, most symptoms could also be explained by com-
mon and less severe diseases than systemic sclerosis (SSc). For example,
there is a likelihood of patients presenting with triphasic discoloration of
the skin – which often occurs in response to temperature changes, i.e. Ray-
naud’s phenomenon – as about 10% of the population are affected by it. On
the other hand, the chance that a general practitioner will see a patient with
actual SSc varies per region but is about 1:10,000 [1]. As only about 1-2% of
people suffering from Raynaud’s phenomenon develop a connective tissue
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disease such as SSc, it is essential to discriminate between patients at risk
and healthy individuals.
Diagnostic criteria for SSc are still lacking. In clinical practice, sclero-
derma is considered as sclerosis proximal from the digits (major criterion)
or two of the following symptoms: sclerodactyly, digital pitting scars or
bibasilar pulmonary fibrosis [2]. However, for research purposes EULAR
and ACR have developed classification criteria which enable researchers to
include patients with similar characteristics in clinical research [3]. Clini-
cally, SSc is subdivided in two categories based on the extent of skin in-
volvement: limited cutaneous SSc (lcSSc) defined as fibrosis distal to the
elbow and knee joint, including the face, and the diffuse cutaneous form
(dcSSc) with more proximal fibrosis [4].
Over the past years, clinical outcomes have improved, presumably due to
better management of complications, but SSc is still considered incurable.
The prognosis mainly depends on the severity of the visceral fibrosis and
ensuing complications, with pulmonary fibrosis and pulmonary hyperten-
sion being the main causes of death. The ideal patient would first present
Raynaud’s phenomenon, puffy fingers or sclerodactyly, but patients may
also present with already established pulmonary fibrosis or pulmonary hy-
pertension. This circumstance makes it hard to start therapeutic interven-
tions in a timely manner and to prevent organ involvement. As a result, the
diffuse cutaneous form (dcSSc) is the most fatal connective tissue disease
known with only a 55% 10-year survival rate [5].
Multiple affected organs can determine morbidity and mortality follow-
ing initiation of SSc: The most important factor is visceral involvement of
the pulmonary tract. In most patients, the pulmonary tract is affected at a
certain point during the course of the disease. For that reason, the develop-
ment of pulmonary fibrosis is regularly checked by high-resolution CT-scan
and pulmonary function tests. Patients developing interstitial lung disease
(ILD) can be treated with cyclophosphamide, mofetyl mycophenolate or
azathioprine, which stabilizes pulmonary function and improves survival.
About one third show a poor response and pulmonary function continues
to decline [6].
A far less frequent but most fatal phenomenon is pulmonary arterial hy-
pertension (PAH) resulting from the proliferation and contraction of the
vascular smooth muscle cells in the pulmonary artery. About 10% of SSc
patients develop PAH over the course of the years, usually evidenced by
changes in exercise capability. These patients have a 3-year survival of about
50%, which strongly affects their prognosis [7].
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Another factor is cardiac disease, which occurs in about 15-35% of SSc
patients and is responsible for approximately 4.5% of deaths in SSc [8]. An
interesting recent observation showed that about 30% of patients suffering
from PAH also have a left-ventricular perfusion defect, whereas they do
not have any defects of the coronary arteries [9]. This could account for
the increased mortality in SSc-related PAH compared to idiopathic PAH
[10]. Patients are treated with phosphodiesterase inhibitors, endothelial re-
ceptor antagonists and prostanoids. All these treatments are to some extent
successful, albeit only temporarily so. Unfortunately, SSc patients with PAH
and significant ILD are excluded from almost all studies. Choosing the right
therapy in these patients is more of an art than a craft.
Before angiotensine converting enzyme-inhibitors were introduced as
standard therapy, hypertensive renal crisis caused death in about 30% of SSc
patients. With therapy this changed to 3% [11]. In recent decades, this com-
plication has been treated early or even prevented and this achievement is
considered as one of the major improvements in SSc care. The development
of hypertension and a decline in renal function should be monitored inten-
sively using laboratory tests including urine analysis of micro-albuminuria.
If a decline is found, it is thought to not only suggest renal involvement
but also a more systemic progression [12]. Being dcSSc and anti-RNA poly-
merase III positive identifies patients at risk of developing a renal crisis
as up to 33% of anti-RNA polymerase III positive patients develop renal
dysfunction [13].
In addition, the gastro-intestinal tract can be involved in SSc. The gastro-
intestinal tract can become fibrotic and hypomotility can arise following
vasculitis of the vaso nervorum. These processes cause a great deal of mor-
bidity and are accompanied by complaints such as difficulty swallowing,
reflux, faecal incontinence, weight loss due to a decrease in absorption,
and loss of energy. The gastrointestinal tract is involved in about 80-90%
of SSc patients and this involvement has a huge impact on their quality of
life [14]. Therapeutic options are purely symptomatic, prescribing proton-
pump inhibitors and advising a high-calorie diet. Furthermore, motility of
the gastro-intestinal tract can be improved with metoclopramide or dom-
peridon. On balance, up to 11 % of patients need parenteral feeding to
maintain a healthy body mass index [15].
In addition, most patients experience muscular weakness, which in most
cases is a more secondary effect. About 20% of patients develop myositis
and are thereby diagnosed with an overlap syndrome [16].
The fibrotic process in the skin starts in the hands and most often also
in the face. This results in a change in appearance, causing psychological
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distress in most patients. Taking this circumstance and the decline in life
expectancy into account, it can be said that SSc patients are more vulner-
able to developing mild to severe depressive symptoms (in about 50% of
patients) [17].
Finally, patients display several external phenomena besides sclerosis,
such as calcinosis (in about 25% of patients) [18] and telangiectasia. Calci-
noses are typically found around the joints and in tendons, not necessarily
in areas affected by sclerosis. Treatment options are limited, mostly involv-
ing surgical removal in cases where the calcinosis impairs movement. Up
to 40% of the patients with SSc develop digital ulcers due to microcircula-
tion impairment, causing disability, pain and the risk of infection. Patients
most at risk of developing this complication are males with long-standing
Raynaud’s phenomenon [19].
In summary, SSc patients can suffer from a broad range of symptoms
seriously affecting their quality of life. This thesis aims to offer added in-
sight into the disease pathology and etiology but also to provide physicians
identifying patients at risk with effective tools.
1.2 to the bench . . .
Three processes mark SSc: immune disturbances, vasculopathy and fibrosis,
characterized by autoantibodies, Raynaud’s phenomenon and sclerotic skin,
respectively. In recent decades, intensive research has failed to show an in-
trinsic defect in fibroblasts, although their activation and increased produc-
tion of extracellular matrix has been shown [20]. Intriguingly, even before
fibrosis is present monocytes/macrophages and T-cells are found in perivas-
cular infiltrates in SSc skin [21]. Furthermore, in situ hybridization studies
show that fibroblasts near these T-cell infiltrates in particular actively pro-
duce collagen [22]. The role of the immune system is also illustrated by
the production of antinuclear antibodies, mainly anti-topoisomerase I and
anti-centromere antibodies, in 90% of SSc patiënts [23]. In addition, evi-
dence from genetic studies shows that gene polymorphisms in genes such
as STAT4 [24 25], IRF5 [26 27] and CD247 [28] are correlated with disease
susceptibility. For that reason, this general introduction is mainly devoted
to developments in the field of immunity and will only briefly consider
fibrosis and vasculopathy.
Before focusing on several immune cells and elucidating their putative
contribution to SSc pathology, one cytokine needs to be addressed in more
detail: transforming growth factor-β1 (TGF-β). TGF-β is the master regulator
of wound healing and fibrosis. It is secreted in high levels by macrophages
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but virtually any cell can produce it to some extent. TGF-β is mainly avail-
able in its inactive form and can be activated by cell-surface integrins, pro-
teases, or reactive oxygen species. An increase in TGF-β receptors and cell-
surface integrins is found on SSc fibroblasts rendering the fibroblasts very
susceptible to TGF-β mediated fibrosis (reviewed in [29]). The clear TGF-β
signature in skin and cells from SSc patients is strong evidence that TGF-β
plays an important role [30 31].
Immune Cells
The importance of the innate immune system as the first line of defense
against pathogens is well established but the downside of a well-equipped
innate immune system in steering towards auto-inflammation or even au-
toimmunity has also been recognized in recent decades. Pathogens of all
kinds are recognized by antigen-presenting cells through pattern recogni-
tion receptors (PRPs). Of these, toll-like receptors (TLRs) are the most im-
portant. The group of antigen-presenting cells (APCs) consists of several
cell types, such as macrophages, monocytes, Langerhans cells, B-cells, plas-
macytoid dendritic cells (pDC), and dendritic cells (DC).
Monocytes/macrophages
The very intriguing finding that the perivascular infiltrates found in non-
lesional skin in SSc patients contain mainly macrophages/monocytes and
CD4+T-cells suggests that an aberrant immune system precedes fibrosis [32
33]. In at least part of SSc patients, monocytes are affected by type I inter-
ferons in the circulation ([34] and chapter 4). In line with findings in sys-
temic lupus erythematosus, monocytes instructed by type I IFN may play
an important role in breaking tolerance [35]. The division of macrophages
into classically activated M1 macrophages and alternatively activated M2
macrophages is potentially interesting in SSc as the M1 type is clearly more
inflammatory and the M2 type is thought to be more tissue-remodeling
and pro-fibrotic. In SSc, there is evidence of a dominant presence of both
M1 and M2, which might reflect the heterogeneity of the disease but also
the change over time (see Table1.1).
The heterogeneity of SSc and the difficulty it imposes on researchers are
illustrated by the finding that MRC1 is exclusively upregulated in CD14+
cells from lcSSc patients with PAH. So there is evidence only in this sub-
set that APCs are alternatively activated [38]. In line with the latter, in-
creased levels of circulating IL 13 found in this subset only. Moreover, there
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M1 M2
High circulating IL-6 [36 37] High circulating IL-13 [38 39]
High circulating TNFα [36] High circulating IL-10 [37 39 40]
High circulating CXCL10 [41] High circulating CCL18 [42]
Type I interferon signature [34 43
44]
Increased expression of CD163
[45 46]
Upregulated MRC1 in lcSSc with
PAH [38]
Table 1.1 – Summary for a predominance of M1 or M2 macrophages in SSc
was found to be increased expression of CD163, another marker for M2
macrophages, on TLR4-activated monocytes from SSc patients with intersti-
tial lung disease, accompanied by an increased production of CCL18 and
IL-10 [45]. Additionally, the expression of CD163 was increased in SSc skin
[46]. In contrast with the findings mentioned previously, Andrews et al.
found CD163 expression to be increased in lcSSc and dcSSc without PAH
or interstitial lung disease. Classifying which markers and cytokines are up-
or down-regulated in several phases of the disease will therefore almost cer-
tainly provide useful information about disease activity and the prognosis
of the SSc patient.
Dendritic cells
Dendritic cells (DC) play a crucial role in linking innate and adaptive im-
munity. They can contribute directly to fibrosis in SSc through production
of TGF-β1. DC seem to co-localize with fibroblasts, suggesting an influence.
The other – probably more important – route through which DC can con-
tribute to fibrosis is by polarizing T-cells. After engaging with an antigen,
TLR activation results in downstream intracellular signaling and produc-
tion of cytokines such as TNFα, IL-6, IL-10, IL-23 and IFNγ. In a recent
report, our group showed an increase of IL-10 production after stimulation
of TLR4 with lipopolysaccharide (LPS) [42]. In chapter 5 of this thesis, we
analyze this response by looking at different clinical phenotypes and vari-
ous different TLR stimulations.
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Langerhans cells
Langerhans cells are important antigen-presenting cells in the human skin.
Studies have shown a significant decrease in Langerhans cells in the SSc der-
mis [47]. When activated, these cells travel to the lymph nodes to instruct
T-lymphocytes. The decreased number of Langerhans cells could suggest
activation of the SSc skin. In the case of inflammation, DC-sign+ dermal
DCs and plasmacytoid DCs [48] assist Langerhans cells in presenting anti-
gen. Our recent data show an increase in DC-sign+ cells and plasmacytoid
DCs in lesional skin of SSc patients (chapter 2 and unpublished data). Fur-
thermore, we have observed a great diversity in the presence of Langerin
positive cells, Langerhans cells (data unpublished). These data suggest an
increase in antigen-presenting activity in SSc skin, warranting further re-
search into this matter.
Plasmacytoid dendritic cells
Plasmacytoid dendritic cells (pDC) are antigen-presenting cells that are
well-known for their type I interferon production, although they are also
capable of instructing T-cells to some extent. Over the past few years, it has
been increasingly appreciated that a substantial number of SSc patients dis-
play a type I IFN signature either in the affected skin or in immune cells
isolated from the circulation. Hence, SSc mimics some of the hallmarks of
SLE [34 43 44]. And although there is evidence for an antifibrotic role of
type I interferons [49], a recent case involved the development of SSc symp-
toms shortly after starting IFNa therapy, suggesting a possible pathogenic
role for these mediators [50]. In this light, it is important to note that IFNα2
can induce the expression of TLR3 in dermal fibroblasts, and that it can do
this more potently in SSc dermal fibroblasts compared to healthy controls.
Interestingly, the induction of TLR3 caused increased IL-6 production after
TLR3 stimulation with polyI:C [51]. IL-6 possesses pro-fibrotic properties
and is increased in SSc [36]. Interestingly, Kim et al. demonstrated an inter-
ferogenic effect of anti-topoisomerase I containing SSc sera [52], after which
Eloranta et al. studied the effector cells and the related mechanism [53]. As
is the case with with SLE, the plasmacytoid DC (pDC) turns out to be the
main IFNα producing cell triggered by RNA containing immune complexes
via an FcγRII and endosome-dependent pathway. The inhibiting effect of
RNase treatment and chloroquine suggests signaling through the TLR3, 7,
or 8 receptor. In contrast to Kim et al., this study did not find a correlation
between anti-topoisomerase I positivity and IFNα production. Moreover,
the IFNα inducing effect was solely found when SSc serum was combined
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with necrotic/apoptotic cells, emphasising the importance of self-RNA to
activate pDCs. Intriguingly, IFNα levels in serum were only increased in
28% of patients but they clearly correlated with digital ulcera and an in-
creased erythrocyte sedimentation rate [54]. It would be fascinating if the
increase in IFNα were to correlate with a progression of the disease, particu-
larly so since it correlates with flares in SLE [55]. As IFNα induces IFNγ, it is
interesting to note that stimulation of scleroderma fibroblasts with increas-
ing levels of IFNγ results in the production of increasing levels of CXCL10,
which is a potent Th1-chemo-attractant, thus suggesting a self-perpetuating
loop in the dermis [56].
In chapter 2 of this thesis, we identify a new factor produced by pDC
isolated from SSc patients. In chapter 4, we demonstrate a clear type I in-
terferon signature in monocytes from SSc patients which is also present in
PBMCs, even in very early stages of the disease.
T-cells
In SSc, CD4+ T-cells are increased in the skin and in the circulation, re-
sulting in an increase in the CD4+/CD8+ ratio [57]. Natural killer T-cells
and γ/δ T-cells seem to be decreased, although the number of SSc patients
investigated is low [58]. In broncho-alveolar lavage fluid, the number of
activated T-lymphocytes was also increased [59]. In contrast to these clear
findings, the precise nature and function of these increased CD4+ T-cells
is a matter of considerable debate. An increase in type 2 cytokines such
as interleukin-4 (IL-4) and interleukin-13 (IL-13) suggests that SSc is a Th2-
mediated disease [39 60 61]. In line with this, Th2 cells stimulate fibroblasts
to produce collagen [22]. By contrast, an increase in TNFα correlating with
pulmonary fibrosis and an increase in CD8+ IFNγ producing cells suggests
a Th1 profile [62]. The assumption that Th1 cells are pro-inflammatory, anti-
angiogenic and anti-fibrotic, and that Th2 cells are anti-inflammatory, pro-
angiogenic and pro-fibrotic makes one realize that these cells can release
essential information on the pathogenesis of the disease.
The identification of interleukin-17 (IL-17) producing T-cells known as
Th17 cells has made yet another T-cell type the subject of considerable in-
terest, as this type was shown to be important in other autoimmune dis-
eases such as rheumatoid arthritis [63] and psoriasis [64]. Combining the
cytokines TGFβ, IL1α, IL-6 or IL-23 increases the expression of RORγt, the
transcription factor specific for Th-17 cells [65-68]. Interestingly, these Th17
inducing cytokines are present in high levels in the circulation of SSc pa-
tients [44 69]. In line with this, we have shown an increase in activated
IL-17 producing CD4+ T-cells in the circulation [70]. These data suggest
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that activated T-cells play a role in SSc but it has not yet been determined
which subtype of cell is important for establishing to what stage the disease
has progressed. Part of the increased activation and proliferation can be ex-
plained by the impaired suppressive function of regulatory T-cells in SSc
[71]. Further analysis of these regulatory T cells has shown that this group
contains an IL-17 producing population [70]. The increasing literature about
the plasticity of T-cells could explain why these phenotypically regulatory
T-cells have an impaired suppressive function, as they might be in transition
towards Th17 cells. An intriguing finding in this respect is that the addition
of SSc plasma to a suppression assay with only healthy control cells im-
pairs the suppressive function of healthy control regulatory T cells too [71].
This plasma contains the increased levels of Th-17 skewing cytokines (Il-6,
IL1α and IL23) mentioned earlier. Further research on the pathogenic role
of these cytokines and other unidentified factors in SSc plasma is therefore
clearly indicated.
Animal models
The role of the immune system in the development of SSc has been in-
vestigated in several animal models. In UCD 200 chickens, for example,
dermal and visceral fibrosis are also preceded by mononuclear infiltration,
demonstrating the role of inflammatory cells in initiating fibrosis [72 73].
Tight skin-2 mice (Tsk-2), another SSc animal model, also shows this early
mononuclear cell infiltration together with autoantibody production resem-
bling human SSc [74 75]. Bleomycin is a glycopeptide antibiotic used as
a chemotherapeutic agent. Well-known side effects are lung fibrosis and
Raynaud’s phenomenon. Repeated subcutaneous injections of bleomycin
in shaved back skin have induced dermal fibrosis closely resembling SSc
[76]. In the murine bleomycin model, immune cells have been activated by
hyaluronan via TLR4 (and directly by bleomycin via TLR2 [77]) and au-
toantibody production has been induced, resulting in a scleroderma-like
phenotype [78].
Vasculopathy
Of the three pathogenic features in SSc, vasculopathy is thought to occur
first. The vascular defects can be made visible with nailfold capillaroscopy,
showing giant capillaries, loss of architectural arrangement, hyperperme-
ability and dropout of capillaries [79]. The lower density and quality of
vessels leads to a reduced blood flow, which in turn causes tissue hypoxia.
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Both Raynaud’s phenomenon as well as the rarefaction of capillaries sug-
gest the presence of hypoxia during certain stages of the disease. In line
with these assumptions, several studies have demonstrated a lowered oxy-
gen pressure in SSc skin [80-82]. Data showing a lower pO2 only in the
lesional SSc skin and a correlation between skin thickness and pO2 suggest
that there is a direct link between fibrosis and tissue hypoxia.
In normal circumstances, hypoxia induces the expression of angiogenic
factors to stimulate angiogenesis. One of the key angiogenic growth fac-
tors is vascular endothelial growth factor (VEGF), which is produced by,
among other things, fibroblasts in response to hypoxia inducible factor-1α
(HIF-1α) [82]. In SSc a disbalance between HIF-1α and VEGF is apparent
and could explain part of the vasculopathy seen in this disease (reviewed
in more detail in [83]). Another mechanism is the absence or aberrant func-
tion of dermal endothelial cells (ECs), which are often cited to explain the
onset of vasculopathy. ECs can be distinguished using immunohistochem-
istry by the expression of CD31, von Willebrand factor (vWF) and vascular
endothelial cadherin (VE-cadherin). Dermis of early dcSSc patients shows a
population of CD31+ endothelial cells with no expression of vWF and VE-
cadherin [84]. Another group observed apoptotic vWF positive cells in skin
sections from early dc SSc patients, indicating apoptosis of EC. The pres-
ence of immunoglobulins (Ig) on these ECs suggests that anti-endothelial
cell-antibodies (AECA), which are known to be present in the serum of SSc
patients [85], play a role.
In conclusion, the vascular reaction to hypoxia in SSc is dominated by
the growth factor VEGF. By contrast, there is the altered quantity and phe-
notype of the ECs and their progenitors, which could be a causal factor
in the appearance of hypoxia in SSc. The fact that this altered phenotype
is not present in the EC of patients who were treated with intensive im-
munotherapy and subsequent stem cell transplantation provides food for
thought [84], as this could imply reversibility of the vascular defects and
might open novel avenues for therapeutic intervention. There is convinc-
ing evidence of increased oxidative stress caused by ischemia-reperfusion
events [86 87]. The precise contribution of the clinically clear hypoxia to
the cellular derogatory mechanism is gradually being unravelled. Figure
1.1 provides a summary of the processes involved.
Heme oxygenase-1
When combining the factors contributing to SSc (hypoxia, inflammation,
fibrosis, TGFβ), there is one factor essential in all these processes: heme
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Figure 1.1 – The left side illustrates the normal situation, with a healthy blood
vessel delivering oxygen to the surrounding tissue. The right side represents the
situation in SSc, where the diseased vessel and overwhelming deposition of colla-
gen fibers prevents the oxygen from reaching the periphery. In the vessel, endothelial
cell (EC) apoptosis occurring as a result of antibody-dependent cytotoxicity is evi-
dent. Surrounding the ECs, activated pericytes are responsible for the deposition of
collagen. The resulting hypoxia leads to a higher cyto- and chemokine production
by DCs, in part triggered by TLR stimulation, and leading to a continuing loop
of TGFβ production, collagen synthesis and myofibroblast formation of fibroblasts.
This in turn leads to a hindered dispersion of oxygen, keeping the vicious circle
going on.
1.3 and back to the bedside 15
oxygenase-1 (HO-1). Heme oxygenase is responsible for the degradation
of heme into biliverdin, free iron and carbon monoxide (CO). Biliverdin is
directly converted into bilirubin by biliverdin reductase, while free iron is
sequestered by ferritin. These three products all have cytoprotective func-
tions and are responsible for the anti-inflammatory, anti-apoptotic and anti-
proliferative functions of HO-1. Moreover, HO-1 and CO decrease prolifer-
ation of smooth muscle cells and fibroblasts, thereby decreasing fibrosis.
In chapter 6 and 7, we investigate the role of HO-1. First as a potential
genetic risk factor as was shown in rheumatoid arthritis. Next, as a factor
not adequately increased due to circulating inhibitors. We also explore the
effect of HO-1 on TLR responses in SSc patients and healthy controls.
1.3 and back to the bedside
Biomarkers
In the last decade, several valuable biomarkers have been discovered that
can aid physicians in judging progression and choosing therapy. However,
a predictive value in early SSc patients not yet proven to be either limited
or diffuse has to date never been shown.
The specific autoantibodies anti-topoisomerase 1 (ATA), anticentromere
(ACA) and anti-RNP are definitely significant when diagnosing a SSc pa-
tient in the early phase consisting of Raynaud’s phenomenon and some
sclerodactylia. ACA is positive in 16-40% of patients and is associated with
lcSSc and digital ulcera [88]. In addition, 20-40% of patients are positive
for ATA and have dcSSc and more organ involvement [88]. Anti-RNP is
associated with lcSSc and overlap syndromes with myositis [88]. Anti-RNA
polymerase III can also be of help in identifying patients who are at risk
of renal crisis and less at risk of pulmonary involvement, as only 7% of
anti-RNA polymerase III positive patents develop interstitial lung disease
[13]. The mean Rodnan skin score, a clinical biomarker, remains the golden
standard in most reports up till now. This is an intriguing and highly il-
lustrative finding, as it only shows that patients’ ten-year survival rate is
worse if their skin thickening has not improved (60% vs 80%) [89]. A better
option is to combine several markers in order to develop a really discrimi-
nating biomarker. The most basic circulating biomarkers used in medicine
are the erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP).
As in most diseases in rheumatology, ESR has some additive value but in
the case of SSc it has never reached regular use in clinical care. CRP seems
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to be increased in about a quarter of SSc patients and is correlated with
dcSSc and the early phase of the disease [90 91].
Combining inflammatory, vascular and early fibrotic markers makes
sense when considering the disease mechanism and will produce a sen-
sitive and specific marker at some point. Combining type I interferon genes
and genes from the fibrosis TGF-β pathway is a promising tool to predict
organ involvement. Clinically, the expression of interferon-regulated genes
Siglec-1 and IFI44 correlated well with the mean Rodnan skin score. Com-
bined with the TGFβ-regulated genes COMP and TSP 1, these could even
be used as a suitable biomarker [31]. As the mean Rodnan skin score is
plagued by tremendous inter- and intra-observer variability (in addition to
the limitations mentioned earlier), assessing these four genes could substan-
tially improve the monitoring of SSc patients.
The second chapter of this thesis is dedicated to a new potent biomarker
and pathogenic factor in SSc, viz. CXCL4. In chapter 3, we describe a list
of new potential biomarkers which could discriminate between different
disease subsets and the progression towards lung fibrosis. We focus on the
inflammatory protein S100A8. The importance of the type I interferon signa-
ture in discriminating certain disease subsets is investigated in monocytes
and reported in chapter 4. This signature is already present in an early
phase of the disease and in patients at risk of developing SSc. In chapter
5, 6 and 7, we aim to gain greater insight into the aberrant function of
dendritic cells and establish their relationship with the biomarkers identi-
fied. Therefore, this thesis introduces new biomarkers as well as suggest-
ing therapeutic targets, as several biomarkers turn out to contribute to the
pathogenic mechanism resulting in SSc.
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Background: Plasmacytoid dendritic cells have been implicated in the
pathogenesis of systemic sclerosis through mechanisms beyond the previously
suggested production of type I interferon.
Methods: We isolated plasmacytoid dendritic cells from healthy persons and
from patients with systemic sclerosis who had distinct clinical phenotypes. We
then performed proteome-wide analysis and validated these observations in
five large cohorts of patients with systemic sclerosis. Next, we compared the
results with those in patients with systemic lupus erythematosus, ankylosing
spondylitis, and hepatic fibrosis. We correlated plasma levels of CXCL4 protein
with features of systemic sclerosis and studied the direct effects of CXCL4 in
vitro and in vivo.
Results: Proteome-wide analysis and validation showed that CXCL4 is the
predominant protein secreted by plasmacytoid dendritic cells in systemic
sclerosis, both in circulation and in skin. The mean (±SD) level of CXCL4 in
patients with systemic sclerosis was 25,624±2652 pg per milliliter, which was
significantly higher than the level in controls (92.5±77.9 pg per milliliter) and
than the level in patients with systemic lupus erythematosus (1346±1011 pg
per milliliter), ankylosing spondylitis (1368±1162 pg per milliliter), or liver
fibrosis (1668±1263 pg per milliliter). CXCL4 levels correlated with skin and
lung fibrosis and with pulmonary arterial hypertension. Among chemokines,
only CXCL4 predicted the risk and progression of systemic sclerosis. In
vitro, CXCL4 downregulated expression of transcription factor FLI1, induced
markers of endothelial-cell activation, and potentiated responses of toll-like
receptors. In vivo, CXCL4 induced the influx of inflammatory cells and skin
transcriptome changes, as in systemic sclerosis.
Conclusions: Levels of CXCL4 were elevated in patients with systemic sclero-
sis and correlated with the presence and progression of complications, such as
lung fibrosis and pulmonary arterial hypertension.
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2.1 introduction
Systemic sclerosis (also called scleroderma) is a complex heterogeneous fi-
brosing autoimmune disorder with an unknown pathogenesis. The way in
which its three major pathologic hallmarks — extensive fibrosis, vasculopa-
thy, and immune dysfunction — are interconnected is unknown. Mechanis-
tic understanding is limited, in part, by a lack of animal models and by
clinically heterogeneous patient populations [1]. This disorder is classified
into two major subtypes on the basis of the extent of cutaneous fibrosis:
limited cutaneous and diffuse cutaneous systemic sclerosis [2]. Pulmonary
fibrosis and pulmonary arterial hypertension are the two most serious com-
plications — currently the major causes of death among patients with this
disorder. Thus, in addition to clarifying pathogenic mechanisms, the iden-
tification of biomarkers for the presence and progression of clinical compli-
cations of systemic sclerosis has potential use in the assessment of disease
activity.
On the basis of key observations by LeRoy [3] that collagen production
was increased in fibroblasts that were isolated from scleroderma skin and
cultured in vitro, much of the research on systemic sclerosis has focused on
altered fibroblast biology. More recent studies, however, indicate that im-
mune cells are important in pathogenesis[4 5]. Indeed, genetic association
studies have revealed that the most highly associated susceptibility markers
include the genes encoding immune signaling molecules T-bet [6], STAT4
[7 8], and IRF5 [8 9] and the T-cell–receptor zeta chain [8]. STAT4 and IRF5
are both implicated in the secretion of type I interferon, a cytokine that has
been shown to be present in both cutaneous and peripheral-blood mononu-
clear cells [10]. Plasmacytoid dendritic cells are the major source of type I
interferon, and as such have been implicated in multiple autoimmune con-
ditions that have a type I interferon signature, including systemic lupus
erythematosus [11], Sjögren’s syndrome [12], and rheumatoid arthritis [13].
Although two studies have shown that serum samples obtained from pa-
tients with systemic sclerosis showed type I interferon– inducing activity,
the role of plasmacytoid dendritic cells in systemic sclerosis has not been
fully explored [14 15]. The aim of our study was to identify a possible role
for plasmacytoid dendritic cells in the pathogenesis of systemic sclerosis
that is associated with the clinical phenotype.
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2.2 methods
Study Patients
In our study, we evaluated 779 patients with systemic sclerosis — 462 with
the limited cutaneous subtype (limited disease) and 317 with the diffuse
cutaneous subtype (diffuse disease). Throughout the study, the patient co-
hort from the Boston University School of Medicine was the identification
cohort for studies of plasmacytoid dendritic cells and included 20 healthy
donors and 53 patients with systemic sclerosis; the latter included 16 pa-
tients with limited disease, 18 with late diffuse disease (duration, >3 years),
and 19 with early diffuse disease (duration, <2 years). In addition, for the
chemokine analysis, plasma was obtained from an additional 22 healthy
donors, 15 patients with limited disease, and 31 patients with diffuse dis-
ease. The replication cohorts comprised patients from the University of Nij-
megen, the Netherlands (148 patients), Lund, Sweden (197), Milan (120),
Verona, Italy (18), Ghent, Belgium (79), and Houston (50). Samples from
an additional 68 patients from Milan were included to compare CXCL4
levels in patients with early systemic sclerosis with levels in patients in
various phases of preclinical systemic sclerosis, including those with only
Raynaud’s phenomenon with or without specific antinuclear antibodies,
anti–topoisomerase or anti–centromere antibodies, or capillary nailfold le-
sions resembling systemic sclerosis.
For the studies of the CXCL4 expression in plasmacytoid dendritic cells,
skin sections were obtained from 3 patients with early diffuse systemic scle-
rosis from Boston University and 6 patients with late diffuse disease from
the University of Dusseldorf, Germany. All patients met the preliminary
criteria of the American College of Rheumatology for the classification of
systemic sclerosis (Table 2.1) [16]. The clinical phenotype of the patients is
described further in the Supplementary Appendix. All samples were ob-
tained after patients provided written informed consent and after approval
of the study by the institutional review board at each participating center.
To compare CXCL4 levels in samples obtained from patients with sys-
temic sclerosis with levels in samples from healthy donors, we obtained
plasma samples from 257 age- and sex-matched healthy persons from the
Nijmegen Biomedical Study [17]. To compare CXCL4 levels in patients
with systemic sclerosis with levels in patients with other clinical conditions,
we determined the levels of CXCL4 in stored samples from 109 patients
with systemic lupus erythematosus who fulfilled the American College of
Rheumatology criteria [18 19] (Table 2.2 in the Supplementary Appendix),
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from 93 patients with ankylosing spondylitis [20] (Table 2.3 in the Supple-
mentary Appendix), and from patients with various stages of liver fibrosis
(see the Supplementary Appendix for details).
Cell-Based Studies and Measurement of Inflammatory Mediators
All the techniques that we used in this study are described in detail in the
Supplementary Appendix. Briefly, we performed proteome-wide analysis
of supernatant from plasmacytoid dendritic cells, using surface-enhanced
laser desorption/ionization–time-of-flight (SELDI-TOF) mass spectrometry.
Quantification of secreted cytokines was performed with the use of an
enzyme-linked immunosorbent assay or Luminex immunoassay. We used
primary endothelial cells and peripheral plasmacytoid dendritic cells to
study the effect of CXCL4 in vitro. To assess CXCL4 function in vivo,
C57BL/6 mice were exposed to subcutaneous CXCL4 for further RNA and
histologic analysis.
Statistical Analysis
We used Student’s t-test or the Mann–Whitney U test for the analysis of
quantitative traits, as appropriate, and the Kaplan–Meier method to esti-
mate survival in patients with high CXCL4 levels at baseline, as compared
with those with low CXCL4 levels, with survival time set at 24 months. Af-
ter verifying that the proportionality of hazards was not violated, we used
Cox regression analysis to estimate the effect size of CXCL4 categorization
on the basis of plasma levels on the time to event; results are presented
as hazard ratios along with their asymptotic 95% confidence intervals. List-
wise deletion was used in cases with missing data.
To assess the most effective cutoff value for CXCL4, we used DeLong’s
method to compute a receiver-operating-characteristic (ROC) curve. The
area (±SE) under the ROC curve was 0.987±0.009 (95% confidence interval
[CI], 0.952 to 0.996; P<0.001). At the cutoff value for CXCL4 of 11,589 pg
per milliliter, the sensitivity was 100%, and the specificity was 94%. At the
cutoff value of 9789 pg per milliliter, the sensitivity was 100%, and the
specificity was 93%. For a practical cutoff for clinical practice, we chose 10
ng per milli liter for CXCL4, to be conservative with respect to sensitivity. P
values of less than 0.05 (all two-sided) were considered to indicate statistical
significance and were adjusted with the use of a Bonferroni correction.
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Limited
cutaneous
systemic
sclerosis
Diffuse
cutaneous
systemic
sclerosis
N 462 317
Women (N, (%)) 378 (82) 218 (69)
Age at onset (years) 42.4 ± 12.3 43.8± 11.2
Disease duration (years) 9.4 ± 8.0 5.8 ± 6.2
Positive ANA 97% 86%
mRSS at inclusion 5.4 ± 2.4 15.9 ± 8.2*
Pulmonary arterial hypertension 39% 23%
Lung fibrosis 26% 48%
Current Therapies:
MMF 0% 41%
Cyclophosphamide 0% 23%
Prednisolone 25% 30%
Hydroxychloroquine 18% 11%
Anti-IL-3 0% 2%
Methotrexate 1% 5%
Tacrolimus 12% 0%
* P<.03; Plus-minus values are means + SD;ANA: nti-nuclear
antibodies, mRSS: modified Rodnan skin score, MMF:
mycophenolate mofetil
Table 2.1 – Disease Characteristics of All Systemic Sclerosis Patients.
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CXCL4 Secretion by Plasmacytoid Dendritic Cells
To assess the production of type I interferon by plasmacytoid dendritic cells,
we isolated BDCA4+ cells from 20 healthy donors and compared results in
their plasmacytoid dendritic cells with those in cells obtained from 54 pa-
tients with systemic sclerosis: 17 with limited disease and 37 with diffuse
disease (Fig. 2.5A in the Supplementary Appendix). Patients with diffuse
disease were further stratified according to disease duration, with 18 pa-
tients in the early-disease group and 19 in the late-disease group. A chro-
mogenic reaction was reproducibly present in the media from the plasma-
cytoid dendritic cells obtained from patients with early systemic sclerosis.
Measurement of multiple inflammatory mediators in these supernatants
showed almost no detectable production of type I interferon or other me-
diators, with differential expression of only interleukin-8 and interleukin-6
(Fig. 2.5B through G in the Supplementary Appendix). Proteome-wide mea-
surements from eight independent experiments robustly showed that only
plasmacytoid dendritic cells from patients with early systemic sclerosis se-
creted a unique pattern of peaks that were identified as CXCL4, CTAP-III,
S100A8/9, and lysozyme (Fig. 2.1A, and Fig. 2.5H in the Supplementary
Appendix). Confirmatory assessments showed markedly increased levels
of CXCL4 in patients with systemic sclerosis (Fig. 2.1B). Increased levels of
CXCL4 messenger RNA (mRNA) were observed only in purified plasmacy-
toid dendritic cells, and increased CXCL4 protein expression was observed
in circulating plasmacytoid dendritic cells (Fig. 2.5I and J) and in plasmacy-
toid dendritic cells in skin from patients with systemic sclerosis (Fig. 2.1C,
and Fig. 2.5K in the Supplementary Appendix).
CXCL4 in the Circulation
In the identification cohort, levels of circulating CXCL4 were markedly
higher in patients with systemic sclerosis than in healthy controls and were
particularly high in patients with early diffuse disease (P<0.001 for both
comparisons) (Fig. 2.2A). Increased CXCL4 levels were successfully vali-
dated in the replication cohort (which included 86 patients with systemic
sclerosis with limited cutaneous disease, 38 with late diffuse disease, and
37 with early diffuse disease) and were compared with 129 age- and sex-
matched healthy donors and 109 patients with systemic lupus erythemato-
sus, 93 with ankylosing spondylitis, and 93 with liver fibrosis (Fig. 2.2B).
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Figure 2.1 – Identification of CXCL4 as the Major Protein Product of Plas-
macytoid Dendritic Cells from Systemic Sclerosis Patients.
Panel A depicts the results from the proteome analysis using SELDI-TOF of super-
natants from plasmacytoid dendritic cells. One out of twelve representative exper-
iments is shown indicating that only the early diffuse Systemic sclerosis patients
display peaks that were predicted as CXCL4, CTAPIII, S100A8/A9 and lysozyme,
respectively. Panel B shows the level of CXCL4 in supernatants from plasma-
cytoid dendritic cells from the different groups investigated using a CXCL4 spe-
cific ELISA; healthy donors (n=20), patients with limited (lSSc, n=16), late diffuse
(ldSSc, n=19) and early diffuse (edSSc, n=18). Panel C. Frozen skin sections from
diffuse Systemic sclerosis (n=9, left), healthy controls (n=6, right) were stained for
the plasmacytoid dendritic cell marker BDCA2 (green), CXCL4 (red) and DAPI-
labeled nuclei (blue). BDCA2+ cells expressing CXCL4 turn up as orange (merged,
lower panels). One representative Systemic sclerosis patient and one healthy control
are shown.
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Figure 2.2 – CXCL4 Levels Are Increased in the Circulation of Systemic Scle-
rosis Patients and Associated with Lung Fibrosis and Pulmonary Arterial
Hypertension. High levels of CXCL4 were observed in the circulation of Systemic
sclerosis patients from the identification cohort (Boston University, Panel A) as
well as in systemic sclerosis patients (n=161) from two independent (Dutch and
Swedish) cohorts in comparison with healthy individuals (age and sex-matched,
n=129), patients with lupus erythematosus (SLE, n=109), ankylosing spondylitis
(AS, n=93) and hepatic fibrosis (n=93) (Panel B). Scleroderma with a high circu-
lating CXCL4 level (> 10 ng/ml, green line) are compared with those having low
levels of CXCL4 (< 10 ng/ml) blue line) with regard to the estimated time with-
out having developed lung fibrosis (Panel C) or pulmonary arterial hypertension
(Panel D) within the first 18 months after the diagnosis systemic sclerosis.
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Increased Levels of Circulating CXCL4 in Systemic Sclerosis and the Association
with Lung Fibrosis and Pulmonary Arterial Hypertension
In addition, in the replication cohort, there were clear differences between
the two groups in previously suggested biomarkers for systemic sclero-
sis, such as CCL5 [21], von Willebrand factor [22], CCL18 [23], CCL2
[24], and CXCL10 [24](Fig. 2.6B in the Supplementary Appendix). In an
exploratory analysis, we found that CXCL4 levels gradually and signifi-
cantly increased per group in the following order: patients with primary
Raynaud’s phenomenon, those with Raynaud’s phenomenon and positive
antinuclear antibodies, and those with very early systemic sclerosis (Ray-
naud’s phenomenon plus anti–topoisomerase or anti–centromere antibod-
ies and the presence of nailfold angiopathy), whereas the levels of CCL2,
CXCL10, CCL5, von Willebrand factor, and CCL18 did not increase (Fig.
2.6C in the Supplementary Appendix). We next assessed the association be-
tween CXCL4 levels and the clinical phenotype. CXCL4 levels correlated
with the extent of skin fibrosis in the limited cutaneous phenotype (R2 =
0.59, P<0.001) and the diffuse cutaneous phenotype (R2 = 0.74, P<0.001).
Patients with high levels of circulating CXCL4 (≥10 ng per milliliter), as
compared with those with low CXCL4 levels, had significantly earlier evi-
dence of lung fibrosis, as measured by a relative decline of more than 30%
in the forced vital capacity (hazard ratio, 3.67; 95% CI, 2.31 to 4.31; P<0.001)
or by the presence of bilateral fibrosis on high-resolution computed tomog-
raphy (CT) (hazard ratio, 2.60; 95% CI, 1.61 to 5.26; P<0.001) (Fig. 2.2C). Fur-
thermore, patients with systemic sclerosis who had evidence of pulmonary
arterial hypertension had markedly increased circulating CXCL4 levels, as
compared with those without such evidence (19,078±629 vs. 5023±329 pg
per milliliter, P<0.001). High CXCL4 levels were associated with the earlier
development of pulmonary arterial hypertension, as determined on right-
heart catheterization (hazard ratio, 8.33; 95% CI, 4.43 to 15.72; P<0.001) (Fig.
2.2D).
We also investigated whether CXCL4 could serve as a biomarker in a
prospective cohort of 79 patients who were followed for 18 months. Pa-
tients who had a high baseline level of CXCL4, as compared with other
biomarkers for systemic sclerosis, had a significantly faster decline in diffu-
sion capacity of the lung for carbon monoxide (P = 0.002), higher prevalence
of high-resolution CT–confirmed lung fibrosis (22% vs. 8%, P<0.001), and
faster progression of skin fibrosis (P<0.001) (Fig. 2.6D in the Supplementary
Appendix). None of the other chemokines that were measured correlated
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with progression. Table 2.4 in the Supplementary Appendix provides a sum-
mary of CXCL4 plasma levels in all the study cohorts.
In Vitro Studies
We examined CXCL4 in vitro using plasma obtained from patients with
systemic sclerosis and commercially available CXCL4. Both the CXCL4 and
plasma induced the secretion of endothelin 1 and down-regulation of the
transcription factor FLI1 in human umbilical-vein endothelial cells (HU-
VECs) and human dermal microvascular endothelial cells (HDMECs). The
addition of anti–CXCL4 antibody attenuated these responses (Fig. 2.3A and
B). In addition, CXCL4 inhibited the effect of vascular endothelial growth
factor on the proliferation of HDMECs (P<0.001), a finding that we specu-
late may underlie the rarefaction of vessels in patients with systemic sclero-
sis (data not shown).
Changes in Endothelial Cells and Augmented Responses in Toll-Like Receptors
Induced by CXCL4
Plasmacytoid dendritic cells and their activation by toll-like receptors are
thought to play a role in systemic sclerosis. On stimulation by ligands of
toll-like receptors, plasmacytoid dendritic cells from patients with systemic
sclerosis secreted more type I interferon than did those from controls, a
difference that was fully reversed by the addition of anti–CXCL4 antibody
or heparinase (Fig. 2.3C and D). In contrast, anti–CXCL12 antibody (SDF-1)
did not have this effect (data not shown).
CXCL4 and Inflammatory Changes in Skin
To examine the possible role of CXCL4 in vivo, we used a recently described
murine subcutaneouspump model [25]. The subcutaneous administration
of CXCL4 for 7 days resulted in a marked infiltration of inflammatory cells
in the dermis and subdermis, as compared with that seen in mice infused
with phosphate-buffered saline as a control (Fig. 2.4A and B). In addition,
CXCL4 administration resulted in a significant increase in the thickness of
dermal and subdermal layers after 7 days (Fig. 2.4C). CXCL4-induced der-
mal thickening was also observed in a longer, 28-day model of daily sub-
cutaneous injection (Fig. 2.7D in the Supplementary Appendix). The influx
of inflammatory cells was confirmed by an increased number of dermal
CD45+ cells in the CXCL4-treated skin, as well as increased expression of
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Figure 2.3 – CXCL4 Induces Endothelial Cell Changes and Augmented Toll-
Like Receptor Responses Recapitulating Observations from Systemic Scle-
rosis Patients. Panel Ademonstrates that LPS, CXCL4, as well as diffuse sys-
temic sclerosis plasma induce endothelin-1 by human umbilical vein endothelial
cells (HUVECs) that could be fully abrogated by the addition a neutralizing anti-
body for CXCL4. In five independent experiments, CXCL4 was shown to signifi-
cantly reduce Fli-1 (P = 0.0006) and induce ET-1 (P = 0.003) expression both on
the RNA and protein level on human dermal microvascular endothelial cells (HD-
MECs) (Panel B). Panel C shows the secretion of IFNα by plasmacytoid dendritic
cells from healthy donors and Systemic sclerosis patients upon stimulation with
ligands for TLR7/8, TLR9, or negative control with the addition of anti-CXCL4 as
indicated.
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CD45 mRNA (Fig. 2.4D). Furthermore, we observed that CXCL4 induced
the expression of the highly proinflammatory CCL2 in the two models (Fig.
2.4E, and Fig. 2.7F in the Supplementary Appendix). During an investiga-
tion of the gene-expression profile in mice that were treated with CXCL4
for 7 days, we found increased mRNA expression of tumor necrosis factor
α, IFIT1, and MX2, the products of type I interferon-inducible genes; of the
profibrotic marker PAI-1; and of the antiangiogenic factor thrombospondin
1 (Fig. 2.7A through C in the Supplementary Appendix).
2.4 discussion
In this study, we found that CXCL4 levels in patients with systemic sclerosis
not only correlate strongly with both skin and pulmonary disease but also
appear to predict progression in systemic sclerosis phenotypes. Collectively,
the identification of CXCL4 as a marker for fibrosis and pulmonary arterial
hypertension may be helpful in early diagnosis and risk assessment, an
important factor in patients who require aggressive treatment. CXCL4 was
one of the most highly and differentially expressed genes in a genomewide
association study involving patients with systemic sclerosis who had pul-
monary arterial hypertension and idiopathic pulmonary arterial hyperten-
sion, as compared with healthy controls [26].
CXCL4 is a 70-amino acid, lysine-rich, 7.8-kDa protein that was first iden-
tified as a product of megakaryocytes and comprises 2 to 3% of the pro-
tein content of activated platelets [27]. CXCL4 is generally well accepted
as one of the most potent antiangiogenic chemokines, influencing angio-
genesis through an integrin-dependent mechanism [28]. The high levels of
CXCL4 that were found in patients with systemic sclerosis are of great inter-
est, since plasma obtained from these patients also showed antiangiogenic
activity, and the disease is characterized by rarefaction of vessels despite
the presence of multiple proangiogenic factors.
In addition to its antiangiogenic activity, CXCL4 inhibits the expres-
sion of the antifibrotic cytokine interferon-γ (a type 1 helper T cell) and
up-regulates profibrotic cytokines interleukin-4 and interleukin-13 (type 2
helper T cells) [29]. It also stimulates the proliferation of T regulatory cells
with impaired suppressive function [30]. Such data might indicate that the
high levels of CXCL4 in patients with systemic sclerosis could be linked
to features of immune dysfunction that have been observed in the disease
[31]. Accumulating evidence suggests a role for CXCL4 in other chronic fi-
broproliferative and inflammatory conditions. CXCL4 was shown to be an
important mediator in atherosclerosis, both in vivo and in vitro [32], and
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Figure 2.4
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Figure 2.4 – CXCL4 Induces Inflammatory Skin Changes In Vivo Resembling
Systemic Sclerosis. Panel A-B depict skin histology from wild-type C57BL/6
mice treated with phosphate-buffered saline (PBS) control (A) or CXCL4 (B) for 7
days using subcutaneous pump model (H&E, left; CD45 IHC, right) at 4x or 20x
magnification. Panel C shows quantification of skin layers thickening after CXCL4
treatment for 7 days using the pump model (n=3/group) as compared to the PBS
controls (* P < 0.05). To quantify infiltrating immune cells after 7 day CXCL4 or
PBS treatment, CD45+ cells in the dermis were counted after immunohistochem-
ical staining (n=3/group) and CD45 mRNA expression in the skin isolated from
proximal or distal area to the pump outlet was measured using qPCR (CXCL4 prox.
n=7, PBS prox. n=4) (Panel D). The expression of pro-inflammatory marker CCL2
induced by CXCL4 after 7 day (CXCL4 prox. n=7, PBS prox. n=4) as compared to
PBS was measured using qPCR as depicted in Panel E.
increased CXCL4 levels have been associated with progressive liver fibrosis
[33]. Intriguingly, despite the fact that CXCL4 induced skin inflammation
in vivo in mice, fibrosis was not observed. In this light, it is tempting to
speculate that although CXCL4 may sensitize various cells to inflammatory
stimuli, culminating in fibrosis, the presence of CXCL4 alone is not suffi-
cient. This hypothesis is supported by our observation that increased levels
of CXCL4 were found in patients with Raynaud’s phenomenon, most of
whom do not have progression to systemic sclerosis.
Our data from cell culture and the murine model lead us to speculate that
plasmacytoid dendritic cells, through the production of CXCL4, are piv-
otal in the onset and perpetuation of systemic sclerosis. In this respect, the
downregulation of FLI1 is of particular interest, since selective endothelial-
cell deletion of Fli-1 in mice leads to down-regulated expression of clas-
sic endothelial-cell markers, which are also seen to be down-regulated in
the vasculature of patients with systemic sclerosis. The phenotype of Fli-
1 knockout mice indicates a profound role for Fli-1 in vessel formation,
maturation, and stabilization [34]. In addition, CXCL4 induces the expres-
sion of thrombospondin 1 and attenuates the effects of vascular endothelial
growth factor. These observations might explain the absence of neovascular-
ization in systemic sclerosis, despite the presence of high levels of vascular
endothelial growth factor. Thus, we speculate that CXCL4 may play a ma-
jor role in vasculopathy associated with systemic sclerosis through altered
FLI1 expression. The effect of FLI1 expression on fibroblasts may also be
important, since FLI1 regulates elevated collagen synthesis, the hallmark of
fibrosis [35].
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Several previous small studies have hinted at increased levels of CXCL4
and other inflammatory markers in the circulation of patients with systemic
sclerosis [23 24 36-39]. In those studies, the observed CXCL4 levels were
attributed to platelet activation, a conclusion inconsistent with increased
mRNA expression by peripheral-blood mononuclear cells, increased secre-
tion of CXCL4 by plasmacytoid dendritic cells, and a lack of association
between increased β-thromboglobulin levels and increased CXCL4 levels in
patients with systemic sclerosis. Our data show that CXCL4 levels corre-
lated highly with disease phenotype and disease progression in five large,
independent, and clinically well-characterized patient cohorts, whereas lev-
els of CCL2, CXCL10, CCL5, von Willebrand factor, and CCL18 did not
show such correlation.
Taken together, our observations suggest that CXCL4 and plasmacytoid
dendritic cells are central to the pathogenesis of systemic sclerosis. The lev-
els of CXCL4 correlated well with the level of fibrosis and the occurrence
and progression of pulmonary arterial hypertension, the two clinical hall-
marks of this disorder. CXCL4 levels were also increased in several other
fibrosing or inflammatory conditions, suggesting that CXCL4 may play a
role in many pathologic conditions.
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2.6 supplementary appendix
Materials and Methods
Patient and Phenotypes
The presence of systemic sclerosis specific autoantibodies, anti-
topoisomerase I and anti-centromere, was assessed by passive im-
munodiffusion against calf thymus extract (Inova Diagnostics, San Diego,
CA) and indirect immunofluorescence of HEp-2 cells (Antibodies Inc.,
Davis, CA), respectively. To investigate the correlation between the level
of skin fibrosis and CXCL4, the modified Rodnan skin score (mRSS) was
assessed [1] within 2 months before or after sampling of plasma. As we
aimed to investigate systemic sclerosis patients that reflect the daily clinical
practice, all use of medications was allowed. No differences were observed
when patients with different therapeutic regimens were compared (data
not shown). The presence of pulmonary fibrosis was determined by
high-resolution computed tomography scan and further defined as a
forced vital capacity (FVC) < 70% of the predicted value and a diffusion
capacity of the lung for carbon monoxide (DLCO) of less than 70% of
predicted. Pulmonary arterial hypertension (PAH) was diagnosed by right
heart catheterization and considered confirmed when the hemodynamic
definition of PAH; mPAP ≥25 mm Hg with a pulmonary capillary wedge
pressure (PCWP) of ≤15 mm Hg and a pulmonary vascular resistance of
>3 Wood units was met. The time-to-develop fibrosis or PAH was assessed
in patients with high or low CXCL4 levels up to 24 months from the first
determination of the molecule. A separate analysis was conducted in all the
patients with PAH and in the subset of PAH patients with isolated PAH,
that is in those without any detectable lung fibrosis before the diagnosis of
PAH (n=10 in high CXCL4 group and n=9 in low CXCL4 group); when the
two populations were separately analyzed no differences in the survival
estimates and in the hazards between groups were observed. In these
analyses, 10 patients were lost to follow up for high-resolution computed
tomography (HRCT) assays (4 with low and 6 with high CXCL4) and 11
were lost to follow-up for assessment of PAH (5 with low and 6 with high
CXCL4).
Liver biopsy and assessment of fibrosis
For the purpose of this study we assessed 93 patients with suspected liver
disease caused by hepatitis infection or alcohol abuse and grouped them
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according to the severity of liver fibrosis. Liver biopsies for histological
assessment of fibrosis were obtained using a 1.6 mm diameter Menghini-
type needle via right intercostal approach with local lidocaine anesthesia
(Hepafix, Braun, Melsungen, Germany). The biopsy site was marked by ul-
trasound examination. No side effects occurred and good quality samples
were obtained. Biopsy specimens were immersed in 2% formaldehyde and
subsequently fixed with paraffin. A van Gieson stain for collagen was as-
sessed for the presence of pericellular and perivenular fibrosis, as well as
the expansion of the portal tracts. The specimens were staged according the
METAVIR scoring system, where F0 indicates the lack of fibrosis, F1 corre-
sponds to portal fibrosis without septa, F2 to the presence of few septa, F3 to
the finding of numerous septa without cirrhosis. F4 indicates the presence
of cirrhosis. Cirrhosis (F4) was diagnosed by histology, ultrasonography or
on clinical grounds. We included a total of 93 patients, a total of 45 patients
had a clinical diagnosis of cirrhosis, while 48 patients had only minimal or
absent liver fibrosis. (F0 in 26 patients; F1 in 22 patients).
Cell isolation and purification
To minimize intra- and inter-assay differences, for the cell experiments
described below blood was drawn simultaneously on at least 6 subjects,
consisting of 1-2 healthy individuals, limited cutaneous systemic scle-
rosis, late diffuse cutaneous systemic sclerosis and early diffuse cuta-
neous systemic sclerosis patients. First peripheral blood mononuclear cells
(PBMCs) were isolated using Ficoll gradient centrifugation as previously de-
scribed [2]. Thereafter, the isolation of plasmacytoid dendritic cells (pDCs)
was performed using magnetic bead isolation (MACS) using the pDC
(CD304/BDCA4) positive selection kit according to the manufacturer’s pro-
tocol (Miltenyi Biotec, Auburn, CA). The positive fraction was reapplied to
the separation column to enhance purity. Purity of the pDC population was
investigated using flow cytometry for the markers BDCA2, CD19, BDCA-1
(CD1c), BDCA-3, CD14 and CD123 (all Miltenyi Biotec, Auburn, CA) (Fig.
S1A). Intracellular staining of pDC for CXLC4 was performed after stimu-
lation of plasmacytoid dendritic cells for four hours with PMA (50 ng/ml;
Sigma-Aldrich, St. Louis, MO) and Ionomycin (1 μg/ml; Sigma-Aldrich, St.
Louis, MO) in the presence of Golgiplug (1 μl/ml; BD Biosciences, San
Jose, CA). Next, for intracellular detection of CXCL4, cells were washed,
fixed and permeabilized according to the manufacturer’s protocol (eBio-
science, San Diego, CA) and incubated with phycoerythrin-conjugated anti-
CXCL4 antibody (IC7952P, R&D systems, Minneapolis, MN). The purity
of pDC was always > 96%. As an extra validation, the frequency of den-
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dritic cell subsets (plasmacytoid dendritic cells, myeloid DC type I (MDC1)
and myeloid DC type I (MDC2)) in the circulation was simultaneously
monitored using the blood dendritic cell enumeration kit (Miltenyi Biotec,
Auburn, CA). To exclude the possibility that the positive selection of plas-
macytoid dendritic cells would have influenced our results, in three consec-
utive experiments the blood samples were split and plasmacytoid dendritic
cells were both positively selected as described above but also negatively
selected using the Diamond pDC isolation kit (Miltenyi Biotec, Auburn,
CA). In these experiments phenotype and cytokine production was noted
to be similar between positively and negatively selected plasmacytoid den-
dritic cells (data not shown). After isolation of plasmacytoid dendritic cells,
the cells were suspended in RPMI (106/ml) and incubated at 37°C for two
hours. In some experiments, plasmacytoid dendritic cells were stimulated
with toll-like receptor ligands for TLR7/8 (R848) or TLR9 (CpG or CpG con-
trol) for 24 h after which supernatants were collected and stored at -80°C.
Anti-CXCL4 (ab9561, Abcam, Cambridge, UK), or Heparinase, a natural
CXCL4 antagonist, was used to counteract the effect of CXCL4. As a con-
trol anti-CXCL12 (LS-B7489, LifeSpan Biosciences, Seattle, WA) was used as
an isotype matched irrelevant antibody.
Human Dermal Microvascular Endothelial Cells and Human Umbilical Vein En-
dothelial Cells
Human dermal microvascular endothelial cells (HDMECs) were isolated
from foreskin tissue as previously described [3]. These cells were cultured
on collagen type I coated plates in EBM medium supplemented with 10%
fetal bovine serum (FBS), EC growth supplement mix, at 37°C under 5%
CO2 in air. The culture medium was changed every other day. HDMECs
harvested between passage 2 and 4 were used for experiments. Tissue cul-
ture reagents, antibiotic-antimycotic solution (penicillin, streptomycin, and
amphotericin B) was purchased from Life Technologies BRL (Grand Island,
NY), EBM kit from Lonza (Walkersville, MD) and FBS from HyClone (Lo-
gan, UT). Human umbilical vein endothelial cells (HUVECs) were isolated
from umbilical cords from healthy donors after obtaining informed consent.
Cells were cultured in RPMI-1640 Dutch modified (Gibco-Invitrogen, Carls-
bad, CA) supplemented with heat-inactivated 10% FBS and 10% human
serum at 37°C and 5% CO2, in 0.2% w/v gelatinized (Sigma–Aldrich, St.
Louis, MO) flasks or plates (Corning, Corning, NY). HUVECs grown in a
12-well plate were treated with CXCL4 (1 and 5 µg/mL, Haematologic Tech-
nologies Inc., Essex Junction, VT), after 24 h, cells and supernatants were
collected for RNA or protein analysis. The systemic sclerosis plasma was
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pooled from 5 patients with diffuse systemic sclerosis. Anti-CXCL4 (ab9561,
Abcam, Cambridge, UK) was used to counteract the effect of CXCL4 in
these studies. ET-1 immunoassay (Assay Designs, Ann Arbor, MI, cat no.
900-020A) was performed according to manufacturer’s protocol. Cultured
HDMECs were treated with CXCL4 (100ng/ml) and/or VEGF (100ng/ml,
positive control) for 24 h. For cell proliferation assay, cells were seeded in
a 96-well plate at a density of 20000 cells/well and were allowed to adhere
overnight. At 48 h cell proliferation was determined by CellTiter 96® AQue-
ous One Solution Cell Proliferation Assay (Promega, Madison, WI) accord-
ing to the manufacturer’s protocol. Briefly, 20 μl of One Solution Reagent
were added to each well followed by 3 h of incubation at 37°C, and ab-
sorbance was read at 450 nm. Results were calculated as percent change in
proliferation in comparison to control from five separate experiments.
Measurement of secreted proteins
supernatants from plasmacytoid dendritic cell in culture
After two hours of incubation in RPMI cultured plasmacytoid dendritic
cells (pDC) were centrifuged, supernatants stored at -80°C, cell purity tested
by flow cytometry and RNA isolated from the remaining pDC. Type I IFN
was assayed in pDC supernatants using an IFNα specific ELISA (Abnova,
Heidelberg, Germany) and retested using the IFNα multiple subset ELISA
(CellSciences, Canton, MA). Multiple cytokines (IL-2, IL-4, IL-6, IL-8, IL-10,
GM-CSF, IFNγ, TNFα, IL-1β, IL-5, IL-7, IL-12, IL-13, IL-17F, G-CSF, MCP-
1, MIP1β, IFNα, IL-23, IL-17A and IL-1α) were tested in pDC supernatants
using the Bio-Plex system (Bio-Rad, Hercules, CA). The sensitivity of the cy-
tokine assay was <5 pg/ml for all cytokines measured. β-thromboglobulin
(β-TG) was measured using a β-TG specific ELISA (Calbiotech, Spring Val-
ley, CA) and CXCL4 levels in supernatant were measured using a CXCL4
specific ELISA (R&D system, Minneapolis, MN) according to manufactur-
ers’ protocols.
plasma measurements Levels of CXCL4, CCL5, CCL2, CCL18 and
CXCL10 were determined in plasma using semi automated ELISA on a
TECAN Freedom EVO 150 robotic pipetting station. Commercial antibody
duosets: Dy795, Dy393, Dy278, Dy394 and Dy466 (R&D Systems, Abbing-
ton, UK) were used to quantify CXCL4, CCL2, CCL5, CCL18 and CXCL10,
respectively. Since plasma samples originated from different collaborating
samples and to correct for differences in sample handling (e.g., platelet
activation) in all plasma samples β-TG and vWF were measured simulta-
neously. No marked differences in these two markers were observed be-
48 cxcl4 as a biomarker in ssc
tween systemic sclerosis patients and/or healthy individuals that would
suggest different sample handling excluding the possibility that differences
in CXCL4 were due to inter-cohort differences. Each antigen was measured
on a separate Nunc MaxiSorp 384 well ELISA plate (Thermo Fisher Scien-
tific, Roskilde, Denmark). For each ELISA procedure we coated plates for
2 h with optimized capture antibody concentration of 1.0, 1.0, 0.5, 0.5 and
1.0 µg/mL for CXCL4, CCL5, CCL18, CCL2 and CXCL10, respectively. Un-
bound antibodies were washed with five steps phosphate-buffered saline
(PBS)/0.5%Tween. Plasma samples were diluted 1/80 for CXCL4, 1/10 for
CCL5 and 1/4 for CCL18, CCL2 and CXCL10 and then added to the plate
with the corresponding capture antibody. Each plate contained four cali-
bration curves consisting of standard plasma sample with known CXCL4,
CCL5, CCL18, CCL2 and CXCL10 concentrations. Dilutions were made in
PBS/1% BSA and incubated for 2 h on the capture antibodies. Unbound
antigens were removed with five wash steps with PBS/0.5% Tween. For
CXCL4, CCL5, CCL18, CCL2 and CXCL10 we added optimized detection
antibody concentration of 0.25, 0.05, 1.0, 0.2 and 0.25 µg/mL, respectively.
After three washing steps with PBS/0.5% Tween, a concentration of 0.15
µg/mL streptavidin/horseradish peroxidase (HRP, M2051, Sanquin, Ams-
terdam, the Netherlands) was added for 2 h to bind the biotin on the detec-
tion antibody. After three wash steps with PBS/1% BSA, the amount bound
antigen concentrations were quantified after addition of Supersignal West
Pico Chemiluminescent Substrate (#34080, Thermoscientific, Rockford, IL)
on a Spectramax Luminescence Microplate Reader (Molecular Devices, Sun-
nyvale, CA). Plasma levels of von Willebrand factor were detected, using
the same semiautomatic procedure, using 0.78 µg/mL mouse monoclonal
directed against human vWF (A0082, Dako, Glostrup, Denmark) as cap-
ture antibody and 0.28 µg/mL HRP-conjugated rabbit polyclonal against
human vWF (P0226, Dako, Glostrup, Denmark) as detection antibody. To
guarantee independent measurements, it was decided to do all laboratory
measurements by investigators that were blinded for the disease state of the
blood samples.
proteomics To study a wide range of (unknown) proteins present in the
supernatant of pDC after two hours of incubation on RPMI 1640 medium
without additions, surface-enhanced laser desorption/ ionization–time-of-
flight mass spectrometry (SELDI-TOF-MS) was applied. The SELDI-TOF-
MS technology (Ciphergen Biosystems, Fremont, CA) consists of the pro-
tein chip array, mass spectrometer and data analysis software. Optimal con-
ditions for pDC supernatant profiling were determined by testing three
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protein chip array surfaces (Q10, CM10 and IMAC-Cu) with different bind-
ing/washing conditions and dilutions of supernatant. The binding/wash-
ing buffer for the anionic exchange arrays (Q10) contained 0.1% Triton X-100
with 0.1 M Tris–HCl (pH 8) or 0.1 M sodium acetate (pH 6) and that for the
cationic exchange arrays (CM10) contained 0.1% Triton X-100 with 0.1 mM
ammonium acetate (pH 4.5 or pH 6). Both Q10 and CM10 chips were pre-
incubated with binding buffer. The metal affinity-binding IMAC-Cu chips
were loaded with 50 μl 0.1 M copper sulfate by vigorous shaking for 10
min. After washing with water, the chip surface was neutralized using 150
μl sodium acetate buffer pH 4 followed by a short wash with water and pre-
incubation with binding buffer (0.1 M Tris–HCl, pH 7.4) containing 0.1%
Triton X-100 and 100 mM or 500 mM NaCl. pDC samples were diluted 1:10
or 1:100 in binding buffer (total volume of 100 μl) and applied at random
and in duplicate to the chip and incubated for 1 h shaking on a mixer. After-
wards, spots were washed six times with 150 μl binding buffer for 10 min
(three times with and three times without 0.1% Triton X-100). Before appli-
cation of the matrix (Sinapinic acid (SPA); Ciphergen Biosystems) in 50%
acetonitrile/0.1% trifluoroacetic acid, another short wash with HPLC-grade
water was performed and the chips were air dried for 10 min. The matrix
was applied twice (0.8 μl each time, 1 min apart) and the chips were air
dried prior to reading on a ProteinChip Reader IIC instrument (Ciphergen
Biosystems), using the following settings: detector sensitivity 9; detector
voltage 2900; positions 20–80 were read with an increment of 10; 50 laser
shots were collected on each position; two warming shots were fired at each
position; lag time focus of 241 ns; laser intensity 180. Calibration was done
with a 7–30 kDa proteins mixture. After baseline subtraction, peak label-
ing was performed with CiphergenExpress Software (version 3.0) for peaks
with a signal-to-noise (S/N) ratio ≥3 in the m/z range from 1.5 to 30 kDa,
and then normalized by total ion current.
western blot analysis of et-1 and fli-1 . Cells were collected
and washed with phosphate-buffered saline (PBS). Cell pellets were sus-
pended in lysis buffer containing 20 mM Tris-HCl, pH 7.5, 15 mM NaCl, 1
mM EDTA, 1 mM EGTA, 1% Triton X-100, 2.5 mM sodium pyrophosphate,
and 1 mM glycerophosphate with freshly added phosphatase inhibitors (5
mM sodium fluoride and 1 mM Na3VO4) and a protease inhibitor mixture
(Sigma-Aldrich, St. Louis, MO). Protein concentration was quantified using
the BCA Protein Assay kit (Pierce, Rockford, IL). Equal amounts of total
proteins per sample were separated via SDS-PAGE and transferred to ni-
trocellulose membranes (Bio-Rad, Hercules, CA). Membranes were blocked
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in milk in Tris-buffered saline with Tween 20 (TBST) overnight at 4°C and
probed with primary antibody overnight at 4°C. After Tris-buffered saline
(TBS) washes, membranes were probed with HRP-conjugated secondary an-
tibody against the appropriate species for 1–2 h at room temperature. Anti-
bodies were used as following: goat anti human ET-1 (Santa Cruz Biotech-
nology, Santa Cruz, CA) at a 1:500 dilution, mouse anti-human FLI-1 (In-
vitrogen, Carlsbad, CA) at a 1:500 dilution, monoclonal mouse anti-human
β-actin (Sigma-Aldrich, St. Louis, MO) at 1:5000 dilution. Protein levels were
visualized using ECL reagents (Amersham Biosciences, Piscataway, NJ).
Immunohistochemistry on Human Skin Sections
Skin samples from nine patients with diffuse systemic sclerosis and six
healthy controls were immediately frozen in liquid nitrogen and stored
at -80°C. For immunofluorescence analysis of the expression of BDCA2
and CXCL4, skin sections were fixed with paraformaldehyde (4%). Subse-
quently, the skin sections were incubated with 1% H2O2 in methanol for 30
min. Blocking steps were performed using donkey serum (5%). Antibodies
directed against human BDCA2 (goat polyclonal; Santa Cruz Biotechnology,
Santa Cruz, CA) as well as CXCL4 (rabbit polyclonal; Abcam, Cambridge,
UK), or corresponding isotype control antibodies were added overnight
at 4°C and followed by washes. Afterwards, the skin sections were incu-
bated with secondary antibodies (donkey anti-goat Alexa Fluor 555, don-
key anti-rabbit Alexa Fluor 488, Invitrogen, Carlsbad, CA) for 45 min as
well as DAPI (Sigma-Aldrich, St. Louis, MO) for 10 min. Sections were
fixed with Fluoromount-G (SouthernBiotech, Birmingham, AL). Immunore-
actions were detected using the Axiovert 200M microscope and visualized
by the software Axiovision 4.7 (Zeiss, Oberkochen, Germany).
Subcutaneous CXCL4 Injection Model.
animals Wild type C57BL/6 mice were purchased from Jackson Labo-
ratory (Bar Harbor, ME). All mice were maintained at the Boston University
School of Medicine Laboratory Animal Sciences Center. Mouse experiments
were conducted under a protocol approved by the Boston University, Insti-
tutional Animal Care and Use Committee and in accordance with AAALAC
guidelines.
in vivo administration of cxcl4 Recombinant murine CXCL4 (Pe-
protech, Rocky Hill, NJ) was administered subcutaneously to 6-8 week old
C57BL/6 mice using two delivery methods. For the pump model, mini-
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osmotic pumps (Alzet, Cupertino, CA) containing 1 µg of CXCL4 in a total
of 200 µl volume were subcutaneously implanted for 7 days as described
previously [4]. Each pump was designed to deliver agent at the rate of 1
µl per hour over 7 days. For the daily subcutaneous injection model, 500
ng of CXCL4 in 100 µl PBS with 0.05% mouse albumin (Alpha Diagnostic,
San Antonio, TX) was injected subcutaneously for 7 or 28 consecutive days.
At the designated time point, mice were sacrificed and the skin (~1 cm2)
surrounding or distal to the pump outlet or injection site was homogenized
in TRIzol (Invitrogen, Carlsbad, CA) for total RNA preparation, or fixed in
formalin for histology.
mouse skin histology and cd45 immunohistochemistry
Mouse skin was fixed in acetic acid–zinc-formalin (Newcomersupply, Mid-
dleton, WI), embedded in paraffin, and sectioned at 4 μm. To visualize skin
morphology, deparaffinized sections were stained with hematoxylin for 2 x
2 min and eosin for 2 min (Surgipath, Leica, Richmond, IL), and mounted.
For immune cells identification, CD45 immunohistochemical staining was
performed using the ABC Vectastain kit (Vector Laboratories, Burlingame,
CA). In brief, deparaffinized sections were rehydrated, steamer-heated for
20 min in BD Retrievagen A (BD Biosciences, San Jose, CA), incubated with
Fc receptor blocker, background buster (Innovex Biosciences, Richmond,
CA), and ABC blocking serum (Vector Laboratories, Burlingame, CA), and
stained with rat-anti mouse CD45 as primary antibody (BD Biosciences, San
Jose, CA). The subsequent incubations with secondary antibody, ABC com-
plex (Vector Laboratories, Burlingame, CA), and DAB as a substrate (Dako
Corp, Carpinteria, CA) were then performed according to manufacturer’s
instructions. Images were acquired using a bright field microscope at 4x
or 20x magnification (BH2 and BX41 Olympus, Center Valley, PA). Skin
layer thickness and cell count were measured using ImageJ software (NIH,
Bethesda, MA).
RNA Preparation and Quantitative PCR (qPCR)
Total RNA was extracted and purified from cells using RNeasy kit
or from mouse skin using TRIzol (Invitrogen, Carlsbad, CA). cDNAs
were developed from 200-300 ng of total RNA using Superscript II re-
verse transcriptase and random primers (Invitrogen Life Technologies,
Rockville, MD). TaqMan primers for human CXCL4 (HS00236998_m1),
human 18s rRNA (4314913E), mouse glyceraldehyde-3-phosphate dehy-
drogenase (GAPDH, 4352339E), mouse Ccl2 (Mm00441242_m1), mouse
Tnf-α (Mm00443259_g1), mouse Ifit1 (Mm00515153_m1), mouse Mx2
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(Mm00488995_m1), mouse Serpine1/PAI-1 (Mm00435858_m1), mouse
Thbs1 (Mm01335418_m1), mouse Cd45 (Mm01293575_m1), mouse Icam-
1 (Mm00516024_g1), mouse Edn1 (Mm00438656_m1) were purchased
from ABI (Applied BioSystems Inc., Foster City, CA). SYBR green
primer sets were mouse E-selectin 5’-tcctctggagagtggagtgc-3’ (forward) 5’-
ggtgggtcaaagcttcacat-3’ (reverse), human Fli-1 5’-ggatggcaaggaactgtgtaa-
3’ (forward) 5’-ggttgtataggccagcag-3’ (reverse), human Et-1 5’-gctcgtccc-
tgatggataaa-3’ (forward) 5’-ccatacggaacaacgtgct-3’ (reverse), and human
GAPDH 5’-ggtctcctctgacttcaaca-3’ (forward) 5’-agccaaattcgttgtcatac-3’ (re-
verse). Relative quantification of gene expression using TaqMan Master Mix
or SYBR green chemistry was measured in ABI StepOnePlus system. Gene
expression was normalized to housekeeping genes 18s ribosomal RNA,
GAPDH, or β2-MG and relative expression of each gene was calculated
using a ΔΔCt formula [5].
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Supplementary Tables
N 109
Gender (female/male) 93/16
Age (years; mean ± SD) 45.8 ± 14.1
Disease duration (years; mean ± SD) 12.9 ± 10.4
Anti-dsDNA (Farr, E/ml; mean ± SD) 50.0 ± 145.9
Complement C3 (gr/l; mean ± SD) 0.97 ± 0.23
Complement C4 (gr/l; mean ± SD) 0.17 ± 0.08
ACR criteria# (N, (%))
Malar rash 35 (32)
Discoid rash 37 (34)
Photosensitivity 49 (45)
Oral ulcers 8 (7)
Arthritis 71 (66)
Serositis 39 (36)
Renal disorder 40 (37)
Neurologic disorder 5 (5)
Hematologic disorder 75 (69)
Immunologic disorder 84 (78)
Antinuclear antibody 106 (98)
# American College of Rheumatology
Supplementary Table 2.2 – Disease Characteristics Patients with Systemic
Lupus Erythematosus.
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N 93
Gender (% female) 73.4%
Age (years; mean ± SD) 44.9 ± 14.1
Disease duration (years; mean ± SD) 22.2 ± 17.3
HLA-B27 positive (%) 86%
Erythrocyte sedimentation rate (mm/hour) 29.7 ± 22.3
C-reactive protein 1.3 ± 1.2
BASDAI# 3.8 ± 2.5
TNFα neutralizing therapies (% usage) 28.1
# Bath Ankylosing Spondylitis activity index
Supplementary Table 2.3 – Disease Characteristics of Ankylosing Spondyli-
tis Patients.
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Cohorts
Controls
(n)
CXCL4
(pg/ml)
SSc
Patients
(n)
CXCL4
(pg/ml)
Identification
Cohort
(plasmacytoid
dendritic cells)
20 374.9 ± 45 53 66203 ± 3133
Identification
Cohort (plasma)
22 90.4 ± 22 46 25143 ± 2533
Replication
Cohorts (plasma)
129 92.6 ± 11 612# 23548 ± 2213
Early Disease
(plasma)*
128 101.4 ± 23 68 28781 ± 3211
Overall Mean 299 94.8 ± 18.7 779 25624 ± 2652
# 612 systemic sclerosis (SSc) patients are from University of Nijmegen,
the Netherlands (n=148), Lund, Sweden (n=197), Milan, Italy (n=120),
Verona, Italy (n=18), Ghent, Belgium (n=79), and Houston, TX (n=50).
*Early disease patients are from Milan (independent to those in the
replication cohort).
Supplementary Table 2.4 – Mean CXCL4 Values in Cohorts.
56 cxcl4 as a biomarker in ssc
Supplementary Figures
Supplementary Figure 2.5 – Panel A: Flow Cytometry in Plasmacytoid Den-
dritic Cells in Systemic Sclerosis
Panel A depicts plasmacytoid dendritic cells from healthy donors, patients with
limited cutaneous Systemic sclerosis (lcSSc), late diffuse cutaneous Systemic scle-
rosis (ldSSc) and early diffuse cutaneous systemic sclerosis (edSSc) patients show
similar expression of the markers BDCA4, BDCA2 and CD123. Expression of these
markers was tested in 6 independent experiments comprising a total of 16 systemic
sclerosis patients and 11 healthy controls. This panel depicts one representative
experiment. Throughout all experiments purity was > 96%.
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Supplementary Figure 2.5 – (Continued) Panel B-G: Cytokine Production
by Freshly Isolated Plasmacytoid Dendritic Cells from Healthy Controls
and Systemic Sclerosis Patients.
Panel B and C represent the production of IL-8, TNFα, MCP-1, MIP1β, IFNγ,
and IFNα by plasmacytoid dendritic cells from healthy individuals or systemic scle-
rosis patients after two and twenty-four hours of incubation, respectively. Panel
D and E show the secretion of the Th2 markers IL-10, IL-5 and IL-13 whereas
Panel F and G show the secretion of IL-6, IL-1β, IL-12, IL23, IL-17F and IL-17A
by plasmacytoid dendritic cells cultured from healthy controls or systemic sclerosis
patients after the indicated time points.
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Supplementary Figure 2.5
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Supplementary Figure 2.5 – (Continued) Panel H-K: Plasmacytoid Den-
dritic Cells from Systemic Sclerosis Patients Preferentially Secrete CXCL4.
Panel H displays the full proteome profile beyond 20kD from the supernatant of
plasmacytoid dendritic cells from one representative systemic sclerosis patients with
early diffuse disease. As in other experiments, no other peaks were present beyond
20kD. Panel I depicts CXCL4 RNA expression in various cell subsets isolated
from healthy controls (n=12) and patients with limited (lSSc, n=14), late diffuse
(ldSSc, n=14), early diffuse systemic sclerosis (edSSc, n=14) from 7 independent
experiments. * indicates P – values < 0.001. Intracellular expression of CXCL4 in
plasmacytoid dendritic cells is shown in Panel J. Panel K represents separate and
overlayed images of isotype controls for plasmacytoid dendritic cell marker BDCA2
(green), CXCL4 (red) and DAPI-labeled nuclei (blue), on a frozen skin section.
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Supplementary Figure 2.6
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Supplementary Figure 2.6 – CXCL4, CCL2 and CXCL10 levels Are Increased
in The Circulation of Systemic Sclerosis Patients and Only CXCL4 Corre-
lates with Scleroderma Risk Unassociated with Platelet Activation.
Panel A displays the absence of β-thromboglobulin (β-TG) in the plasmacytoid
dendritic cells supernatant that excludes platelet contamination (n=119) and in-
creased levels of β-TG in the circulation of Systemic sclerosis patients compared to
healthy controls. However, β-TG levels do not mirror CXCL4 plasma levels indicat-
ing that the CXCL4 in the circulation of systemic sclerosis patients is mainly com-
ing from plasmacytoid dendritic cells. CXCL4 levels in systemic sclerosis patients
(n=441) by far exceed those of chemokines previously suggested to be associated
with systemic sclerosis phenotype (Panel B) and those observed in healthy donors
(n=128). Panel C represents the circulating levels of CXCL4, CCL2, CXLC10,
CCL5, vWF and CCL18 in scleroderma patients, healthy donors (C, n=128) and
in comparison with individuals with primary Raynaud’s phenomenon (R, n=16),
persons with Raynaud’s phenomenon and antinuclear antibodies (R+, n=10) and
those with very early systemic sclerosis (veSSc, n=30). * indicates P – values <
0.001.Panel D shows that in a prospective cohort of 79 patients followed over 18
months, only a high baseline of CXCL4, but not, CCL2, CXLC10, CCL5, vWF and
CCL18, predicted a worse outcome both of lung function (capacity of the lung for
carbon monoxide (DLCO)) as well as for skin progression (modified Rodnan skin
score (mRSS)).
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Supplementary Figure 2.7
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Supplementary Figure 2.7 – CXCL4 Induces Systemic Sclerosis-like Effects
in Subcutaneous Pump and in Subcutaneous Injection Models.
Panel A shows gene expression of wildtype-C57BL/6 mice treated with CXCL4
or phosphatebuffered saline (PBS) control for 7 days using the subcutaneous im-
planted pump model. Skin area located distally or locally to the pump outlet was
isolated and mRNA expression for CCL2, TNF-α, IFIT1, MX2, PAI-1 and Thbs
induced by CXCL4 were evaluated using qPCR as compared to the PBS controls
(PBS local n=4, CXCL4 local n=7). Panel B displays that based on mRNA expres-
sion of CCL2, IFIT1, and MX2, the presence of 0.05% mouse albumin in PBS as an
additional unrelated control protein in a 7-day daily subcutaneous injection model
did not lead to any noticeable differences (PBS n=3, PBS 0.05% albumin n=2,
CXCL4 0.05% albumin n=3). Panel C shows that using qPCR, mRNA expres-
sion of the endothelial cell activation markers Eselectin, ICAM1 and Endothelin-1
after 7 day treatment of CXCL4 in a pump model were comparable to the PBS
controls (PBS local n=4, CXCL4 local n=7).Panel D depicts skin histology from
wild-type C57BL/6 mice treated with PBS control (top) or CXCL4 (bottom) for 28
days using daily subcutaneous injection model at 4x magnification (H&E). Panel
E shows quantification of skin layers thickening after CXCL4 treatment for 28 days
(n=5/group), as compared to the PBS controls (* P < 0.05, ** P < 0.01). The ex-
pression of pro-inflammatory marker CCL2 induced by CXCL4 after 28 day daily
injection (n=5/group), compared to PBS, was measured using qPCR as depicted in
Panel F.
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68 proteomic analysis identifies s100a8/a9
Background: Systemic sclerosis (SSc) is an autoimmune disease characterized
by fibrosis of the skin and the internal organs. Except for anticentromere
and anti-topoisomerase I antibodies there are no reliable circulating markers
predicting SSc susceptibility and/or prognosis. This study has exploited a
proteome-wide profiling method with the aim to identify new markers to
identify SSc or its phenotype.
Methods: 40 SSc patients were included for proteomic identification. Patients
were stratified as having diffuse cutaneous SSc (dcSSc) (n= 19) or limited
cutaneous SSc (lcSSc) (n=21) according to the extent of skin involvement. As
controls 19 healthy donors were included. Blood was drawn and plasma was
stored before analyzing with the SELDI-TOF-MS. For replication the cohort
was extended with 50 SSc patients.
Results: Proteomic analysis revealed a list of 25 masspeaks that were differen-
tially expressed between SSc patients and healthy controls. One of the peaks
was suggestive for S100A8, a masspeak we previously found in supernatant
of plasmacytoid dendritic cells from SSc patients. Increased expression of
S100A8/A9 in SSc patients was confirmed in replication cohort compared
to controls. Intriguingly, S100A8/A9 was highest in patients with limited
cutaneous SSc having lungfbrosis.
Conclusions: S100A8/A9 was robustly found to be elevated in the circulation
of SSc patients suggesting its use as a biomarker for SSc lung disease and the
need to further explore the role of TLR in SSc.
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3.1 introduction
Systemic sclerosis (SSc) is a complex autoimmune disease characterized by
extensive fibrosis of the skin and the internal organs, leading to severe debil-
itation and premature death. Usually, SSc clinical phenotype are subdivided
into limited cutaneous SSc (lcSSc) and diffuse cutaneous SSc (dcSSc).[1]
Currently, there is no effective therapy that halts the progression of fibrosis.
In addition, the development of effective therapies is severely hampered
due to a lack of knowledge on the disease pathogenesis and/or absence of
biomarkers that identify those patients at risk for complications.
Over the past decade, techniques to identify biomarkers for early recog-
nition of disease, prognosis and/or therapy responses have dramatically
improved. To our knowledge, hitherto these techniques were not widely ap-
plied to patients with SSc. One potential technique to find biomarkers is to
measure the circulation proteome. The proteome represents the net result
of interactions between genetic background and environmental factors and
may be considered as the signature of the disease, hereby circumventing
the limitations of RNA transcriptional profiling. Past studies were not able
to identify a single protein capable of discriminating between controls and
patients, illustrating the complex protein network responsible for a disease
phenotype.[2] By harnessing the surface-enhanced laser desorption ioniza-
tion time-of-flight mass spectrometer (SELDI-TOF-MS) we aimed for the
identification of proteins differentially expressed between SSc patients and
their healthy counterparts. In addition, we aimed to identify proteins able
to distinguish clinical SSc phenotypes.
3.2 methods
Patient inclusion
Blood samples were prospectively collected from 21 lcSSc patients, 19 dcSSc
patients and 19 healthy controls for proteomics and 60 additional samples
were used for replication. The local ethics committee from the RUNMC ap-
proved the study protocol. Venous blood was collected in a 10 ml lithium-
heparin Vacutainer (BD). The samples rested for 10 min at room tempera-
ture and were then centrifuged at 3000 rpm for 10 min. All samples were
aliquoted and immediately frozen at -80 C until further use. Patient’s char-
acteristics are summarized in table 3.1. All patients fulfilled the American
College of Rheumatology criteria for SSc.[3] Patients were subdivided in
limited or diffuse SSc on the basis of the extent of skin involvement as
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Controls lcSSc dcSSc
n=19 n=67 n=33
Age (SD) 37(12) 59(13) 53(14)
Female % 73 85 60
Disease duration - 10.8 (7.6) 6.7 (4.1)
ANA % - 97 91
ATA % - 25 20
ACA % - 39 3
Lungfibrosis - 42 52
PAH - 18 6
Table 3.1 – Patient characteristics of all included patients. SD = standard de-
viation. ANA = antinuclear antibodies, ATA = anti-topoisomerase antibodies, ACA
= anti-centromere antibodies. Lungfibrosis is defined as significant bilateral fibrosis
on HRCT. PAH = pulmonary artery hypertension defined as a mean pulmonary
artery pressure above 25 mmHg in the presence of normal wedge pressure.
described by LeRoy et al.[1] Pulmonary arterial hypertension (PAH) was
defined as mean pulmonary artery pressure above 25 mmHg confirmed by
right heart catherization in the presence of a normal wedge pressure. In-
terstitial Lung Disease (ILD) was defined as significant bilateral fibrosis on
high resolution computed tomography scan.
SELDITOF-MS
Plasma samples were fractionated before protein profiling with a strong
anion exchange Q ceramic resin (Bio-Rad Labs, Hercules, CA, USA) ac-
cording to manufacturers’ protocol,[4] which resulted in six fractions. The
SELDI-TOF-MS technology (Ciphergen Biosystems, Fremont, USA) consists
of the protein chip array, mass spectrometer and data analysis software.
The analyses were performed at a Ciphergen ProteinChip array system us-
ing IMAC ProteinChip arrays with copper surface (IMAC-Cu). The metal
affinity-binding IMAC-Cu chips were loaded with 50 μl 0.1 M copper sul-
phate by vigorous shaking for 10 min. Calibration was done with a 7–30
kDa proteins mixture. After baseline subtraction, peak labelling was per-
formed with CiphergenExpress Software (version 3.0) for peaks with a
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signal-to-noise (S/N) ratio ≥3 in the m/z range from 1.5 to 30 kDa, and
then normalized by total ion current.
S100A8/A9 measurement by ELISA.
Supernatant from plasmacytoid dendritic cells (pDC) was retrieved from
cultures as described previously (Chapter 2). Concentrations of S100A8 and
S100A9 in serum and supernatant were determined by a sandwich enzyme-
linked immunosorbent assay (ELISA) system established as described pre-
viously.[5 6] S100A8 and S100A9 form noncovalently associated complexes
in the presence of extracellular calcium concentrations, which are detected
by our ELISA system.[6] We therefore calibrated our ELISA with the na-
tive S100A8/A9 complex, and the data are expressed as ng/ml S100A8/A9.
For comparison with earlier studies, internal control sera were used as a
reference in all ELISA studies.[5-7]
Statistical analysis for proteomics
Data analysis was performed using the software GenePattern for statistics
and hierarchical clustering.[8] For comparisons a T test was used and ad-
justed P values were calculated using exhaustive permutation, when possi-
ble, or 100.000 fold permutation when software limits were reached. Hier-
archical clustering was performed based on Pearson correlation coefficients.
Identifying M/Z scores The program TagIdent was used to suggest candi-
date proteins corresponding to the M/Z scores (<explanation>) from the
heatmaps by performing a query on the molecular weight (+/- 1%) of each
protein.[9] The scan in UniProtKB/Swiss-Prot was restricted by organism
name “homo sapiens”, and the use of the keyword “secreted”, referring to
the cellular component of the protein.
Gene Ontology
Gene Ontology was performed on the predicted protein lists using the
Functional Annotation tool of the Database for Annotation, Visualization
and Integrated Discovery (DAVID) v6.7. A functional annotation chart
was generated based on the terms GOTERM_BP_FAT, GOTERM_CC_FAT,
GOTERM_MF_FAT selected within the category of gene ontology, BBID,
BIOCARTA, KEGG pathway, REACTOME pathway.selected within the cate-
gory of pathways, INTERPRO, PANTHER family, PIR superfamily, SMART
selected within the category of Protein domains; Bind, Reactome interac-
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tion, ucsc tfbs selected within the category of Protein interactions; and run
using the following options Threshold: Count 2; EASE 0,1 and Display: Fold
Enrichment; Bonferroni.[10]
Statistical analysis for replication
Plasma S100A9/A9 levels are shown throughout the paper as mean ± SEM.
Differences were considered significant for p<0.05. Students T-test was used
based on the normal distribution of the data. All statistical analyses were
performed using Graphpad Prism (GraphPad Prism 4.0 by Graph Pad soft-
ware, La Jolla, California, USA).
3.3 results
SELDI-TOF MS analysis reveals 25 candidate proteins that distinguish SSc from
healthy controls.
By CART analysis of the 25 mass peaks being the most differentially ex-
pressed between healthy controls and SSc patients we were able to predict
SSc accurately in 88% of the SSc patients and predicted 74% of the healthy
controls correctly in the overall dataset (Table 3.2, Figure 3.1A). Although
we found proteins significantly differentially expressed at mean between
lcSSc, dcSSc and healthy controls, these did not reach an optimal treshold
>65% in receiver operator curves and were therefore considered not able to
predict SSc clinical subtypes consistently . Interestingly the masspeak 10866
showed a quite similar pattern to 10569 and was siginificantly increased in
lcSSc compared to HC specifically (AUC=0.76). Both masspeaks are close
to the known weight of S100A8.
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Peak pH
frac-
tion
putative candidate proteins p-value
after per-
mutation
Fold
Change
9124.8 org IL-8 p<0.001 2.164
9128.9 7 CXCL7 p<0.001 5.395
4801 5 Cathepsin family p<0.001 4.023
7869.2 9 Platelet factor 4 variant, CCL4, CCL5,
CXCL2
p=0.001 2.119
9093.8 5 Beta defensin 116 p=0.002 2.878
3111.1 org Atrial Naturetic Factor p=0.002 2.28
4371.4 org TNFa p=0.002 2.248
2771.1 9 Hepsidin-25 p<0.001 15.649
2769.4 7 Hepsidin-25 p<0.001 18.66
2769.4 7 Hepsidin-25 p<0.001 18.66
3726.5 org Neutrophil Defensin 4 p=0.003 2.474
4639.5 org Apoptosis regulator BAX p=0.003 1.747
1263.9 9 Chymotryptin family p=0.003 2.177
8768.6 3 Apolipoproteine CIII p=0.004 2.869
1239 9 Chymotryptin family, minor HC
antigen HB-1
p=0.004 2.545
22811 7 complement C1q p=0.005 1.542
3598.8 org Neutrophil Defensin 5 p=0.005 3.137
3502.3 9 Neutrophil Defensin 3 p=0.005 2.531
4147 3 Pancreatic prohormone p=0.006 3.694
4543 9 PENK-A p=0.006 4.002
7647.1 org Platelet factor 4 variant, IGF1 p=0.006 2.201
10569 9 S100A8 S100A9 and other members
S100 family
p=0.007 4.061
8363.5 9 IL8 p=0.007 5.802
4663.2 7 Apoptosis regulator BAX p=0.008 1.643
9526.8 7 Interferon alpha-inducible protein 27-
like protein 1
p=0.009 1.574
4481.1 org Beta defensin 133, LL37 p=0.01 1.628
Table 3.2 – PDifferentially expressed protein peaks between healthy con-
trols and SSc patients.
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Figure 3.1
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Figure 3.1 – Panel A. Twenty-five protein peaks significantly differentially ex-
pressed between SSc patients and healthy controls. Peaks are clustered based on un-
supervised hierarchical clustering by spearman correlation. Panel B. S100A8/A9
levels in supernatant from pDC from 14 HC, 7 lcSSc and 19 dcSSc patients were
increased in lcSSc compared to HC and dcSSc (p<0.0001). Panel C. Serum levels
of S100A8/A9 from 61 lcSSc patients and 30 dcSSc patients showed an increased
level in patients compared to the known upper cut-off of healthy controls (450) and
an significant increase of S100A8/A9 in lcSSc with lungfibrosis compared to lcSSc
without (p=0.008) and in anti-topoisomerase (ATA) positive patients (p=0.004).
Validation of S100A8/A9 as a biomarker for SSc and its clinical phenotypes
We previously identified a masspeak suggestive for S100A8 in the SELDI-
TOF-MS analyses of plasmacytoid dendritic cell (pDC) supernatant (see
Chapter 2) and now we found a peak suggestive for S100A8 in plasma.
Therefore we aimed at validation of the potentially increased expression
of S100A8/A9 in the supernatant of pDCs from 28 SSc patients and in
the circulation of 91 SSc patients by ELISA. In pDC supernatant from lc-
SSc S100A8/A9 is specifically increased (145,4 ± 30,5 vs 35,4 ± 8,7 (HC)
p= 0.0003 and vs 32.2 ± 5.8 (dcSSc) p<0.0001) (Figure 3.1B). There was
no increment of S100A8/A9 levels in dcSSc pDC supernatant. S100A8/A9
was markedly higher in plasma of SSc patients (530 ± 32) compared to
the known cut-off level of 450 in healthy controls (mean + 2SD).[11] In
line with the observations using SELDI-TOF, S100A8/A9 were not discrim-
inative between lcSSc (529 ± 41) and dcSSc (532 ± 54) patients. Further
analysis revealed that S100A8/A9 levels are specifically increased in lcSSc
patients with lung fibrosis compared to those without (642 ± 80 vs 426 ± 27;
P = 0.008). In patients with dcSSc S100A8/A9 levels were similar in those
with or without lung fibrosis. Patients with anti-topoisomerase I antibodies
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(ATA) show higher S100A8 levels than those being ATA negative unrelated
to their disease subtype (676 ± 70 vs 470 ± 34; P = 0.004) (Figure 3.1C). Other
clinical features were not correlated with S100A8/A9 levels.
3.4 discussion
Beside the lack of effective therapy, the current biggest unmet need in clin-
ical care for patients with systemic sclerosis is the absence of biomarkers
predicting disease course and/or treatment response. Given the potential
complex circuitry that leads to SSc itself or its heterogenic disease course
we chose to harness and non-hypothesis driven approach to identify robust
biomarkers for SSc disease clinical phenotype. Using two different meth-
ods we robustly replicated S100A8/A9 as a molecule that is significantly
increased in SSc patients and associated with lung fibrosis in those patients
with lcSSc.
As S100A8/A9 is considered as an endogenous ligand for TLR4, the role
of TLRs in SSc and/or fibrosis is further substantiated by our data. TLR4
signaling in SSc patients was previously shown to induce transforming
growth factor ß responses in SSc tissues and cytokine by dendritic cells from
SSc patients in a higher magnitude compared to that observed in healthy
donors.[12 13] Moreover, whereas TLR4 signaling was able to induce fibrob-
last proliferation and pulmonary fibrosis,[14] inhibiting this pathway inhib-
ited lung fibrosis induced by lipopolysaccheride.[15] These observations
advocate a role of TLR4 signaling in SSc and are in line with the observa-
tion that S100A8/A9 levels are increased in SSc and correlate with lung
fibrosis in patients with lcSSc. The discrepancy between the correlation in
patients with lcSSc vs. dcSSc is however remarkable. Especially in the light
of the recent publication showing S100A8/A9 being increased mainly in
the dcSSc population, possible explained by the known differences between
Asian and Caucasian populations.[16] This study also showed a clear cor-
relation with lung fibrosis as was previously suggested by Hesselstrand et
al. on broncho-alvealar lavage fluid in SSc.[17] Perhaps this suggests that
the etiopathogenesis of lung fibrosis in patients with lcSSc is different from
that in patients with the diffuse clinical phenotype in different cohorts. The
contribution of anti-topoisomerase I antibodies to the development of skin
and lungfibrosis as suggested by Yoshizaki et al,[18] could partly explain
these differences as it is correlated to S100A8/A9 levels. As potent type I
Interferon producing cells pDC gained interest in diseases like systemic lu-
pus erythomatosous and SSc. A recent publication showed their capability
of producing S100A8/A9.[19] Furthermore their activation by ATA is sug-
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gested before by Eloranta et al.[20] These data show that pDCs might play
different role in different disease subtypes of SSc and different phases of the
disease. In ATA positive lcSSc patients activation of pDC could play a part
on the way towards lung fibrosis, an important complication and therefore
an important hypothesis to pursue in further research.
Besides S100A8/A9, other candidate molecules such as the CXCL4 fam-
ily found to be differentially expressed are of interest. CXCL4 was recently
identified as a novel biomarker for SSc skin- and lung fibrosis (Chapter
2) and correlated well with S100A8/A9 (see supplementary Figure 3.2).
Whether S100A8/A9 is an additional biomarker useful for early detection
of SSc risk remains to be investigated in bigger studies. Similarly, the ob-
servation that IL-8 (as shown before [21]) and other inflammatory markers
such as TNFα, hepcidin 25 and complement C1q are likely to be highly ex-
pressed in the circulation of SSc patients warrants further investigation as
these molecules have been found to be implicated in a plethora of chronic
inflammatory diseases. Further studies need to resolve whether a combi-
nation of these candidate molecules even further increase the potential to
discriminate SSc phenotypes.
In conclusion, S100A8/A9 levels were increased in SSc patients and es-
pecially in lcSSc with lung fibrosis. This implies a role for S100A8/A9 as a
biomarker for SSc lung fibrosis as well as a role for TLRs in this disease.
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Supplementary Figure
Supplementary Figure 3.2 – CXCL4 correlated well with S100A8/A9 in the
47 SSc patients in which we performed both measurements.
CXCL4 was measured in these patients as described in reference [6]: Pear-
son r 0.53, r2 0.28, p=0.001.
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Background: Although reported in definite SSc, the presence of an IFN
signature in the episode preceding definite SSc has not been characterised so
far.
Methods: The expression of eleven IFN type I inducible genes was tested in
whole blood samples from 30 healthy controls (HC), 12 subjects with primary
Raynaud’s phenomenon (RP), 19 early SSc (eaSSc) patients, 7 definite SSc
patients without fibrosis (ncSSc), 21 lcSSc and 10 dcSSc subjects. The
correlation between IFN activity in monocytes, B cell activating factor (BAFF)
mRNA expression and type III procollagen N-terminal propeptide (PIIINP)
serum levels was tested.
Results: In all patient groups studied, higher IFN scores were observed
compared to HC. A IFN score ≥7.09 discriminated HC from SSc patients
(sensitivity=0.7, specificity=0.88, AUROC=0.82); the prevalence of an
elevated IFN score was: HC=3.3%; RP=33.3%, eaSSc=78.9%, definite
SSc=100%, lcSSc=42.9%, dcSSc=70.0%. In monocytes an IFN score ≥4,12
distinguished HC from fibrotic SSc patients (sensitivity=0.62, specificity=0.85,
AUROC=0.76). Compared to IFN-negative subjects, IFN-positive subjects had
higher monocyte BAFF mRNA levels (19.7±5.2 vs 15.20±4.0„ p=2.1*10-5)
and serum PIIINP levels (median = 6.0 [IQR, 5.4 – 8.9] vs median = 3.9
[IQR, 3.3 – 4.7], p=0.0004).
Conclusions: An IFN type I signature is observed in SSc patients from the
earliest phases of the disease, even before overt skin fibrosis. The presence of
IFN type I signature in monocytes is correlated with BAFF mRNA expression
and serum PIIINP levels, supporting a contribution in the pathogenesis and
progression of SSc.
4.1 introduction 83
4.1 introduction
Systemic sclerosis (SSc) is a complex autoimmune disease with extensive
fibrosis, vascular alterations and immune activation among its principal fea-
tures [1]. With an incidence of 1-2 per 100.000 it is a rare disease in which
chronic oxidative stress and inflammation lead to organ failure ending up
in severe fibrosis of skin and internal organs. Ultimately, these disease hall-
marks culminate in profound decline in the quality of life and premature
death. Raynaud phenomenon (RP) is the first manifestation of SSc in 95%
of cases and can precede the onset of SSc by years. The presence of RP, spe-
cific autoantibodies and typical features at the nailfold videocapillaroscopy
(NVC) in absence of any other additional clinical or laboratory features,
allows to identify a specific group of patients termed early SSc patients
(eaSSc) [2], who are considered to have a high chance to develop SSc [3].
The American College of Rheumatology (ACR) / European League Against
Rheumatism (EULAR) Scleroderma Classification Criteria Committee pro-
posed new criteria to identify definite SSc patients even when overt skin
or lung fibrosis may not be present (4). It is now clear that in most cases,
the natural history of SSc can be viewed as a continuum where the disease
develops from RP, to a very early disease stage where only NVC and/or
autoantibody alterations are present (eaSSc), to a state where the first def-
inite SSc manifestation can be observed and eventually progress to a full
blown disease with cutaneous and visceral fibrotic features. It is currently
unknown to what extent the different stages of the disease differ from each
other in terms of immunological abnormalities. Yet, focussing on the study
of early disease stages could provide new prognostic tools and therapeu-
tic windows of opportunity to prevent the onset of fibrosis and end-stage
organ failure.
Potential candidates for the understanding of the immunological prop-
erties of SSc in its early stages are type I interferons. Studies on genetic
risk factors for SSc revealed genes involved in the interferon (IFN) type I
signalling pathway such as STAT4 and IRF5 [4-7]. Furthermore, a substan-
tial part of SSc patients displays IFN type I activation either in the affected
skin or in immune cells isolated from the circulation [8-10]. Clinically, the
expression of the IFN type I induced genes Siglec-1 (CD169) and IFI44 in
skin biopsies correlated with modified Rodnan Skin Score (mRSS), currently
the only available disease progression marker [11]. It is widely accepted
that plasmacytoid dendritic cells (pDCs) are the main source of IFN type
I. Upon activation of toll-like receptors (TLRs) by so-called danger signals,
pDCs start to secrete marked amounts of IFN type I. In SSc it was recently
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shown that pDCs produce increased levels of type I IFN after TLR9 stimula-
tion[12]. This IFN type I release is reflected by the IFN type I induced gene
expression pattern, the IFN type I signature, observed in multiple systemic
autoimmune diseases [13 14].
One of the most important cell types affected by IFN type I are mono-
cytes. Monocytes stimulated by IFN type I differentiate into activated DCs
and macrophages and in combination with other triggers, direct the im-
mune system into potentially harmful conditions like autoimmune diseases.
Previously we found a monocyte IFN type I signature in 55% of primary
Sjögren’s syndrome (pSS) patients compared to 4.5% of healthy controls
(HC) [15]. One of the genes that strongly correlated with the presence of
the IFN type I signature was B cell activating factor of the tumor necrosis
factor family (BAFF) [15]. Interestingly, BAFF serum levels were found to
correlate with the extent of skin fibrosis in SSc patients [16].
All considered, disentangling the IFN type I activity in different phases
of disease and its role in the pathogenesis of SSc is highly justified. In this
study we analysed for the first time the prevalence of the IFN type I signa-
ture in individuals with primary RP and eaSSc next to definite SSc patients.
We then further investigated the presence of the IFN type I signature in
monocytes from two independent cohorts of limited and diffuse SSc pa-
tients, focussing on assessing the relation between IFN type I and other
important parameters of SSc pathogenesis such as BAFF expression and
collagen synthesis.
4.2 patients and methods
Patient collection
A two-stage study was conducted; as a first step, whole-blood analysis was
conducted on healthy controls (HCs) and SSc patients at different disease
stages and without clinical fibrotic features; as a second step, monocytes
isolated from a different cohort were used from HCs and SSc patients with
overt skin fibrosis.
For whole blood analysis subjects were enrolled at the Referral Center for
Systemic Autoimmune Diseases, Fondazione IRCCS Ca’ Granda Ospedale
Maggiore Policlinico di Milano, Milan, Italy. Overall, 12 subjects with pri-
mary Raynaud’s phenomenon (RP), 19 early SSc (eaSSc) patients following
the LeRoy and Medsger criteria [2] and 38 definite SSc patients according to
the ACR/EULAR 2013 classification criteria (4), were included. Definite SSc
patients were further subdivided based on the extent of skin involvement
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(18) into the limited SSc (lcSSc) (n=21), diffuse SSc (dcSSc) (n=10) and SSc
without cutaneous involvement (ncSSc) (n=7) subsets. Thirty age and sex-
matched HCs were also included; characteristics from patients and controls
are summarized in Table 4.1.
For monocyte cells analysis, 58 definite SSc patients with fibrotic skin
features were considered. Of those, 28 SSc referred to the department of
Rheumatology, Radboud University Nijmegen Medical Center (RUNMC),
the Netherlands and 30 SSc patients to the department of Immunology,
Erasmus Medical Center, Rotterdam, the Netherlands. As above, these pa-
tients were stratified as lcSSc (n=42) and dcSSc (n=16) [17 18].
The presence of SSc specific autoantibodies, namely anti-topoisomerase I
(ATA) and anti-centromere (ACA) and anti-RNP, was tested according to lo-
cal laboratory standards. Pulmonary fibrosis was defined as the presence of
fibrosis on high-resolution computed tomography scan (at least 5% of the
whole parenchyma) combined with a restrictive pulmonary function pat-
tern (forced vital capacity or diffusing capacity for carbon monoxide < 80%
of the predicted). Pulmonary artery hypertension was diagnosed by right
heart catheterization and considered present when the mean pulmonary
artery pressure was greater than 25 mmHg at rest in the presence of a nor-
mal wedge pressure.
As a comparator group 27 HCs were also included. Characteristics of pa-
tients and controls that underwent monocyte cells analysis are summarized
in Table 4.2. Blood samples were obtained with informed consent under
local Institutional Review Board approval.
Whole blood collection
Blood was collected in PaxGene tubes (PreAnalytix, Hombrechtikon, CH)
according to manufactures protocol and stored at -80°C. Total RNA was
purified according to manufacturers instructions using the RNA blood ex-
traction extraction kit (PreAnalytix, Hombrechtikon, CH).
Blood collection and isolation of monocytes
Blood was collected in clotting tubes for serum preparation (stored at -80°C)
and in sodium-heparin tubes for PBMC preparation as described in detail
elsewhere [19]. CD14 positive monocytes were isolated from frozen PBMCs
by magnetic cell sorting system (Miltenyi Biotec, Bergisch Gladbach, Ger-
many) according to the manufacturer’s recommendations. The purity of
monocytes was >90% (determined by morphological screening after trypan
4.2 patients and methods 87
Controls
(n=27)
SSc Limited
(n=42)
SSc Diffuse
(n=16)
Demographics
N females (%) 70 81 63
Age (years) 46.0±15 52.0±14 54.0±10
Disease duration (years) - 6.5±4.9 3.9±5.5
Rodnan skin score - 3.6±3.0 11.5±7.6
Pulmonary hypertension - 20 13
Lung fibrosis - 35 69
ANA positivity - 93 100
ACA positivity - 43 13
ATA positivity - 22 25
RNAP positivity - 5 15
Values are the mean (± SD), median (25% quartile,75% quartile), or
number (%) of patients, depending on whether the data are dichotomous
or continuous following a normal distribution or not.
Table 4.2 – Clinical and demographic characteristics of the patients in-
cluded for monocyte cell analysis
blue staining and FACS). As reported elsewhere positive versus negative
selection of immune cells did not influence gene expression profiles [20].
Total RNA was isolated from purified monocytes using RNAeasy columns
according to the manufacturer’s instructions (Qiagen, USA) and as previ-
ously described [21].
Real Time Quantitative Polymerase Chain Reaction (RQ-PCR)
The expression levels of 11 IFN type I inducible genes (IFI27, IFI44L, IFIT3,
IFITM1, SERPING1, IFIT1, IFIT2, LY6E, IFI44, XAF3 and MXA) were as-
sessed [15]. RNA was reverse-transcribed to cDNA using a High-Capacity
cDNA Reverse Transcription Kit and RQ-PCR analysis was performed us-
ing predesigned primer/probe sets (Applied Biosystems, Foster City, Cal-
ifornia, USA). For calculation of relative expression, all samples were nor-
malized against expression of the household gene ABL [22]. Fold change
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values were determined from normalized CT values using 2ΔΔCT method
(User Bulletin, Applied Biosystems, Foster City, California).
Radioimmunoassay for quantitative N-terminal propeptide III
For quantitative assessment of intact N-terminal propeptide of type III (PI-
IINP) procollagen, a Radioimmunoassay (RIA-) kit was used according to
manufacturer’s protocol (UniQ, Orion Diagnostica, Espoo, Finland); frozen
sera (stored at -80°C), collected at the time of patient-inclusion were ana-
lyzed. Measurement range: 1.0-50µg/l, detection limit: ±0.3µg/l, defined as
twice the standard deviation (SD) of the 0-binding value.
Data analysis
To reduce data complexity, the expression levels of the 11 IFN I genes were
submitted to unsupervised principal component analysis (PCA) via the IBM
SPSS 20.0 software. The subset of genes that explained the 0.95 of the total
variance of the data was assessed and a total score obtained summing the
individual IFN gene expression values was obtained and used for further
statistical considerations (see below). Given that the expression of IFN type
I inducible genes is not normally distributed, log transformations of expres-
sion values was performed and IFN scores are calculated as described for
pSS and SLE [15 23]. MeanHC and SDHC of each gene in the HC-groups
were used to standardize expression levels.
The distribution of IFN scores in the different groups was compared via
ANOVA with Tukey’s HSD post-hoc correction after verifying that data
were normally distributed via the Shapiro-Wilk test and homogenously dis-
tributed around the mean (skewness between -2.5 and 2.5). A cut-off for
the monocyte IFN to differentiate HC and SSc patients was calculated via
ROC analysis; the optimal cutoff was chosen as the one that maximized
the J statistic (Youden index). For whole blood IFN scores, having verified
that these were equally distributed between HCs and patients with primary
RP (see Results below), a cut-off was similarly calculated to differentiate be-
tween HCs and RP (class=0) and SSc (class=1) subjects. Categorized patients
were compared with clinical variables by means of Pearson’s chi square test
or Fischer exact test, in case of categorical data, or by means of Student’s
t-test, in case of continuous data; Mann-Whitney’s U test was used instead
when the normality assumption was not met. A nominal alpha level equal
to 0.05 after correction for multiple tests according to Bonferroni, was used.
Correlations among continuous variables were performed via Pearson’s r.
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Normally distributed data are presented as mean ± standard deviation (SD),
median and interquartile ranges (IQR) are used elsewhere.
4.3 results
The IFN type I signature is present at the earliest phases of the disease, even before
overt skin fibrosis
PCA sorted out 6 genes (IF127, IF144L, IFIT1, IFIT2, IFIT3 and Serping1)
that explained >95% of the total variance among the different stages of the
disease. The IFN score was significantly increased in patients in every stage
of the disease compared to HC or controls with RP. Figure 4.1 depicts the
distribution of IFN scores according to the different groups along with the
significant pairwise comparisons. The mean ± SD values for the IFN scores
were as follows: HCs, 0.406 ± 4.502; RP, 4.829 ± 10.057; eaSSc, 12.775 ± 9.969;
ncSSc, 26.365 ± 13.856; lcSSc, 9.151 ± 10.085; dcSSc, 12.04 ± 9.906.
After cutpoint analysis, a positive IFN score defined as values ≥7,09 was
able to discriminate between healthy controls and patients with a sensitiv-
ity of 0.667, a specificity of 0.881 and AUROC of 0.823. The prevalence of
subjects with positive IFN scores according to the disease status was: HC,
3.3%; RP, 33.3%; eaSSc, 78.9%; ncSSc, 100%; lcSSc, 42.9%; dcSSc, 70.0% (χ2
= 41.789, 5 degree of freedom [df], p = 6.2 * 10-8 ).
No correlation was found between IFN scores and the age at the onset of
RP, disease duration or the age at blood drain. Neither was there a correla-
tion between ATA positivity and the IFN score. In non-fibrotic SSc patients
IFN scores were higher in the 17 ACA+ patients compared to the 21 ACA-
patients (IFN scores = 20.84 ± 12.26 vs 6.24 ± 9.2; p =1.7 * 10-4 ); no dif-
ferences were observed as far as fibrotic SSc patients were concerned (IFN
scores = 8.85 ± 9.44 vs 10.86 ± 10.45 in ACA+ vs ACA- patients; p = NS).
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Figure 4.1 – Prevalence of IFN type I signature in whole blood in the ealiest
phases of disease and SSc patients
Distribution of IFN scores in HC, RP, eaSSc, ncSSc, lcSSc and dcSSc. IFN type
I positive cases are depicted in red. One-way ANOVA was performed followed by
Tukey’s HSD to perform pair wise comparisons. * represents p-values <0.05 **
represents p-values <0.01 *** represent p-values <0.001
Monocytes of fibrotic SSc patients have higher IFN type I signature than controls
PCA identified a subset of 5 genes (IFI44L, IFIT3, IFITM1, IFIT1 and MXA)
to explain 96% of the total variance of the 11 IFN type I inducible genes
within the fibrotic SSc cohort. In figure 4.2 the distribution of monocyte IFN
scores according to the different groups along with the significant pairwise
comparisons is shown. The mean ± standard deviation (SD) values for the
monocytes IFN scores were as follows: HCs, 0 ± 4.088; lcSSc, 4.993 ±6.583;
dcSSc, 7.36 ± 6.291.
After cutpoint analysis, a positive IFN score defined as values ≥4.124
was able to discriminate between patients and controls with a sensitivity of
0.621 and a specificity of 0.852 (AUROC 0.76). The prevalence of subjects
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with positive IFN scores according to the disease status was: HC, 14.8%;
lcSSc, 59.5%; dcSSc, 68.8% (χ2 = 16.91, 5 df, p = 2.1*10-4). Overall these
results confirm at the cellular level the results observed in whole blood,
where IFN type I genes are over-expressed in SSc patients and, specifically
in fibrotic SSc patients, compared to HCs.
No significant differences were observed between lcSSc and dcSSc pa-
tients or when autoantibodies or the other clinical parameters were taken
into account. Remarkably, all patients positive for anti-RNP antibodies (n=4)
had a positive IFN score, yet the number of anti-RNP positive patients was
too low to draw any relevant conclusions.
IFN type I signature is positively correlated with monocyte BAFF mRNA, PIIINP
serum levels
BAFF mRNA levels positively correlated with monocyte IFN scores (Pear-
son’s r = 0.601, p = 1.2*10-9), Figure 4.3A. Accordingly, mRNA BAFF levels
were higher in IFN type I signature positive (n=40) compared to signature
negative subjects (n=45) (19.7 ± 5.2 vs 15.205 ± 3.95, p = 2.1*10-5), Figure
4.3B. BAFF mRNA levels were found to be higher in dcSSc patients com-
pared to controls (20.022 ± 5.7 vs 15.802 ± 3.784, p = 0.022, Tukey’s HSD),
while no differences were found between dcSSc and lcSSc or HC and lcSSc
(mean mRNA BAFF levels in lcSSc = 17.265 ± 5.255).
We next investigated whether an indicator of de novo collagen type III
synthesis, namely N-terminal propeptide of type III collagen (PIIINP), is
increased in subjects positive for the IFN type I signature. PIIINP levels
positively correlated with IFN scores (Spearman’s rho = 0.573, p < 0.0001).
Subjects with positive IFN scores had higher PIIINP levels compared to
IFN-negative ones (median = 6.00 [IQR, 5.40 – 8.90] vs median = 3.90 [IQR,
3.25 – 4.70], p=0.0004), figure 4.3D. We then found increased PIIINP levels
in SSc compared with HC (median = 5.80 [IQR, 4.10 – 6.93] vs median =
3.70 [IQR, 3.20 – 4.70], p=0.0005), Figure 4.3C, but no differences between
dcSSc and lcSSc patients (median = 5.75 [IQR, 4.28 – 8.00] vs 5.80 [IQR, 4.03
– 6.95]). None of the clinical parameters did correlate with BAFF mRNA or
PIIINP serum levels.
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Figure 4.2
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Figure 4.2 – (Continued) Prevalence of IFN type I signature in monocytes of
SSc patients
Panel A: Heatmap showing gene expression of 5 IFN type I inducible genes in
monocytes of lcSSc patients (n=42), dcSSc (n=16) and HC (n=27). On the left the
HC are depicted and on the right the SSc patients are depicted and subdivided into
lcSSc and dcSSC. Red color indicates high gene expression and cases are depicted
according to ascending IFN scores. Panel B: Distribution of IFN scores in lcSSc
and dcSSc patients and HC. IFN type I positive cases are depicted in red. One-way
ANOVA was performed followed by Tukey’s HSD to perform pair wise comparisons.
*** represents p-values <0.001
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Figure 4.3 – IFN type I signature is positively correlated with BAFF mRNA
and PIIINP serum levels and faster disease development
Panel A: BAFF mRNA expression in HC (n=27), limited (n=42) and diffuse SSc
patients (n=16). Panel B: BAFF mRNA expression in IFN type I signature -
positive (n=40) and -negative subjects (n=45). Panel C: N-terminal propeptide
III (PIIINP) (μg/l) in serum from HC (n=19) and SSc patients (n=42). Panel D:
N-terminal propeptide III (PIIINP) (μg/l) in serum from subjects positive (n=14)
and negative (n=28) for IFN type I signature. IFN type I positive cases are depicted
in red. Independent T-test was used to compare means in (A-B) where horizontal
lines represent means. Mann-Whitney U test was used in (C-D) where horizontal
lines represent medians. *** represents p-values <0.001
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4.4 discussion
In rheumatic disorders one of the main challenges is to identify patients as
soon as possible to start treatment and prevent irreversible damage. Here
we show for the first time that an IFN type I signature is present in SSc
patients before overt fibrosis develops and since the earliest phases of the
disease (eaSSc). After assessing the prevalence of IFN type I signature in the
different stages of disease, we focused on testing the presence of IFN type
I activity, reflected by the presence of a monocyte IFN type I signature, and
we found it increased in approximately two third of SSc patients. Moreover,
the IFN type I signature is associated with high BAFF mRNA expression
and high serum PIIINP levels.
The prevalence of IFN type I signature is highest in eaSSc and definite
SSc patients with neither evidence of skin fibrosis nor of internal organ
involvement. This underlines the presence of inflammation and immune
modifications which can be suitable for therapeutic targeting before - and
thereby preventing - the onset of fibrosis, introducing a paradigm shift in
the handling of SSc in its earliest identifiable phase. Prospective studies to
assess the development of fibrotic features or of internal organ damage in
eaSSc or ncSSc that that have increased IFN scores without clinical evidence
of fibrosis, may further clarify the predictive capability of IFN type I signa-
ture and its role as a biomarker of disease progression. The finding that
patients with systemic lupus erythematosus and SSc share a common IFN
type I signature (26) and the promising results of a phase one trial with
sifalimumab, an anti-IFNα monoclonal antibody, may offer the promise of
an adequate therapy in the early phase of disease in a selected subgroup of
SSc patients.
In this light, the observation that IFNα is able to induce the expression of
TLR3 in SSc dermal fibroblasts [24]), leading to a self-perpetuating inflam-
matory loop, might directly link pDC activation, IFN type I and the onset
of fibrotic events. In addition, IFNα2 has been reported to induce TLR3-
induced production of the profibrotic cytokine IL-6. SSc fibroblasts showed
an augmented TLR3 response to IFNα2 compared with HC fibroblasts [24].
Our observation that collagen synthesis as represented by elevated PIIINP
serum levels is increased in IFN type I signature positive SSc patients, is in
line with these data.
Next to the direct effect of IFN type I on fibrosis, an indirect effect through
upregulated BAFF production is possible. BAFF serum levels correlate with
the extent of skin fibrosis in SSc [16] and we found elevated BAFF mRNA
levels in monocytes of IFN type I signature positive SSc patients. A recent
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report suggested BAFF being increased mainly in the early phase of the
disease [25], in line with our findings on the IFN type I signature. No BAFF
serum protein levels were assessed since we previously reported a lack of
correlation between BAFF monocyte mRNA and BAFF serum protein [15],
although monocytes are the major producers of BAFF protein. This might
be caused by the fact that only the soluble BAFF protein is measured by
commercial BAFF ELISAs and not the membrane bound form.
In contrast to earlier studies [26], we did not find an association between
ATA and IFN type I signature. This might be related to the limited ATA
positivity in our study. However, in support of our findings Eloranta et
al. reported that ATA did not correlate with the presence of IFN type I
using a functional approach [27]. Similarly, we did not find any correlation
between IFN signature and mRSS; albeit disappointing, these results are
in line with York et al (10) who showed that the expression of IFN type I
inducible gene Siglec-1, does not correlate with the mRSS in dcSSc [9]. We
further pursued the question if the IFN type I signature is more frequent
in dcSSc, which is denied by our data in line with earlier studies [10 28].
Interestingly the signature is not confined to the early phase of the disease,
but remains present in later stages as recently shown with an IFN type
I induced chemokine profile [28]. Finally, the lack of a clear correlation
between the IFN type I signature and most clinical parameters leaves the
intriguing question what defines the IFN type I positive patients unresolved.
SSc is an heterogenous disease and the need to understand the mechanisms
that characterize the first phases of the disease and/or its progression is
often unmet. In the present work we show that prototypical immunological
mechanisms are distinguishable from the very beginning of the disease,
when systemic sclerosis is not full blown yet, and we hypothesize that these
mechanisms may later influence the turnover of collagen and the appraisal
of skin fibrosis. At the moment it is not possible to tell whether the IFN type
I signature may represent a marker of disease progression and may allow
the identification of a subgroup of patients at greater risk for an unfavorable
evolution. Nonetheless, the so far neglected possibility to identify those
patients and the possibility to provide an early therapeutic intervention,
warrant further studies in this field.
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Background: Systemic sclerosis (SSc) is an autoimmune disease with an
unclear pathogenesis. Accumulating evidence suggests that Toll-like receptor
(TLR) activation on dendritic cells plays a key role in autoimmune diseases.
Here we mapped TLR-mediated cytokine responses of monocyte-derived DCs
(moDCs) and myeloid DCs (mDCs) from patients with limited and diffuse cu-
taneous SSc, early or late after disease onset. We further investigated whether
the pattern of TLR-stimulated cytokines was reflected in the circulation.
Methods: For in vitro experiments, 45 SSc patients were included. Patients
were stratified as having diffuse or limited cutaneous SSc on the basis of the
extent of skin involvement and further divided in those having late (lcSSc
> 3 yrs, dcSSc > 2 yrs) or early disease. DCs were stimulated with ligands
for TLR2, TLR3, TLR4, TLR7/8 or combinations of these. Plasma samples
were collected from SSc patients (n=167) from comparable SSc phenotypes.
IL-6, TNFa, IL-12, IL-10 and IFNγ were measured from DC supernatants
and plasma using a Bioplex assay. The phenotype of moDCs was characterized
using flow cytometry.
Results: The stimulation of DC subsets from early lcSSc and dcSSc patients
with ligands for TLR2, TLR3 or TLR4 resulted in higher secretion of IL6 and
TNF compared to those having late disease or healthy controls. Remarkably,
the production of IL-12 was lower upon stimulation with TLR ligands in most
SSc patients, whereas the secretion of IL-10 was very high in patients with the
diffuse SSc phenotype, particularly in those having early dcSSc. In contrast
to healthy controls, the combination of various TLR ligands led to reduced
cytokine secretion in all SSc patients. Circulating levels of these cytokines
further underscored the presence of differences between various SSc phenotypes.
Conclusions: Here we present data suggesting altered DC function in patients
with SSc. In early phases of disease the observed alterations in DC cytokine
secretion typically promote Th2 skewing of cell responses, which has been
previously suggested in this disease. Thus, altered TLR-mediated activation of
DCs may be responsible for Th2 skewed T cell activation in SSc that be the
cause for fibrogenic T cell cytokines, such as IL-4 and IL-13. DC targeting
could thus offer new avenues for therapeutic intervention.
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5.1 introduction
Systemic Sclerosis (SSc) is a complex autoimmune disease characterized by
excessive deposition of matrix molecules leading to fibrosis. The hallmark
of SSc is skin fibrosis, however, the lungs, heart and gastrointestinal tract are
often affected, leading to considerable morbidity and premature death. Al-
though the pathogenesis of SSc is not well understood, it is recognized that
three seemingly disparate processes: vascular injury, immune activation
and fibrosis, underlie its clinical appearance. The vascular pathology is char-
acterized by microvascular endothelial cell activation, injury and apoptosis.
Pathologies of the immune system are typified by increased CD4+ T cells,
γδ-TCR+ lymphocytes and IL-4 producing CD4+CD8+ double-positive T
cells in lesional skin, and circulating autoantibodies [1 2]. Finally, the fi-
brotic process is characterized by fibroblast activation and subsequent de-
position of extra-cellular matrix.
Several studies in SSc have focused on the role of fibroblast activation,
which is generally thought to underlie organ fibrosis. Indeed, seminal stud-
ies demonstrated that SSc fibroblasts explanted from lesional skin syn-
thesize increased collagen in vitro compared to fibroblasts isolated from
healthy controls [3 4]. Although these studies suggested an intrinsic defect
of fibroblasts in SSc more recent studies have questioned this interpretation
and propose that fibroblast abnormalities in SSc skin are at least partially
dependent on local factors that stimulate the fibrotic phenotype. Mononu-
clear cell infiltration is one of the earliest events observed in involved skin
from SSc patients and these cells release potent regulators (cytokines) of
inflammation and tissue remodeling. Accumulating evidence suggests the
involvement of a myriad of inflammatory mediators in SSc, such as IL-1α,
IL-23, IL-6, and IL-17, none of which are made specifically by fibroblasts.
In contrast, the main producers, or in the case of IL-17 inducer, of these
mediators are professional antigen presenting cells, of which DCs are the
most influential. Moreover, TGFβ, a profibrotic cytokine thought to be of
paramount importance in this condition, is highly secreted by DCs.
Dendritic cells (DCs) are the professional antigen presenting cells that
control the balance between immunity and tolerance [5]. In this light, sev-
eral autoimmune conditions have been associated with aberrant function
of DCs, including diabetes [6], multiple sclerosis [7 8], systemic lupus ery-
thematosus (SLE) [9] and rheumatoid arthritis (RA) [10]. To carry out their
surveillance function, DCs express a plethora of pattern recognition recep-
tors among which the Toll-like receptor (TLR) family is the most thoroughly
studied. TLRs belong to the family of pattern-recognition receptors (PRR),
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which were first identified to recognize microbial components, known as
pathogen-associated patterns (PAMPs). However, increasing evidence indi-
cates that TLRs can also be activated by numerous “host-derived” agonists
(so-called endogenous ligands or alarmins) [11]. This latter observation un-
derlies the recent increased interest for TLR and their potential implication
in numerous autoimmune syndromes (reviewed in [12]).
In SLE and RA, DCs are thought to be implicated in the disease process
by the production of type I interferons (IFN) a ‘cytokine signature’ that has
repetitively been found in these conditions [13 14]. Type I IFN are produced
upon stimulation of TLR3, TLR7/8 and TLR9 by subpopulations of DCs,
particularly plasmacytoid DC, but also by myeloid DCs ([15-18]. In this
respect, several reports showing an IFN signature in SSc underscore the
potential importance of DCs in this disorder [19-22]. The aforementioned
abundance of mediators such as IL-17, IL-23 and IL-1α in SSc patients fur-
ther underscores the potential importance of DCs [19 23 24]. In addition,
we previously demonstrated that endogenous TLR4 ligands are more abun-
dantly expressed in the circulation of patients with SSc, suggesting a pos-
sible role for TLR mediated immune activation in this disease [25]. Finally,
the conundrum that surrounds the induction of TGFβ suggests a potential
role for TLRs in SSc. The trigger(s) that drive TGF-β production and/or ac-
tivation is largely unknown. However, recent literature suggests a role for
the ‘milieu interior’ that triggers APC to secrete TGF-β probably designed
to dampen immune responses and limit tissue damage. For example, Zy-
mosan, a ligand for TLR2 was shown to induce IL-10 and TGF-β expressing
macrophages that were able to induce immunological tolerance in vitro [26].
In addition, TLR4 has been shown to be crucial in the development of hep-
atic fibrosis [27]. Thus, while the emerging picture of the pathogenesis of
SSc is one of enormous complexity, many observations suggest a role for
DCs and TLR-mediated DC activation in this condition.
We show here that the stimulation of DCs from SSc patients with sin-
gle TLR ligands results in the increased production of various cytokines
compared to that seen by DCs from healthy controls. Interestingly, TLR-
stimulated IL-12 secretion was lower in SSc patients with early disease
whereas IL-10 production was markedly increased. Stimulation with combi-
nations of TLR agonists resulted in a much lower secretion of inflammatory
mediators by DCs from SSc patients compared to that in healthy controls.
Again, IL-10 secretion was higher in by DCs from SSc patients, suggesting
that TLR agonists in patients with SSc might stimulate strong Th2 skewing.
The resulting may play an important role in the production of profibrotic
mediators such IL-13.
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Characteristics Limited
cutaneous
SSc
Diffuse
cutaneous
SSc
Number 24 21
Women (N, (%)) 20 (83) 17 (81)
Age at onset (years, mean ± SD) 41.3 ± 12.3 36.4 ± 11.8
Disease duration (years, mean ± SD) 8.8 ± 9.1 6.3 ± 0.9
ANA Positivity (%) 100 95
mRSS at inclusion Not assessed 23.5 ± 7.9
Pulmonary hypertension (n (%)) 13 (54) 7 (33)
Lung fibrosis (n (%)) 13 (54) 14 (67)
Current treatments (%):
MMF 0 24
Cyclophosphamide 0 19
Prednisolone 25 57
Hydroxychloroquine 17 0
Anti-IL-3 0 10
Methotrexate 0 0
Tacrolimus 13 0
ANA: anti-nuclear antibodies, mRSS: modified Rodnan skin score,
MMF: mycophenolate mofetil; IL-3, interleukin 3; SSc, systemic
sclerosis
Table 5.1 – Clinical characteristics of patients with SSc included in cell-
based experiments
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5.2 methods
Patient collection
For in vitro experiments, twenty-five patients presenting at the Arthritis
Center, Boston Medical Center and seventeen patients visiting the Radboud
University Nijmegen Medical Center (RUNMC) were included in the study.
All of the patients met the American College of Rheumatology preliminary
criteria for the classification of SSc [28]. For in vitro experiments, patients
were subdivided as having limited cutaneous SSc (lcSSc, n=24) or diffuse
cutaneous SSc (dcSSc, n=21) on the basis of the extent of their skin involve-
ment (table 5.1 for clinical characteristics) [29]. A further subdivision was
made between early and late disease based upon the duration of disease
listing as early dcSSc of those having a disease duration < 2 years and
late those of which had diffuse SSc longer than 3 years. As a comparator
group 22 healthy controls were studied. For the measurement of circulat-
ing levels of TNFα, IL-6 and IFNγ plasma from healthy controls (n=28) and
167 SSc patients (elcSSc n=42, llcSSc n=68, ldcSSc n=34, edcSSc n=23) from
the Boston University area, RUNMC area and Lund University Hospital
area were analyzed (table 5.2 for clinical characteristics). Treatment was in-
vestigated 6 months before the study. Blood samples were obtained with
informed consent under local Institutional Review Board approval.
Isolation and culture of monocytes, monocyte-derived Dendritic Cells, myeloid
BDCA-1 (CD1c)+ DCs.
PBMCs were isolated from heparinized venous blood by using density-
gradient centrifugation over Ficoll-Paque (Amersham Bioscience). Low den-
sity cells were collected and washed extensively with citrated PBS contain-
ing 5% FCS. Monocytes were obtained using CD14 microbeads and MS
columns (Miltenyi Biotec Inc., CA, USA). The positive selection kit for
BDCA-1 (CD1c) + myeloid DC from Miltenyi Biotec was used to isolate
myeloid DCs from the PBMC fraction according to the manufacturers pro-
tocol. Monocytes and myeloid DCs were suspended in culture medium in
a concentration of 0.5x106 cells/ml and transferred to 96 well (100 μl) cul-
ture plates and stimulated. DCs were generated by culturing isolated mono-
cytes in RPMI-1640 Dutch modification (Invitrogen Life Technologies) sup-
plemented with 10% FCS and antibiotic-antimycotic (Invitrogen Life Tech-
nologies) in the presence of IL-4 (500 U/ml; Schering-Plough, NJ, USA)
and GM-CSF (800 U/ml; Schering-Plough, NJ, USA) for 6 days in a con-
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Characteristics Limited
cutaneous
SSc
Diffuse
cutaneous
SSc
Number 111 57
Women (N, (%)) 90 (81) 44 (77)
Age at onset (years, mean ± SD) 43.3 ± 13.5 33.4 ± 10.8
Disease duration (years, mean ± SD) 12.3 ± 10.1 7.1 ± 4.9
ANA Positivity (%) 98 97
Pulmonary hypertension (n (%)) 41 (37) 26 (46)
Lung fibrosis (n (%)) 66 (59) 23 (40)
Current treatments (%):
MMF 0 16
Cyclophosphamide 0 28
Prednisolone 31 62
Hydroxychloroquine 21 0
Anti-IL-3 0 0
Methotrexate 0 12
Tacrolimus 8 0
ANA: anti-nuclear antibodies, MMF: mycophenolate mofetil; IL-3,
interleukin 3; SSc, systemic sclerosis
Table 5.2 – Clinical characteristics of patients with SSc included for sero-
logical experiments
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centration of 10x106 cells per 10 ml culture medium in 75-cm2 cell culture
flasks (Corning, NY, USA). Fresh culture medium (5 ml) with the same sup-
plements was added at day 3 where after the DCs were harvested at day
6. DCs were resuspended in fresh culture medium in a concentration of
0.5x106 DCs/ml and either transferred to 24 well (1 ml) or 96 well (0.1 ml)
culture plates and stimulated as described.
Flowcytometric analysis of CD14, CD86 and MHC expression on moDCs
Phenotypical analysis of monocyte-derived DCs was performed using
standardized flow cytometry protocols as described previously [30]. DCs
were characterized by staining with mAbs against human CD14 (Miltenyi
Biotec Inc., CA, USA), CD86, MHC-II DR/DP clone Q1514 (BD Bioscience,
NJ,USA). Cells were measured with a fluorescence-activated cell sorter
(FACSCalibur; BD Biosciences) and analyzed with FlowJo 8.7.3, (Treestar,
OR, USA) for the proportion of positive cells and the mean fluorescence
intensity relative to cells stained with the relevant IgG isotype controls.
Stimulation of moDC and myDC with TLR ligands
Freshly isolated monocytes, myeloid DCs and day 6 monocyte-derived
DCs were re-plated in a concentration of 0.5x106 DCs/ml and either trans-
ferred to 24 well (1 ml) or 96 well (100 μl) culture plates for DCs or to
96 well (100 μl) culture plates for monocytes, and myeloid DCs. Cells
were then stimulated with TLR agonists for 24 hours for the collection
of supernatants. The concentration in which the TLR agonists were used
was as follows unless otherwise described: pLPS (TLR4, 100 ng/ml, E.
coli, Sigma-Aldrich, Netherlands), R848 (TLR 7/8, 2 μg/ml, InvivoGen,
France), Pam3Cys (TLR2, 5 μg/ml, EMC microcollections, Germany) and
Poly(I:C) (TLR3, 25 μg/ml, InvivoGen, France). E. coli Lipopolysaccharide
was double-purified at our laboratory according to the phenol-water extrac-
tion method to remove any contaminating proteins prior to use.
Measurement of cytokines
Levels of IL-10, TNFα, IL-12p70 and IL-6, were measured in the super-
natants using commercially available kits (Bio-Rad, CA, USA) according
to the manufacturer’s instructions. Cytokine levels were measured and an-
alyzed with the Bio-Plex system (Bio-Rad). The sensitivity of the cytokine
assay was < 5 pg/ml for all cytokines measured. IL-6, TNFα, IL-12, IL-10
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and IFNγ were measured in the plasma of SSc patients and healthy controls
using the Bio-Plex system.
Statistical analysis
Values are shown throughout the paper as mean ± sem. Proportions of
lymphocyte subpopulations were compared using the Student’s t test for
normally or not normally distributed population where appropriate. Rela-
tionships between different values were examined using Pearson’s correla-
tion coefficient and Spearman’s rank correlation tests. All statistical analy-
ses were performed using Graphpad Prism (GraphPad Prism 4.0 by Graph
Pad software Inc.)
5.3 results
TLR mediated stimulation of freshly isolated monocytes from SSc patients indicate
an altered response compared to healthy controls.
Monocytes provide an easy means to screen for potential alterations in the
myeloid lineage because they are easily accessible in relatively large quan-
tities. To test for dysregulated monocyte signaling in SSc, we positively
selected monocytes using magnetic bead isolation and stimulated them
with specific agonists for TLR2 (Pam3Cys), TLR3 (Poly-IC) or TLR4 (LPS)
for 24 hrs and measured the pro-inflammatory mediators IL-1β, IL-6 and
TNFα. Monocytes from SSc patients (n=6) secreted significantly higher lev-
els (pg/ml) of IL-6 then those from healthy controls (n=6) upon stimulation
with Pam3Cys (8518 ± 105 vs. 4134 ± 1425, P = 0.01), LPS (9176 ± 480 vs.
7606 ± 937, P = 0.03) and Poly-IC (320 ± 50 vs. 189 ± 40, P = 0.06). Likewise,
the production of IL-1β, TNFα and IL-10 after TLR mediated stimulation
showed similar trends, although small sample sizes precluded definitive
conclusions (data not shown). Altogether, these data suggested that TLR
responses by cells from the myeloid lineage might be different between SSc
patients and healthy controls and prompted us to more carefully define
these differences in DCs.
Monocyte-derived DCs from different SSc phenotypes display an augmented but
differential inflammatory response towards TLR ligands.
The hallmark feature of SSc is fibrosis of the skin and the discrimination
of clinical phenotypes of SSc is based upon the extent of skin disease. Be-
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cause of a clearly distinct organ involvement and autoantibody repertoire,
diffuse cutaneous (dcSSc) and limited cutaneous SSc (lcSSc) are often con-
sidered as two different, but closely related, disease entities. In addition, the
clinical presentation often evolves between the early phases or late phases
dcSSc, with progressive skin involvement frequently seen in early disease
(typically during the first two years of disease) and stable and sometime
improving disease in later phases (generally after 3 years). In limited cuta-
neous SSc (ldSSc) the skin involvement is not proximal of the elbow or knee
joint, but is associated with other complications, most notably pulmonary
hypertension. For these studies, we divided SSc patients into four different
categories; limited (lcSSc) vs. diffuse (dcSSc) cutaneous disease and early
(disease duration < 2 yrs, elcSSc and edcSSc) vs. late (> 3 yrs, llcSSc and
ldcSSc) disease. To investigate whether alterations in innate immunity and
DC function might underlie some of the clinical distinctions between these
disease subsets, we stimulated monocyte-derived DCs from these four SSc
subgroups and healthy controls with ligands for TLR2 (Pam3Cys), TLR3
(Poly-IC), TLR4 (LPS) and TLR7/8 (R848). After 24 hrs of co-incubation,
the secretion of the inflammatory mediators TNFα, IL-6, IL-12 and IL-10
was measured in culture supernatants. Interestingly, DCs from patients
with early dcSSc produced significantly more TNFα and IL-6 upon stimula-
tion with TLR2, TLR3 or TLR4 compared to those DCs from all other SSc
phenotypes or healthy controls (Figure 5.1A and B). Although DCs from
elcSSc patients also showed trend towards increased production of these
inflammatory mediators upon stimulation with TLR ligands, no statistical
significance was reached.
In contrast to the augmented TNFα and IL-6 secretion upon TLR2, 3 and 4
ligands by DCs from early dcSSc patients, the secretion of IL-12 upon stim-
ulation with TLR4 or TLR7/8 was significantly lower compared to controls
(Figure 5.1C). DC from patients with early lcSSc also showed decreased
IL-12 secretion upon TLR4 or TLR7/8 stimulation. Notably, DCs obtained
from patients with late lcSSc or late dcSSc secreted comparable levels of
IL-12 production as healthy donors.
The secretion of IL-10 by DCs from patients with dcSSc, both those hav-
ing early as well as late disease, were markedly increased upon stimulation
with TLR2 and TLR4 ligands (Figure 5.1D). However, DCs from patients
with late dcSSc secreted consistently less IL-10 than DCs from early dcSSc
upon TLR2- or TLR4-stimulation. Together these data clearly indicate that
the secretion of several key immunoregulatory cytokines is differently reg-
ulated in DCs derived from patients with lcSSc compared to dcSSc and also
depends upon disease duration. Notably, monocytes, moDCs and mDCs
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Figure 5.1 – Single TLR ligand mediated stimulation of monocyte-derived
DCs results in an aberrant cytokine pattern between SSc patients and in
comparison with healthy controls. In these experiments moDCs were cultured
from healthy controls (n=22), SSc patients with elcSSc (n=10), llcSSc (n=14), ed-
cSSc (n=11) and ldcSSc (n=10) and subsequently stimulated with ligands specific
for TLR2 (Pam3Cys), TLR4 (LPS), TLR3 (Poly-IC) and TLR7/8 (R848). After 24
hrs of incubation, IL-6 (Panel A), TNF-α (Panel B), IL-12 (Panel C) and IL-10
(Panel D) were measured in the collected supernatants.
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from SSc patients showed a very low and comparable level of spontaneous
production of these cytokines. Therefore, in all figures, the data is corrected
for spontaneous production.
Stimulation of SSc moDC with combination of TLR2/3 and TLR3/4 ligands leads
to shift in classical Th1/Th2 cytokine production.
It is likely that multiple TLR ligands are recognized simultaneously in vivo
underscoring the importance of studying the effects of combinations of TLR
agonists. To further explore this in SSc, we stimulated moDCs with com-
binations of TLR2 and TLR4 (TLR2/4), TLR2 and TLR3 (TLR2/3), TLR2
and TLR7/8 (TLR2/7/8) and TLR3 and TLR4 (TLR3/4) agonists. Consis-
tent with the recent literature, TLR2 agonists inhibited the secretion of IL-6
and TNFα induced by TLR4 from DCs from healthy controls (p-values <
0.001) ([31], unpublished observations). In contrast, the addition of a TLR2
ligands did not markedly inhibit the secretion of IL-6 and TNFα in patients
with early lcSSc and dcSSc resulting in a markedly higher levels of these
individuals compared with those having late lcSSc and dcSSc disease and
healthy controls (figure 5.2A and B). Although the combination of TLR2/4
ligands in early lcSSc and dcSSc patients led to TNFα and IL-6 secretion lev-
els that were higher then those observed in DC supernatants from healthy
controls, all other TLR ligand combinations led to a markedly blunted pro-
duction of IL-6, TNFα in all SSc patients (p-values all < 0.001) (figure 5.2A
and B).
The secretion of IL-12 closely followed the pattern of IL-6 and TNFα with
the only difference that the combination of TLR2 and TLR4 agonist resulted
in similar levels in all individuals tested. Intriguingly and in contrast with
these latter observations, combinations of TLR2/4, TLR2/3 and TLR3/4 lig-
ands led to a markedly higher production of IL-10 in patients with the dc-
SSc phenotype, especially those having early disease (figure 5.2D). Notably,
the combination of TLR2 and TLR7/8 ligands did not induce cytokine pro-
duction in any of the investigated groups.
Phenotypical analysis reveals no differences between moDCs from healthy controls
and SSc patients.
The level of maturation of monocyte-derived DCs is reflected by the cy-
tokine profile and by the expression of various surface markers. Since we
observed a markedly different cytokine pattern between moDCs from SSc
clinical subsets upon TLR mediated stimulation, we investigated whether
5.3 results 113
Figure 5.2 – Simultaneous stimulation of moDCs with multiple TLR lig-
ands potentiates cytokine secretion in healthy controls but inhibits this re-
sponse in SSc patients. In these experiments moDC were cultured from healthy
controls (n=22), SSc patients with elcSSc (n=10), llcSSc (n=14), edcSSc (n=11)
and ldSSc (n=10) and subsequently stimulated with ligands specific for combina-
tions of TLR2/4, TLR2/3, TLR2/7/8 and TLR3/4. After 24 hrs of incubation, IL-6
(Panel A), TNF-α (Panel B), IL-12 (Panel C) and IL-10 (Panel D) were mea-
sured in the collected supernatants.
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these observations could be the result of an altered moDC phenotype in
SSc subsets. To this aim, the expression of CD14, CD86 and MHC-II were
investigated on moDCs from HC (n=10), elcSSc (n=5), llcSSc (n=6), edcSSc
(n=6), ldcSSc (n=7) patients was investigated using flow cytometry (Figure
5.3). We saw no clear difference in the expression of these markers between
groups neither on the number of positive cells or on the mean fluorescence
intensity suggesting that the altered phenotype of moDCs from SSc patients
cannot be detected using these markers of DC maturity.
TLR mediated stimulation of Myeloid DCs
Since controversy exists in the literature regarding the relevance of in vitro
cultured DCs, we also studied cytokine secretion from freshly isolated
myeloid DCs (mDCs). Consistent with our observations with regard to in
vitro generated DCs, mDCs from early lcSSc and early dcSSc produced
significantly more IL-6 and TNFa upon TLR2, TLR3, TLR4 and TLR7/8 me-
diated stimulation compared to those from healthy controls and patients
with late lcSSc and late dcSSc . This observation closely parallels the find-
ings on moDC (compare Figure 5.4A, B with Fig. 5.1A, B). In addition TLR2,
TLR3 and TLR7/8 stimulated mDCs from all groups (including controls) se-
creted relatively lower levels of TNF compared to in vitro matured moDCs
(Fig. 5.4B).
In accordance with that observed on moDCs, mDCs from early lcSSc and
early dcSSc patients secreted less IL-12 upon TLR4 stimulation compared
with healthy controls, or patients with late lcSSc or late dcSSc (compare
Figure 5.4C with Fig. 5.1C). The striking stimulation of IL-12 by TLR7/8
seen in moDCs was not seen in fresh mDCs from healthy controls or any
of the patient groups (Fig 5.4C). Thus, we could not confirm the striking
decrease in IL-12 secretion seen upon TLR7/8 by moDC from patients with
early lcSSc and dcSSc (Fig. 5.1C).
Notably, as seen in moDCs, mDCs from dcSSc patients produced signifi-
cantly more IL-10 upon TLR2 or TLR4 mediated stimulation (compare Fig.
5.4d with 1d). This difference reached statistical significance in both early
and late dcSSc but was more pronounced in those patients with the edcSSc
phenotype (Fig. 5.4D). mDCs stimulated with TLR3 and TLR7/8 ligands
produced little IL-10 and was similar between all groups investigated.
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Figure 5.3 – MoDCs from healthy controls (n=10) and SSc patients (n=24)
do not display a different activation phenotype. MoDCs were cultured from
monocytes in the presence of IL-4 and GM-CSF for 6 days. On day 6, moDCs
were analysed for the expression of CD14, CD68 and MHC-II using flowcytom-
etry. Panel A displays the percentage positive cells for each marker investigated.
Panel B reflects the mean fluorescence intensity of each marker within the sorted
population.
116 tlr-mediated dc cytokine production in ssc
Figure 5.4 – Freshly isolated myeloid DCs stimulated with TLRs display
similar secretion pattern as compared with moDCs. Myeloid DCs were pos-
itively isolated with MACS bead selection after which they were brought into cul-
ture for 24 hrs. Immediately after isolation, the myeloid DCs were stimulated with
ligands specific for TLR2 (Pam3Cys), TLR4 (LPS), TLR3 (Poly-IC) and TLR7/8
(R848). In these experiments, mDCs were cultured from healthy controls (n=10),
SSc patients with elcSSc (n=8), llcSSc (n=6), edcSSc (n=8) and ldcSSc (n=9). Af-
ter 24 hrs of culture, IL-6 (Panel A), TNF-α (Panel B), IL-12 (Panel C) and IL-10
(Panel D) were measured in the collected supernatants using Bio-plex assays.
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Circulating cytokine levels reflect TLR mediated cytokine secretion by DCs in SSc
phenotypes.
To test relationship between in vitro TLR-stimulated cytokine secretion and
in vivo cytokine production, we tested the circulating levels of IL-6, TNFa,
IL-12, IL-10 and IFNγ in a large set of SSc patients in comparison to healthy
controls. Both IL-6 and TNFa levels were significantly increased in SSc (all
clinical phenotypes, P < 0.001) compared with healthy controls. Cytokine
levels observed in elcSSc and edcSSc were higher (P < 0.01) compared to
those with a disease duration larger then 2 and 3 years for diffuse and
limited SSc, respectively (Figure 5.5A and B). In line with our observations
regarding the production of IL-12 and IL-10 by moDCs and mDCs from
SSc patients, the production of IL-12 was higher in longstanding disease
compared with those having early disease whereas the levels of IL-10 were
markedly higher in those patients having early diffuse (P < 0.0001) and late
diffuse (P < 0.001) compared to all other individuals tested (Figure 5.5 C
and D). As a hallmark cytokine of the Th1 responses, we also measured
IFNγ levels in SSc patients. IFNγ was increased in lcSSc, but not dcSSc
patients. The increase was significant in elcSSc (P = 0.003) and even higher
an more significant in patients with llcSSc phenotype (P < 0.0001) (Figure
5.5E). Thus, circulating levels several of the cytokines increased upon TLR
stimulation of DC further suggests the presence of Th1/Th2 difference in
SSc phenotypes and mirrors the pattern from moDCs and mDCs derived
from comparable SSc phenotypes.
5.4 discussion
Although a role for TLRs have been addressed in many inflammatory con-
ditions including autoimmune diseases, their role in SSc have not been sub-
jected to similar scrutiny. Here, we show for the first time, that monocytes
and monocyte-derived DCs from SSc patients display an aberrant cytokine
pattern compared to those from healthy controls. Interestingly, the patients
with early progressive disease had a more pronounced production of IL-
6 and TNFα upon single ligand TLR stimulation, whereas their counter-
parts with longstanding disease showed a similar production compared to
healthy controls. Together with the observation that early SSc patients pro-
duce much less IL-12 but, especially those having early diffuse SSc, produce
markedly higher levels of IL-10, this suggests that early in the disease an
augmented inflammatory response exists that is directed towards the Th2
axis.
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Figure 5.5
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Figure 5.5 – Circulating cytokine patterns suggest a different M1/M2 profile
in SSc phenotypes. Circulating levels of IL-6 (Panel A), TNFα (Panel B), IL-12
(Panel C), IL-10 (Panel D ) and IFNγ (Panel E) were measured in plasma sam-
ples from healthy controls (n=28), SSc patients with elcSSc (n=43), llcSSc (n=68),
edcSSc (n=34) and ldcSSc (n=23) originating from three independent international
cohorts.
Many studies have previously shown prominent Th2 immune skewing
in SSc. For instance, plasma levels of IL-4, IL-13 and IL-10 were increased
in SSc [32 33]. Likewise, several studies show that T cells from affected
sites such as skin [34 35] and bronchoalveolar lavage fluid [36-38] from SSc
patients have higher Th2 type cytokines. More recently, the existence of a
skewed Th2 response in SSc was further substantiated by a study from Boin
et al. were specific T cell surface markers were analysed displaying a Th2
phenotype [39]. The pathways that underlie such Th2 skewing have thus far
not been identified. T cell priming is orchestrated by DCs and is dependent
upon the cytokines released by these DCs. Whereas IL-12 is a potent inducer
of Th1 response, IL-10 in the absence of IL-12 primes Th2 responses. Our
finding of decreased circulating IL-12 levels early in disease followed by
increased levels in late disease is consistent with an earlier report [40]. The
observation that DCs from SSc patients, especially those obtained from SSc
patients having early disease, secrete less IL-12 and more IL-10 upon TLR
mediated activation indicates that altered TLR signaling and DC activation
might at least partly explain these findings. Since some of the T cell-derived
cytokines released as a result of T cell skewing, such as IL-13, can contribute
to fibrosis, these results suggest that DC dysfunction may play a key role in
SSc pathogenesis.
During normal life we constantly encounter various micro-organisms that
are battled by means of an effective innate and adaptive immune response.
In addition to exogenous TLR ligands, multiple endogenous TLR ligands
are likely to be released after various modes of cell stress such as trivial
trauma or exercise, for examples. This, it is generally accepted that both en-
dogenous as well exogenous ligands bind TLRs, subsequently driving im-
mune responses [41 42]. In systemic lupus erythematosus endogenous TLR
ligands are well-documented, resulting from autoantibody complexes that
include nucleic acid components. Autoantibodies directed against DNA
and RNA-binding proteins also occur in SSc and might in some cases
act as TLR7 and or TLR9 ligands [43]. Aside from these autoantibody-
containing immune complexes, endogenous ligands have only been identi-
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fied for TLR4, but may exist for other TLRs as well. Recently, our group ob-
served increased circulating TLR4 ligands in SSc patients [25 44]. Although
the study size did not allow an analysis between limited and diffuse SSc pa-
tients, these data at least suggest that increased TLR4 signaling may activate
DCs in patients with SSc.
Beside autoantibody patterns, there are no clear immunologic features
that distinguish limited versus diffuse SSc. Although our study did not re-
veal differences in IL-6, TNFa and IL-12 production by moDCs from differ-
ent SSc clinical phenotypes, the production of IL-10 was markedly different,
being increased in diffuse patients upon TLR mediated activation but com-
parable with healthy donors in limited SSc. Based upon these observations
it is tempting to speculate that alternatively activated APC may predomi-
nate in patients with diffuse SSc, whereas limited SSc patients have APC
with a more classically activated phenotype. Such hypothesis is further sub-
stantiated by the observation that IFNγ, a cytokine that drives M1 (and in-
hibits M2) formation was increased only in limited SSc patients. There are
many markers that are thought to be specific for either the M1 or M2 APC.
For instance, were CXCL8, CXCL10 and CXCL16 are typically expressed
by M1 APC, M2 APC express high levels of CCL1, CCL18 and CCL22 (re-
viewed in [45]). Further characterization of the expression of such markers
might reveal a specific pattern in these two clinical SSc phenotypes and
might be helpful in the clinical decision-making and insights in disease
pathogenesis.
Although stimulation with single TLR ligands produced results that were
generally consistent with observed alterations in circulating cytokine levels,
ligand combinations indicated the complexity of the effects of TLR activa-
tion on DC biology. Stimulation of DCs from all clinical phenotypes with
TLR ligand combinations including TLR2 resulted in decreased production
of IL-6, TNFα and IL-12, which was present in all SSc clinical phenotypes
whereas the combination of TLR3 and TLR4 resulted in synergistically en-
hanced cytokine production in some but not all patient subgroups, as re-
cently described [25 46]. Again, IL-10 secretion remained significantly in-
creased in patients having the early diffuse SSc phenotype. These latter ob-
servations strongly suggest that SSc patients in general have a diminished
Th1 response upon the recognition of endogenous and exogenous TLR lig-
ands and that patients with early diffuse SSc have a markedly skewing of
the immune response to Th2.
Altogether, the unrelenting and destructive progression of the fibrotic
process in SSc remains a major medical challenge for which therapies are
desperately needed. Here we provide novel insights into the different TLR
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response by moDC and myeloid DCs from different SSc phenotypes. These
observations provide clear impetus for pursuing studies directed at further
elucidating the effects different TLR ligands and DC mediated activation of
immune responses in this condition.
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6.1 introduction
Systemic sclerosis (SSc) is a chronic autoimmune connective tissue disease
leading to extensive fibrosis of skin and internal organs [1]. One of the phe-
nomena of interest in SSc pathogenesis is hypoxia [2]. A protein strongly
involved in hypoxia responses is the cytoprotective enzyme heme oxyge-
nase 1 (HMOX1), a stress-response protein catalyzing the degradation of
heme into biliverdin, carbon monoxide (CO) [3]. Both biliverdin and CO are
known for their anti-oxidant and anti-inflammatory effects [4]. We hypoth-
esized that polymorphisms in HMOX1 may influence susceptibility to SSc
by determining the levels of HMOX1 following transcriptional activation.
Individuals with short (GT)n repeats have been shown to induce HMOX1
faster than people with long (GT)n repeats, which is associated with pro-
tection against a wide range of pro-inflammatory diseases [5]. To address
this hypothesis we investigated this (GT)n repeat and a single nucleotide
polymorphism (SNP) (HMOX1 -413A>T) in the HMOX1 promoter region
using a large cohort of clinically well-documented SSc patients.
6.2 methods
Patients and Controls
The study population was composed of 604 SSc patients and 1378 healthy
controls from the Netherlands, Spain and Germany. The characteristics and
classification criteria of this cohort have been published previously (table
6.1)[6].
Genotyping
Custom Taqman assays were constructed for both genotyping the SNP at
position -413 in the HMOX1 promoter region and the HMOX1 repeat, both
construction and genotyping have been previously described [7].
Data analysis
Association analysis was performed by Chi-square tables and Fisher’s ex-
act test. Pooled OR was performed with Mantel-Haenszel meta-analysis.
Survival analysis was performed using Kaplan-Meier curves and Log Rank
(Mantel-Cox) statistics. For the power calculation of the combined analyses
we considered a minor allele frequency of 0.42 as displayed in the control
6.3 results 129
population, under a multiplicative model our study than reaches a power
of 75% to detect an OR of 1.2 and 97% to detect an OR of 1.3.
6.3 results
No significant heterogeneity between the three European populations was
detected. We did not observe any differences in the allele distribution of
the HMOX1 -413A>T SNP when comparing SSc patients with their healthy
counterparts nor when comparing cinical phenotypes of SSc (Table 6.1).
Moreover, no association was found when scrutinizing dominant and neg-
ative effects of this polymorphisms in SSc. Likewise, no differences were
present comparing (GT)n repeat length. There was no combined effect of
the (GT)n repeat and the HMOX1 -413A>T SNP nor in a multi-linear re-
gression model consisting of the SNP and (GT)n repeat (SSc p=0.761, lcSSc
p=0.672, dcSSc p=0.443).
When studying the possible effect of the (GT)n length or the HMOX1
-413A>T SNP on development of PAH and/or pulmonary fibrosis in 15
years from the development of the first non-raynaud’s SSc symptom no ef-
fects were observed. There was no correlation between the (GT)n repeat
length and the time to develop pulmonary fibrosis (p=0.064) and PAH
(p=0.889) neither was there a significant difference in the Kaplan-Meier sur-
vival curves for pulmonary fibrosis (log rank p=0.198, Breslow p=0.295) and
PAH (log rank p=0.693, Breslow p=0.496).
6.4 discussion
In this study we show that two functional variants within the HMOX1 pro-
motor do not influence susceptibility to SSc nor its clinical phenotype. How-
ever, based on the observations that HMOX1 is aberrantly expressed in SSc
models, pulmonary fibrosis and PAH [8-10] the regulation, either epige-
netically or post-translational, of HMOX1 stays an potentially important
molecular pathway in SSc.
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Background: Systemic sclerosis (SSc) is a severe disease characterized by
inflammation and fibrosis. Heme Oxygenase-1 (HO-1) is a heme-degrading
enzyme that mediates resolution of inflammation and is induced upon
mediators abundantly present in SSc. The chemokine CXCL4 is increased
in the plasma of SSc patients. We therefore hypothesized that the ongoing
inflammatory response observed in SSc is due to aberrant HO-1 expression
caused by increased levels of CXCL4.
Methods: In total 92 SSc patients and 48 healthy controls were included.
By measuring the generated total bilirubin in plasma in vivo HO-activity
was assessed. HO-1 expression levels were determined with Western-Blot in
monocytes before and after induction of HO-1 with cobalt protoporphyrin
(CoPP) with or without CXCL4. Monocyte derived DCs (MoDC) were
stimulated with several TLR ligands with or without pre-stimulation with
CoPP for 24 hours. Cytokine levels were measured in the supernatants using
the Luminex Bead Array.
Results: SSc patients have lower plasma levels of bilirubin compared to
controls. Western-blot analysis shows low HO-1 expression in immune cells
from SSc patients. CoPP treatment induced HO-1 in both moDC from SSc
patients and controls. Co-stimulation with CXCL4 completely abrogated
CoPP-induced HO-1 expression. Induction of HO-1 adjusted the TLR
responses of SSc immune cells, especially the IL-12 production in response to
TLR4 and TLR8 ligands.
Conclusions: HO-activity in SSc patients is decreased despite the presence of
many HO-1 inducers. Blocking of CXCL4 in SSc patients could offer a novel
therapeutic target that attenuates the TLR-mediated inflammation and promote
cytoprotective effects through HO-1.
7.1 introduction 135
7.1 introduction
Systemic sclerosis (SSc) is a complex heterogeneous fibrosing autoimmune
disorder with unknown pathogenesis. SSc is typified by three pathological
hallmarks: endothelial dysfunction, chronic immune activation and exten-
sive extracellular matrix formation. Clinically, these events are translated
into the development of fibrosis of skin and internal organs. Nowadays,
there is accumulating evidence that supports a role for hypoxia in the onset
and/or perpetuation of the disease. For instance, oxygen levels measured
in affected skin are lower in SSc patients [1 2] and end-products from the
oxidative stress pathway such as isoprostane are increased in SSc patients
[3]. How hypoxia possibly contributes to the pathology observed in SSc
remains enigmatic.
The heme oxygenase (HO) system is the most potent mechanism to pro-
tect the human body against the detrimental effects of hypoxia. HO is the
rate-limiting enzyme that catalyzes the degradation of heme into biliverdin,
ferrous iron and carbon monoxide (CO) [4]. Subsequently, biliverdin is
converted to bilirubin by biliverdin reductase. Heme oxygenase-1 (HO-
1) is the inducible isoform expressed in many cells in response to stress
and it is therefore known as a key cytoprotective, anti-oxidant, and anti-
inflammatory enzyme. Iron is scavenged by co-induced ferritin. These char-
acteristics are mainly due to the products of HO-activity; bilirubin, carbon
monoxide (CO) and ferritin that are orchestrating potent anti-inflammatory
and anti-oxidant functions [5 6]. Rare cases of HO-1 deficiency in humans
show increased susceptibility to oxidative stress and a pro-inflammatory
state with severe endothelial damage providing in vivo relevance for its
pivotal role [7]. Mounting evidence highlights the increased expression of
HO-1 in multiple autoimmune diseases. For example, in rheumatoid arthri-
tis (RA) HO-1 is increased in synovial tissue and in vitro studies demon-
strated that upregulation of HO-1 in RA-derived synoviocytes suppressed
inflammatory responses [8], and RA patients with higher HO-1 levels have
a better long-term radiographic outcome [9]. Furthermore, exploiting an ex-
perimental lupus model, the induction of HO-1 expression abrogated the
onset of nephritis [10] and in patients suffering from systemic lupus erythe-
matosous HO-1 expression was decreased in monocytes [11]. Interestingly,
the upregulation of HO-1 prevented the onset of fibrosis in various settings,
including a bleomycin-induced pulmonary fibrosis model [12 13]. The pro-
tective value of HO-activity is due to all effector molecules as CO specifi-
cally decreases pulmonary hypertension and bilirubin decreases right ven-
tricular fibrosis and heart failure in a chronic hypoxia mouse model [14].
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Over the past few years accumulating evidence points towards a primary
immune defect in SSc. For instance, various groups have now robustly
demonstrated that SSc patients display altered circulating cytokine levels.
Intriguingly, a substantial number of patients display a type I interferon
(type I IFN) signature both in the circulating immune cells as well as in
the skin and lungs [15-17]. As the main driver of the Type I IFN produc-
tion is TLR-mediated activation of plasmacytoid dendritic cells, the pres-
ence of this signature suggests chronic activation of this pathway in SSc pa-
tients, which has been advocated by multiple studies. [18 19]. More recently,
we identified high levels of the chemokine CXCL4 as an early prognostic
marker and a molecule involved in SSc pathology, further substantiating
the role of a dysregulated immune system in this disease [20].
Interestingly, CXCL4 was previously found to suppress CD163 on
macrophages, which was associated with the inability to upregulate HO-1
upon response to hemoglobin [21]. Moreover, CXCR3B, one of the receptors
for CXCL4, has shown to inhibit HO-1 expression [22]. This led us to pos-
tulate that SSc patients suffer more from hypoxia due to a dysfunctional
HO system in part driven by increased levels of CXCL4. Here we demon-
strate that SSc patients indeed display lower expression and activity of HO-
1 and demonstrate that this is correlated with an altered TLR-mediated
cellular activation. TLR-mediated dysfunction was reversed by HO-1 induc-
tion. Neutralization of CXCL4 and inducing the cytoprotective HO system
opens novel avenues for therapeutic intervention.
7.2 methods
Patient recruitment and description
All samples were obtained with written informed consent after approval
of the Institutional Review Board from the Radboud University Medical
Centre (RUMC) and the Boston University School of Medicine. For the cell-
based part of this study we included 31 SSc patients presenting at the out-
patient clinic of the RUMC in Nijmegen, The Netherlands. For comparison
in each experiment at least one healthy control was included resulting in
22 healthy controls in total. Plasma was collected from 41 SSc patients vis-
iting the Boston Arthritis Center and subsequently plasma was collected
from 19 healthy controls in Boston. In this cohort the plasma was taken
after Ficoll gradient centrifugation, therefore full blood was diluted with
PBS. Plasma was also collected from 27 SSc patients at the RUMC and from
15 Dutch healthy controls. Therefore venous blood was collected in a 10
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HC lcSSc dcSSc
N 48 46 46
Women (N, (%)) 36 (74) 35 (76) 29 (63)
Age ± SD 29 ± 6 54 ± 12 * 51 ± 12 *
Disease duration (years) ± SD 9.0 ± 7.6 5.2 ± 5.3 *
Positive ANA (%) 83% 85%
Positive ATA (%) 22% 30%
Positive ACA 22% 7%
PH 17% 35%
Lung fibrosis 35% 46%
Therapies
MMF 4% 9%
Cyclophosphamide 15% 11%
Prednisolone 15% 24%
SD = standard deviation. ANA = antinuclear antibodies, ATA =
anti-topoisomerase antibodies, ACA = anti-centromere antibodies.
PH = pulmonary hypertension. For cyclophosphamide percentage
depicts patients ever treated with cyclophosphamide. * p < 0,01
Table 7.1 – Patient characteristics of all included patients.
ml lithium-heparin Vacutainer (BD). The samples rested for 10 min at room
temperature and were then centrifuged at 3000 rpm for 10 min. All samples
were aliquoted and immediately frozen at -80 C until further use. Carbon
monoxide was measured in the exhaled breath of 46 patients with SSc, 9
patients with other autoimmune diseases and 13 healthy controls. Patients’
characteristics from both cohorts are shown in table 7.1. All patients met
the American College of Rheumatology criteria for SSc [23]. Patients were
further subdivided as having limited SSc (lcSSc) or diffuse SSc (dcSSc) ac-
cording to the Le Roy criteria on the basis of the extent of skin involvement
[24]. The presence of lung fibrosis was assessed as previously described us-
ing high resolution computed tomography [25]. Pulmonary hypertension
was suspected when pulmonary artery pressure (PAP) on echography was
≥ 35 mmHg. A right-heart catheterization followed and the diagnosis was
established when the mean PAP was above 25 mmHg [25].
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In vivo measurement of HO-activity
To assess HO-activity in patients, we measured two products of the en-
zymatic reaction of this protein [26-28]. Total bilirubin was measured in
plasma using the high-pressure liquid chromatography (HPLC) technique
in an identification cohort with 41 patients from Boston, US and in 27 pa-
tients in a replication cohort from Nijmegen, Netherlands [29]. For the pa-
tients from Boston plasma diluted with PBS was used, therefore measured
total bilirubin levels are lower compared to the patients from Nijmegen. Car-
bon monoxide (CO) levels in exhaled breath were measured in 46 patients
and 13 healthy controls using the COCO2 Puff analyzer (Everest Biomed-
ical Instruments Company) [30]. To further interpret the data, CO was
also measured in 9 patients with other auto-inflammatory diseases (OAD).
These patients were diagnosed with systemic lupus erythematosous (n=2),
rheumatoid arthritis (n=1), psoriatic arthritis (n=1), spondylarthropathie
(n=1), polymyositis (n=3) and Sjogren syndrome (n=1). Patients actively
smoking were excluded from measurement.
Isolation and culture of monocytes and monocyte-derived DCs
PBMCs were isolated from heparinized venous blood using density-
gradient centrifugation over Ficoll-Paque (Amersham Bioscience). Low-
density cells were collected and washed extensively with citrated PBS con-
taining 5% FCS. Monocytes were obtained using CD14 microbeads and
MS columns according to manufacturer’s protocol (Miltenyi Biotec). DCs
were generated by culturing isolated monocytes in RPMI-1640 Dutch mod-
ification (Invitrogen Life Technologies) supplemented with 10% FCS and
antibiotic-antimycotic (Invitrogen Life Technologies) in the presence of IL-4
(500 U/ml; RnD) and GM-CSF (800 U/ml; RnD) for 6 days at a concentra-
tion of 5x106 cells per 10 ml culture medium in 75-cm2 cell culture flasks
(Corning). Fresh culture medium (5 ml) with the same supplements was
added at day 3. The DCs were harvested at day 6. DCs were resuspended
in fresh culture medium in a concentration of 0.5x106 DCs/ml and either
transferred to 24 well (1 ml) or 96 well (0.1 ml) culture plates and stimulated
as described.
Isolation of lung fibroblasts
Lung tissues were obtained as previously described from patients under-
going lung transplant surgery at the University of Pittsburgh and nor-
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mal donors whose lungs were not used for transplantation using a pro-
tocol approved by the Institutional Review Board [31]. Primary fibroblasts
were cultured from lung tissues as described and maintained in culture in
DMEM/10% FBS/antibiotic and antimycotic [31 32]. All fibroblasts were
used directly after isolation.
Measurement of HO-1 levels
From each patient moDCs and freshly isolated monocytes were stored for
measurement of HO-1 protein level and mRNA level. RNA was isolated
from 1x106 cells using Trizol extraction. HO-1 mRNA levels were assessed
with RT-PCR using primers with the following sequences: fw CTGACC-
CATGACACCAAGGAC rv AAAGCCCTACAGCAACTGTCG. HO-1 pro-
tein levels were assessed as described previously [29]. In brief, cells were
collected, pelleted by centrifugation and lysed for 30 minutes on ice us-
ing lysis buffer (1 mM EDTA, 0.5% Triton-X-100, 25 µg/ml leupeptin, 25
µg/ml pepstatin, 100 µM phenylmethylsulphonyl fluoride, 3 µg/ml apro-
tinin in PBS, pH 7.2, all Sigma-Aldrich). Cell lysates were centrifuged for
10 min. at 20,000x g at 4°C and total protein was separated by SDS/PAGE
using a 12.5% gel. Subsequently, proteins were blotted onto a nitrocellulose
membrane using a BioRad wet blotting system. Afterwards, the membrane
was blocked overnight at 4°C using Odyssey Blocking Buffer (Westburg BV,
Leusden, the Netherlands). The blot was then incubated for 1 hr at RT with
rabbit-anti-HO-1 Ab (1:5000; Stressgen/ITK, Uithoorn, the Netherlands).
Mouse-anti-β-actin Ab was simultaneously incubated to serve as a pro-
tein loading control (1:100,000, Sigma-Aldrich). Antibodies were diluted in
Odyssey Blocking Buffer containing 0.1% Tween-20. Afterwards, the mem-
brane was washed three times for 10 min. with PBS containing 0.1% Tween-
20. The secondary antibodies, goat-anti-rabbit Alexa Fluor 680 (1:10,000,
Rockland, Heerhugowaard, the Netherlands) and goat-anti-mouse IRDye
800 (1:10,000 Sigma-Aldrich) were incubated for 45 min. at RT in Odyssey
Blocking Buffer containing 0.1% Tween-20 and 0.01% SDS. After thorough
washing, the membrane was scanned using the Odyssey Infrared Imaging
System (LI-COR Biosciences). Expression of HO-1 was assessed using chan-
nel 700 and β-actin expression was determined using channel 800. Intensity
of the bands was determined using the Odyssey application software.
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Preparation of porphyrin solutions
Cobalt protoporphyrin (CoPP) was obtained from Frontier Scientific, Carn-
forth, UK. All solutions were freshly prepared as previously described [29].
In short, the substance was dissolved together with Trizma base in a 0.1-M
NaOH solution and further diluted in H2O. After the pH was adjusted to
pH 8 with HCl, H2O was added to obtain a 2-mM solution. The solutions
were then filter-sterilized, protected from light and directly used.
Induction of HO-1 and stimulation of moDC with TLR ligands and CXCL4.
Monocyte-derived DCs were re-plated in a concentration of 0.5x106 DC-
s/ml and either transferred to 24 well (1 ml) or 96 well (100 μl) culture
plates. HO-1 was induced in DCs by adding 10 μM CoPP for 24 hours as pre-
incubation. The kinetic study revealed that HO-1 protein level was clearly
increased with 10μM CoPP for 24 hours (data not shown). Cells were then
stimulated with TLR agonists for 24 hours for the collection of supernatants.
The concentration in which the TLR agonists were used is as follows unless
otherwise described: pLPS (TLR4, 100 ng/ml, E. coli, Sigma-Aldrich) and
R848 (TLR 7/8, 2 μg/ml, InvivoGen). The used E. coli Lipopolysaccharide
was double-purified at our laboratory according to the phenol-water extrac-
tion method to remove any contaminating proteins. MoDC’s were stimu-
lated with purified human CXCL4 5 µg/ml (Haematologic Technologies
Inc.).
Measurement of cytokines
Levels of IL-10, TNFα, IL-12p70 and IL-6 were measured in the supernatants
using commercially available kits (Bio-Rad, Veenendaal, The Netherlands),
according to the manufacturer’s instructions. Cytokine levels were mea-
sured and analyzed with the Bio-Plex system (Bio-Rad). The sensitivity of
the cytokine assay was <5 pg/ml for all cytokines measured.
Statistical analysis
Values are shown throughout the paper as mean ± SEM. Differences were
considered significant for p<0.05. Paired or unpaired Student’s T test was
used as indicated based on the experimental setup. Correlation was tested
with the Pearson R test. All statistical analyses were performed using
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Graphpad Prism (GraphPad Prism 4.0 by Graph Pad software, La Jolla,
California, USA).
7.3 results
Low expression of bilirubin and carbon monoxide reflects low HO-1 activity in SSc
patients.
As HO-1 degrades heme into free iron, CO and biliverdin, which in turn is
directly converted into bilirubin, we measured plasma bilirubin levels as a
measure of systemic HO-1 activity in vivo. Bilirubin levels in SSc patients
with limited cutaneous (P = 0.02) and diffuse cutaneous (P = 0.001) SSc
(identification cohort n = 41) were lower compared to their healthy counter-
parts. (Fig 7.1a). This observation was replicated in a second cohort compris-
ing 27 SSc patients and 15 healthy donors (Fig7.1b). To further support the
lack of HO-1 activity in SSc patients, we measured CO concentration in the
breathing gas from SSc patients (n=48), patients with other autoimmune dis-
eases (n=9) and healthy donors (n=13). In line with the low bilirubin levels
measured, SSc patients failed to increase exhaled CO levels in comparison
to patients with other autoimmune disease (p<0.05) (Fig 7.1c).
HO-1 protein levels are low in isolated cells from SSc patients
As low HO-1 levels could have a marked impact on the function of vari-
ous immune cells we next investigated the level of HO-1 in lymphoid and
myeloid immune cell subsets between SSc patients and healthy donors. In
healthy controls HO-1 activity is expected to be low as there should be no
apparent stress inducers present, as there are in SSc. In line with low plasma
bilirubin levels, monocytes from SSc display equal HO-1 protein levels to
monocytes from healthy donors, despite the presence of HO-1 inducers in
SSc patients (Fig 7.1d). Similarly, T-cells and plasmacytoid DC from SSc pa-
tients showed remarkable similar HO-1 protein levels compared to those
from healthy controls (data not shown). Intriguingly, lung fibroblasts from
SSc patients had notably low levels of HO-1, despite the presence of many
HO-1 inducers (Fig 7.1e).
CXCL4 inhibits the up regulating potential of HO-1 in immune cells.
Since the observed low levels of HO-1 could be caused by either an inherent
defect in the regulation or by exogenous factors actively down regulating
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Figure 7.1 – HO-1 activity is decreased in patients with systemic sclerosis.
(Panel a) Bilirubin levels are decreased in plasma from SSc patients either lcSSc
n=13 (p=0.03) or dcSSc n=28 (p=0.001) compared to healthy controls n=20 in this
Boston Arthritis Centre cohort. Measurement in plasma diluted with PBS. (Panel
b) Bilirubin levels are decreased in plasma from lcSSc patients (n=18) and dcSSc
patients (n=9) compared to healthy controls (n=15) in a Dutch cohort (p=0.008
and p=0.03 respectively). (Panel c) CO levels in exhaled breath are low in SSc
patients (n=46) and healthy controls (n=13). Patients with other autoimmune dis-
eases (OAD) (n=9) have a significantly increased amount of CO in exhaled breath
(p=0.03). (Panel d) HO-1 protein levels in healthy control (n=3) monocytes and
lcSSc (n=4) and dcSSc monocytes (n=1) are comparably low. Protein content was
measured by Western blot and corrected for beta-actin presence. Per donor 1,0*106
were used. Data of one experiment are shown. (Panel e) HO-1 protein levels in
lung fibroblasts from SSc patients are low.
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HO-1 expression we set off to determine the cellular potential to increase
HO-1 expression. To this aim, monocyte-derived DCs (moDCs) were gen-
erated from SSc patients and healthy donors and stimulated with CoPP, a
known potent HO-1 inducer. MoDCs from both healthy donors and SSc pa-
tients were fully capable of increasing HO-1 levels after stimulation on RNA
level (data no shown) and on protein level (Fig. 7.2a). Hence, we next pos-
tulated that exogenous factors underlie the low HO-1 expression ex vivo
and investigated the recently discovered biomarker CXCL4 as a potential
candidate orchestrating this phenomenon. CXCL4 is excessively expressed
in the serum of SSc patients [33]. To this aim, we stimulated moDCs with
CoPP in the absence or presence of CXCL4 and demonstrated that HO-1
could be induced in both moDC from SSc patients and healthy controls.
Moreover, the HO-1 inducing effect of CoPP was completely abrogated by
co-exposure to CXCL4 (Fig 7.2b). Further support for the role of CXCL4
in the inhibition of HO-1 regulation originates from the observation that
there is a clear reverse correlation between circulating CXCL4 and bilirubin
plasma levels in SSc patients whereas no correlation was found in healthy
donors (Pearson r -0,42 P = 0,03) (Fig 7.2c).
Induction of HO-1 leads to diminished augmentation of TLR responses.
Since we previously demonstrated that DCs from SSc patients produce
more inflammatory cytokines upon TLR-mediated stimulation compared
to those from their healthy counterparts [18], we studied whether the in-
duction of HO-1 expression in SSc DCs would exert an inhibitory effect on
TLR-mediated cytokine production by DCs from SSc patients. We show that
the induction of HO-1 inhibits TLR4 (867 ± 264 vs. 523 ± 182; P = 0,002) and
TLR7/8 (1354 ± 482 vs. 890 ± 323; P = 0,04) mediated secretion of IL-12 (Fig
7.2d) as well as IL-10 secretion by TLR4 (315 ± 95 vs 236 ± 78 P = 0,02) (Fig
7.2e) in SSc patients. We did not find any differences in IL-6 secretion after
TLR stimulation. For TNFα a significant increase in response to LPS was
seen in HC and SSc retrieved DCs respectively (4632 ± 1005 vs 8000 ± 1880
P = 0,008 for HC and 4989 ± 830 vs 7533 ± 1242 P = 0,0005 for SSc). This
was not seen after R848 stimulation (Fig 7.2f). This data support the notion
that the defective HO-1 induction observed in SSc patients could underlie
the increased TLR response observed in SSc.
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Figure 7.2
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Figure 7.2 – Low HO-1 function is restored by HO-I inducers and inhibited
by CXCL4.(Panel a) MoDC of both patients and controls are able to upregulate
HO-1 in response to CoPP stimulation for 24 hours measured by Western blot.
Per condition, we used 1,0*106 moDC. Data are pooled from several experiments,
dcSSc n=7, lcSSc n=9 and HC n=8. The Western blot shown is an example from
one experiment. Paired Student’s T test was used. * P <0.02 (Panel b) MoDC from
healthy controls are cultured in the presence or absence of CXCL4 for 24 hours
and thereafter CoPP is added to induce HO-1 for an additional 24 hours. CXCL4
inhibits the upregulation of HO-1 in healthy donors (n=2). (Panel c) Bilirubin
levels in dcSSc patients (n=27) inversely correlate with CXCL4 levels in vivo,
Pearson r -0.42 P = 0.03. (Panel d) IL-12 levels (pg/ml) in response to TLR4
and TLR7/8 stimulation in moDC from HC (n=20, black bars) and SSc patients
(n=28, gray bars) are affected by HO-1 induction. (Panel e) IL-10 levels (pg/ml)
in moDC from SSc patients in response to TLR4 were similarly affected by HO-
1 upregulation. (Panel f) TNFα levels (pg/ml) in response to TLR4 increased by
HO-1 upregulation in both HC and SSc derived moDC.
7.4 discussion
We observed that SSc patients display lower levels of bilirubin and fail to
increase HO-1 in vivo despite the ample presence of HO-1 inducers, such as
hypoxia and inflammatory mediators. Furthermore, we demonstrated that
the low activity of HO-1 in SSc patients is likely due to the high circulat-
ing levels of the recently identified biomarker CXCL4, since co-exposure
to CXCL4 abrogated CoPP mediated induction of HO-1. The observed IFN
type I signature in a substantial part of SSc patients suggests the activa-
tion of plasmacytoid dendritic cells as the main source of IFN type I and
the excessive production of CXCL4 [15 34-36]. Indeed, an increased TLR
response in SSc patients is now robustly reported and suggested to directly
drive a pro-fibrotic loop [18 37-40]. The increase of TNFα after LPS stimula-
tion is contrary to known mouse data but in line with recent human data
in a human endotoxemia model (data not published). In balance with a
down-regulated IL-12 and IL-10 this could still result in a positive effect on
the fibrotic events in SSc patient although further studies are warranted to
answer this. Accumulating evidence directly links aberrations in TLR sig-
naling with fibrosis, which may directly link defective HO-1 signaling to
SSc pathology [17][13]. Furthermore a prolonged inflammatory phase is a
major cause of fibrosis, myofibroblast formation and excessive extracellular
matrix deposition [41]. As an example, pharmacological HO-1 induction
via CoPP has been shown to prevent liver fibrosis and to attenuate already
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existing fibrosis in Mdr2 deficient mice [42]. In both bleomycin-induced
pulmonary fibrosis and a diet-induced hepatic fibrosis model, it was shown
that HO-1 induction ameliorates, whereas inhibition of HO-activity exacer-
bates, oxidative stress, inflammation, and fibrosis formation [43].
Interestingly, immune cells derived from SSc patients are still able to in-
duce the anti-inflammatory and anti-oxidant enzyme HO-1 when stimu-
lated in vitro and in the absence of CXCL4. In line with our findings, SSc
dermal fibroblasts previously showed no increased HO-1 levels compared
to healthy controls. Induction of HO-1 in vitro showed a very potent re-
sponse to hypoxia of these dermal fibroblasts by increasing the HO-1 pro-
duction [44], so this also underlines that SSc patients are able to increase
their HO-1 expression in stressful conditions. In contrast to this finding, SSc
lung fibroblasts showed low HO-1 levels and were not able to induce HO-1
after curcumin stimulation in vitro [45]. This difference can be explained
either by the use of different stimuli or by the fact that dermal fibroblasts
were cultured longer than lung fibroblasts and therefore might have lost the
inhibitory effect of CXCL4.
After finding that pDC-derived high CXCL4 plasma levels were associ-
ated with the SSc phenotype, we now provide evidence that further eluci-
dates the down-stream pathways leading to SSc. CXCL4-mediated preven-
tion of HO-1 induction aggravates the inflammatory, oxidative and fibrotic
processes. CXCL4-mediated inhibition of HO-1 induction is likely mediated
by CXCR3B triggering. CXCR3B is the receptor for CXCL4 and has been
shown to inhibit HO-1 expression by increasing the Bach1/Nrf2 ratio [46].
Our observations may provide a novel possibility to monitor disease activity
as HO-1 activity can be measured by CO levels in exhaled breath in combi-
nation with plasma total bilirubin. Besides its potential prognostic utility, it
is tempting to speculate that restoring HO-1 function normalizes inflamma-
tory cell functioning and circulating levels of pro-inflammatory mediators
in SSc patients and therefore exerts beneficial clinical effects. As such, HO-1
inducers like heme arginate (HA) that were recently tested in a phase II clin-
ical trial for acute myocardiological infarction (NCT00483587) and a phase
III clinical trial for ischemia reperfusion injury (NCT01430156) might have
clinical efficacy in SSc patients. Alternatively, we could elevate the levels
of HO-effector molecules. In a double-blind, placebo-controlled cross-over
study, we previously demonstrated that we can increase bilirubin levels by
inhibiting UGT1A1-activity using atazanavir resulting in amelioration of
vascular function and plasma antioxidant capacity in diabetes patients [47].
These promising clinical protective effects of HO-effector molecules war-
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rants further research into the role of these molecules in the treatment of
SSc.
Altogether, we demonstrate a significant role for HO-1 in the altered TLR
response in SSc patients and show that CXCL4 inhibits HO-1 induction, fur-
ther supporting the rationale for neutralization of CXCL4 and subsequent
induction of HO-1 and its effector molecules as novel clinical targets in SSc.
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Part IV
C L O S I N G

8
F I N A L C O N S I D E R AT I O N S
Patients with SSc suffer from fibrosis of their skin and internal organs,
which eventually results in premature death. As a result of strategic funding
of research into what are known as orphan diseases and the great dedica-
tion shown by several researchers, insights into the etiology of these pro-
cesses have dramatically increased over the last two decades. These devel-
opments have led to a paradigm shift, revealing immune disturbances and
vascular changes as the initiating events resulting in fibrosis. This thesis
aims to provide greater insight into the importance of the immune system
in the initiation and progression of a pathological cascade resulting in fibro-
sis.
I will first summarize the final considerations for each individual chapter,
providing a general synthesis of the findings described throughout this the-
sis. Important future perspectives and therapeutic targets will be discussed,
going –once again– from the bench to the bedside.
chapter 2 – cxcl4 , a new marker and target in ssc
In this thesis, we showed that serum CXCL4 identifies patients at risk of
developing SSc and further organ involvement. In vivo and in vitro CXCL4
clearly affects endothelial cells and fibroblasts and changes them in ways re-
sembling scleroderma. CXCL4 thus clearly contributes to mechanisms caus-
ing this pathology. Future studies will determine whether an increase in
CXCL4 is sufficient reason to start stronger therapy. Such therapy will be
an improvement compared to yearly check-ups with HRCT and ultrasound
of the heart and it will surely be cost-effective.
In addition to the effects on endothelial cells and fibroblasts described
in chapter 2, CXCL4 induces a specific profile in macrophages clearly dif-
ferent from the generally familiar M1 or M2 macrophages [1]. These M4
macrophages, as they are called, show higher expression of genes encoding
for S100A8, CCL18, CCL22, CD32, and MMP7, for instance. In chapter 2,
we showed that pDC from SSc patients produce high levels of CXCL4 as
well as increased levels of S100A8. This may be part of an autocrine ampli-
fication loop further increasing the pro-inflammatory situation. In chapter
3, we showed an association between pulmonary fibrosis and circulating
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levels of S100A8 in lcSSc patients. The origin of S100A8 could be the M4
macrophage. Assuming that this is the case, it is worth noting that CCL18
(another M4 marker) also correlates with lung fibrosis [2]. Furthermore,
MMP7, which is known to be profibrotic, is increased in SSc patients and
associated with lung fibrosis [3]. Accordingly, the report of Gleissner et al.
[1] on M4 macrophages emphasises that CXCL4 could be the origin of all
these known indicators of fibrosis.
In conclusion, CXCL4 appears to be a useful indicator of clinical progres-
sion. It causes changes in several effector cells, resulting in damaged tissue
and disease. In addition, CXCL4 levels in SSc are far more increased than
in diseases such as SLE, ankylosing spondylitis or liver fibrosis. Therefore,
CXCL4 is a promising target for therapy. A prospective trial will be needed
to determine the predictive capability of CXCL4. Up till now, the data have
been promising.
chapter 3 – a non-hypothesis-driven search for biomarkers
in the proteome
In chapter 2, we used SELDI-TOF to analyze the proteome produced by acti-
vated pDCs from SSc patients. The interesting findings described in chapter
?? encouraged us to use the same approach to plasma from healthy controls,
lcSSc and dcSSc patients. Using SELDI-TOF proteome analysis, S100A8 was
revealed as a stress response enzyme increased in SSc.
In this general discussion, I would like to add some perspective on how
S100A8 could be involved in SSc. S100A8 is a secondary response gene
induced in monocytes and macrophages by TLR3, -4 and -9 ligands in an
IL-10 dependent way [4]. Moreover, S100A8 can function as a TLR4 ligand
itself, thus creating a self-perpetuating loop of inflammation [5]. SSc serum
was found to contain TLR-4 ligands and induce IL-10 production in moDCs
[6]. In chapter 5, we described an increase in IL-10 production in moDC in
response to TLR ligation, suggesting that these cells might be the source
of the increased S100A8. The increase in IL-10 in response to TLR ligation
was mainly seen in dcSSc patients though, whereas S100A8 is increased in
both disease subsets, while, most interestingly, in lcSSc an increase is seen
in patients suffering from pulmonary fibrosis. Therefore, in lcSSc another
mechanism could play a role. From a pathophysiological point of view, the
regulatory role of S100A8 could act as an oxygen radical scavenger. An
increased level of S100A8 could be a healthy reaction of several cell types to
the oxidative stress present in SSc. It is tempting to speculate that a slightly
increased S100A8 serum level in lcSSc patients is a sign that the body has
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signalled the presence of oxidative stress and tries to cope with it. A major
drawback of this effect would be that fibroblasts, having a TLR4 receptor
too, would also be activated by S100A8, contributing to progressive fibrosis
and possibly progressive pulmonary fibrosis. This mechanism was recently
unraveled [7]. In summary, I suggest that in dcSSc S100A8 has a role in
TLR stimulation and oxidative stress, whereas in lcSSc oxidative stress is
the most prominent determinant.
The study reviewed in chapter 3 has several limitations and should be
regarded as a non-hypothesis-driven exploration of the proteome to be used
for generating hypotheses. One of the remarkable differences with chapter
2 is that CXCL4 is not identified using SELDI-TOF. For this study, we used
plasma retrieved from heparin vacutainers instead of the more preferable
EDTA tubes. This choice was mainly based on availability in our clinic but
could possibly explain why the previously identified biomarker CXCL4 was
not identified in this study, because CXCL4 is bound by heparin [8].
chapter 4 – the presence of an ifn type i signature in ssc
In this chapter, we showed the presence of an IFN type I signature in about
a third of SSc patients. This presence of type I IFNs is seen in the early phase
of the disease. Immune complexes containing DNA or RNA are potent in-
ducers of type I IFNs through FcγR-dependent internalization followed by
TLR 7 and/or TLR 9 signaling in pDCs. Chapter 2 clearly showed that
pDCs are activated and that type I IFNs are induced, in addition to CXCL4
being produced. These activated pDCs in their turn affect the adaptive im-
mune system. For example, IFN type I prolong T-cell survival. Therefore,
inhibiting pDCs and TLR signaling with agents such as bortezomib and
TLR9 antagonists, thus adapting strategies already used in hematology [9],
would offer new therapeutic interventions in the early phase of SSc.
The proteome analysis performed in chapter 3 also revealed a mass peak
that could be a type I IFN. The family of type I IFNs is large and measuring
these cytokines to assess type IFN activity is considered a dreadful task.
By identifying only one type I IFN in this family as being significantly
increased, the task would become feasible. Further studies to replicate a
specific increase in IFN 27 are needed.
Intriguingly, CXCL4 and the type I IFN signature are both increased in
the early, pre-clinical phase of the disease. The possibility of CXCL4 in-
ducing a type I IFN signature or a role for an autocrine self-perpetuating
loop should be the subject of research in the following years. This could
result in a novel screening method for patients suffering from Raynaud’s
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phenomenon only and for identifying patients at risk of developing SSc, as
well as, most interestingly, intervening with therapy and preventing disease.
chapter 5 – dendritic cells show aggravated tlr responses
To summarize, chapter 5 dealt with a more reactive innate immune sys-
tem, especially in the early phase of disease, skewing adaptive immunity
towards an anti-inflammatory but profibrotic situation. The importance of
the innate immune system in rheumatic disease has long been recognized,
but the behavior of antigen-presenting cells, especially dendritic cells, has
not yet been studied in SSc. In chapter 5, we showed that by analyzing cy-
tokine production in response to several TLR ligands it is possible to make
a distinction between patients in the early and late phases of the disease
and patients having lcSSc or dcSSc. The increase in IL-6 and TNFα and
the decrease in IL-12 after stimulation of several TLRs skews naïve CD4+
T-cells into Th2 cells. These Th2 cells are less inflammatory but more profi-
brotic and have been shown to be prominently present in affected sites in
SSc patients (skin and broncho-alveolar fluid). Moreover, these increased
levels of IL-6 and TNFα could also skew T-cells towards Th22 cells. The
Th22 cells produce IL-22, causing epidermal hyperplasia, keratinocyte pro-
liferation and, moreover, fibrosis (nicely summarized in [10]). In SSc, the
number of circulating Th22 cells is increased compared to controls [11] and
IL-22 is increasingly present in the skin [12]. Interestingly, IL-22 has been
shown to induce the production of S100A8 and LL-37 in skin, both showing
up in the proteomics analysis in chapter 3. The distinct TLR responses in
the early phase of the disease are most prominently present in response to
TLR4 ligation. In addition to our data showing increased circulating levels
of an –endogenous– TLR4 ligand, the group of Varga et al. recently showed
increased expression of TLR4 in skin and lung tissue [7]. More interestingly,
they identified a new endogenous TLR4 ligand (fibronectin EDA) that had
already been shown to be strongly implicated in fibrosis [13]. In addition
to indirect profibrotic effects of TLR4 signaling through activation of DC,
there could also be a direct role for TLR signaling in fibroblasts. These data
build further on the hypothesis that S100A8, which is known to be a TLR4
ligand and increased in lcSSc with lung fibrosis (chapter 3), is a biomarker
preceding fibrosis.
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chapter 6 – the absence of genetic susceptibility for an ho-1
disbalance in ssc
Heme oxygenase-1 is a stress-induced enzyme with cytoprotective and anti-
inflammatory properties. In SSc there are several HO-1 inducers present
such as TGFβ, IFNα, hypoxia, IL-10, and oxidative and inflammatory stress
in general. Single nucleotide polymorphisms in the promoter of the HO-1
gene or differences in the GT repeat length in the promoter are associated
with susceptibility to several inflammatory diseases and cancer [14-17]. In
chapter 6, we showed the absence of genetic susceptibility for HO-1 deregu-
lation in SSc patients. Based on the results discussed in chapter 7, it became
clear that SSc patients were perfectly able to regulate HO-1 correctly if they
were not hampered by CXCL4.
A growing number of papers on associations between single nucleotide
polymorphisms and SSc, in combination with substantial efforts in perform-
ing genome-wide association studies, have advanced our understanding of
the genes involved in susceptibility to SSc. After identifying susceptibil-
ity genes, the main question that remains is whether these variants have
functional consequences contributing to the disease mechanism. The HO-1
promoter single nucleotide polymorphism, for example, clearly affects the
amount of HO-1 protein present following induction by stress. In our study,
we saw the same effect (data not published). This is just a small and simple
example of the effects of susceptibility genes in disease. These questions are
to be answered in the upcoming years.
chapter 7 – a tapered ho-1 activity in ssc
In chapter 7, we showed a remarkably low activity of HO-1 as measured in
circulating bilirubin levels, exhaled CO and the protein levels. Further ex-
periments showed that CXCL4, which is markedly increased in SSc (chapter
2), is a potent inhibitor of HO-1 upregulation in response to stress. More-
over, this low HO-1 expression could have an effect on TLR response, as
increasing HO-1 in vitro partially normalized the altered cytokine produc-
tion of SSc-derived cells in response to TLRs. Blocking CXCL4 and inves-
tigating the effects on stress response, HO-1 induction and TLR signaling
in vitro and in vivo are interesting targets for developing novel therapeutic
strategies.
In addition to having an effect on TLR-signaling, an increase in HO-1
activity would have positive results for patients due to the cytoprotective
effects of HO-1 activity products, particularly bilirubin with its known pro-
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tective effects on vascular endothelium. As CXCL4 presumably is the main
inhibitor of HO-1 in SSc patients, blocking CXCL4 with therapeutics would
enable an increase in HO-1 products. In future, when starting patients on
anti-CXCL4 therapy, bilirubin would be an easily accessible marker of effect.
However, anti-CXCL4 ¬still has a long way to go before it can be considered
a suitable candidate for clinical practice. Positive effects of increasing biliru-
bin can be exploited earlier. For example, a trial to be started in the near
future is expected to increase bilirubin with atazanavir and will hopefully
prevent progression of vascular damage.
The response to TLR stimulation found in moDCs in chapter 5 differs
from that found in chapter 7, especially as regards the absence of increased
cytokine production. This may be explained in part by the fact that the pa-
tients included in the Boston arthritis centre (chapter 5) were selected on
being early and quite severely affected. In fact, most of the dcSSc patients
included in chapter 5 were from this Boston cohort. The presence of type
I IFN most prominently seen in the early phase of disease (chapter 4) and
also the heightened CXCL4 levels already seen in this early phase (chap-
ter 2), together with the potentiated TLR response seen in chapter 5, give
substance to the idea that aberrations in immune responses are present at
a very early stage of the disease. In chapter 7, the number of early patients
was too low to investigate possible differences in cytokine production but
this could very well explain the difference in TLR response between chap-
ter 5 and 7. In chapter 5, when isolating fresh myeloid DC and stimulating
those with TLR4 ligands, we did see a slight increase in IL-12 production,
more in line with the findings in chapter 7. Further studies are needed to
reveal the exact nature of different TLR responses in SSc.
8.1 final synthesis
In summary, this thesis further underlines the importance of balancing the
immune system in the pathogenesis of SSc and highlights the use of this
knowledge in selecting biomarkers to be used in daily clinical practice. Fig-
ure 8.1 summarizes these new findings.
8.2 future perspectives
For the bench. . .
How to address heterogeneous, multifactorial syndromes in a sensible sci-
entific manner is an important question to be answered by contemporary
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medicine. It is important to find an answer to this question in order to ad-
vance our understanding of the mechanistic processes in combination with
the multiple causes underlying such syndromes as cardiovascular diseases
and rheumatoid arthritis. SSc is such a syndrome. Since SSc is not as preva-
lent as the syndromes referred to above and hence receives less funding, or
at least less stable funding, it is of utmost importance to clearly consider
what research topics merit funding. Below I will discuss several current
themes in SSc research from the perspective of this thesis and give my opin-
ion on the relevance the thesis may have.
Figure 8.1
It is obvious that tolerance is breached in SSc patients. The discussion of-
ten focusses on the factors that breach tolerance in these patients. However,
is it relevant to know what specifically breaches tolerance? In the multifac-
torial diseases covered by rheumatology, it is highly probable that there are
hundreds of distinctive ways in which tolerance may be breached, such as
a recent viral or bacterial infection, a sunburn, exposure to chemicals or a
change in intestinal bacteria. All of these cause an inflammatory response
that apparently can go awry and turn against the body itself, either directly
or indirectly. Although reports addressing possible initiating events such
as CMV infections, parvovirus B19 and helicobacter pylori infections [18
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19] are stimulating to read and provide a useful perspective on the process
causing multifactorial disease, it is hard to imagine how they would lead to
improvements in care for patients.
So the specific agent that breaches tolerance is not relevant but the mecha-
nisms that come into play following this breach clearly are, as they provide
an opportunity to intervene and stop the detrimental cascade of events caus-
ing morbidity and mortality. An integrated approach, analyzing the genetic
susceptibility profile combined with proteomics and possibly even func-
tional assays of immune cells can help identify common pathways in this
mostly heterogeneous and multifactorial disease. These common pathways
would be ideal targets for new therapeutics.
Another approach would be to re-classify patients. Patients would not be
classified as lcSSc and dcSSc based on their skin involvement but as IFN
type I-SSc, hypoxic-SSc and CXCL4-SSc, so that a tailor-made, individual-
ized therapy could be prescribed based on this. This approach may sound
futuristic but taking the tremendous progression made in the last decade
into account, it may become reality in the upcoming decade.
For the bedside. . .
Following other developments in rheumatology, one of the main priorities
in SSc is to identify patients as early as possible. The considerable effort
to classify early SSc with updated criteria makes it possible to achieve this
objective [20]. As we now have criteria to include patients in a study in a
very early phase of their disease, we can start the exciting part of treating
patients very early and see if we can limit the progression of the disease to
a minimum. This thesis further aims to set up guidelines for identifying pa-
tients at risk in a very early phase using markers such as CXCL4, S100A8,
IL-6, IFN type I signature and bilirubin levels. Combining these markers
could offer a very useful diagnostic panel. Together with already known
specific auto-antibodies, genetic susceptibility and the early clinical classi-
fication criteria, these markers can hopefully indicate individual patients’
risks and suggest specific treatments for these patients.
This thesis encourages the development of new therapeutics. Blocking
CXCL4 by an mAb or blocking its receptor is a promising new option. This
option would at least circumvent the drawback of other and stronger im-
mune modulators, that is to say, an increase in susceptibility to infectious
diseases. Moreover, it would address a causative chemokine instead of the
general immune system. MDX-1100, an agent that attacks the chemokine
CXCL10, has shown promising effects in rheumatoid arthritis, illustrating
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the usefulness of this chemokine-addressing strategy in treating rheumato-
logical diseases [21]. Antibodies against cytokines are another form of ther-
apy already used in the broad field of rheumatology. Although anti-TNF
therapy did not seem successful in SSc [22], anti-IL6 mAb (tocilizumab)
could be promising. Several reports have shown that IL-6 was increased,
while it was seen in chapter 5 of this thesis that there was increased produc-
tion of IL-6 by moDC after TLR stimulation. Hence, the new option could
be of therapeutic value during the early phase of the disease in particular.
Blocking IL-6 would change the instructions and might prevent formation
of Th17 cells in favor of functional regulatory T-cells. Although knowledge
of T-cells affected in SSc is increasing [23-27], the contribution of the adap-
tive immune system and the possibilities for intervening therapy in this
respect warrant further research.
In manifest SSc, improving the quality of life presents an altogether dif-
ferent challenge. Attacking the early phase and preventing sclerosis are in-
deed more exciting treatment options but these will not prevent people
continuing to develop debilitating forms of fibrosis requiring urgent action.
Here the increasing knowledge in the broad field of fibrosis (skin or any
organ) will open new perspectives for therapeutic interventions. Fibrosis is
reversible and efforts to reverse it come from all fields in internal medicine.
In conclusion, the field of basic research and new therapeutics in SSc will
continue to be exciting the coming years. This thesis gives new directions
and a new perspective for future research, which will hopefully lead to
improvements in care for SSc patients. It further exemplifies in what ways
medicine benefits from translational research. The fruitful interaction be-
tween medical doctors and basic scientists that I experienced are key to this
part of science. Medical students should be given the opportunity to benefit
from this interaction during the initial stages of their studies. They should
be encouraged to exploit their basic scientific interests as early as possible,
but they should also be allowed to do so during the post-graduating phase,
with funding being made available and translational meetings being set up
for them to participate in. This will eventually lead to the major improve-
ments in care still needed in medicine in general and, more specifically, in
SSc.
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N E D E R L A N D S E S A M E N VAT T I N G
Systemische sclerose (SSc) is een aandoening waarbij het bindweefsel in
de huid en de interne organen worden aangetast door fibrose. Dit is een
soort verlittekening van de huid en organen waardoor de ziekte ook vaak
sclerodermie wordt genoemd. Patiënten presenteren zich met klachten van
een strakke huid beginnend bij de handen (sclerodactylie), het fenomeen
van Raynaud en kleine wondjes aan de vingertoppen (digitale ulcera en
‘pitting scars’). In de vroege fase van de ziekte kan er daarbij sprake zijn
van zwelling van de handen gepaard gaande met jeuk. SSc is een zeldzame
ziekte die in Nederland 1 op de 100.000 volwassenen tussen de 30-50 jaar
treft. De ziekte treft meer vrouwen dan mannen waarbij de verhouding in
de literatuur varieert tussen de 4:1 en 14:1. Er is een indeling in twee kli-
nische vormen op basis van de uitgebreidheid van de fibrose van de huid;
bij de gelimiteerde subvorm beperkt de fibrose zich tot distaal van de el-
lebogen en de kniegewrichten en in het geval van diffuse SSc verspreidt
de fibrose zich over het hele lichaam. Bij beide vormen kunnen de interne
organen betrokken zijn al is de prognose in het geval van gelimiteerde SSc
wel gunstiger dan bij diffuse SSc. Met een tienjaars overleving van maar
55% is diffuse systemische sclerose namelijk de meest fatale bindweefsel-
ziekte in de kliniek. De prognose hangt grotendeels af van de mate van
orgaanbetrokkenheid. Daarbinnen zijn longfibrose en pulmonale arteriële
hypertensie (PAH) grotendeels verantwoordelijke voor de mortaliteit.
Naar de oorzaak van systemische sclerose is al vele jaren onderzoek ge-
daan maar met name in de laatste tien jaar hebben wetenschappers hier
meer inzicht in gekregen. De belangrijke rol van het afweersysteem, ook
wel immuunsysteem, is in die jaren onderkend door onder andere geneti-
sche studies. Met dit proefschrift vergroten wij het inzicht in de rol van het
afweersysteem. Daarnaast belichten wij het nut van verschillende onderde-
len van het afweersysteem als markering van bijvoorbeeld progressie van
de ziekte, de kans op het ontwikkelen van longfibrose of de kans op het ont-
wikkelen van de ziekte. Het immuunsysteem als markering in systemische
sclerose dus. Hieronder volgt een samenvatting van het in mijn manuscript
uitgebreider gepresenteerde werk.
165
166 nederlandse samenvatting
dendritische cellen
De dendritische cel zoekt het lichaam af naar onregelmatigheden zoals bac-
terien, virussen of toxische stoffen. Als hij iets signaleert dan regelt hij dat
het wordt aangevallen en opgeruimd. In die zin bepaalt de dendritische cel
als een soort generaal de tactiek en de heftigheid van de aanval. In patienten
met systemische sclerose hebben wij het gedrag van deze cellen in reactie
op verschillende soorten alarmsignalen onderzocht (hoofdstuk 5). De dend-
ritische cellen van patienten blijken veel heftiger te reageren dan dezelfde
cellen van gezonde controles. Zij produceren veel meer interleukine-6 (IL-
6). Dit is het meest uitgesproken bij patienten in de beginfase van de ziekte
met de diffuse vorm van systemische sclerose. Ook in het plasma van pa-
tienten zijn hogere waardes van hetzelfde interleukine-6 te vinden, weer
met name in de beginfase van de ziekte. Interleukine-6 is een belangrijk
eiwit dat zorgt voor veel activatie van de rest van het afweersysteem. De in
die zin ontspoorde dendritische cel speelt in de beginfase een belangrijke
rol.
heme-oxygenase 1
Waarom deze dendritische cel ontspoort is een interessante vraag. Een van
de mogelijk bijdragende factoren is het enzym heme-oxygenase 1 (HO-1).
Dit is een enzym dat bij elke vorm van alarm of stress wordt geproduceerd
om eigenlijk juist te voorkomen dat het afweersysteem ontspoort. In patien-
ten met reumatoide arthritis is al eerder aangetoond, op basis van geneti-
sche vatbaarheid, dat zij minder goed in staat zijn om HO-1 in hoge mate
te maken en ook daar vind je een verhoogde activiteit van de dendritische
cel. In patienten met systemische sclerose blijkt deze genetische vatbaarheid
echter niet aanwezig te zijn (hoofdstuk 6). Echter, de aanwezigheid van het
enzym HO-1 blijkt wel sterk verlaagd (hoofdstuk 7). Dit kan bijdragen aan
de ontsporing van de dendritische cel en daarmee de over-activiteit van het
afweersysteem.
cxcl4
Naast dendritische cellen bestaan er in het afweersysteem nog speciale soor-
ten dendristische cellen, onder andere de plasmacytoide dendritsche cel
(pDC). Van deze cel is eerder in systemische lupus erythomatosus aange-
toond dat hij een belangrijke rol heeft. De pDC van patienten met systemi-
sche sclerose blijkt een grote hoeveelheid CXCL4 te produceren (hoofdstuk
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2). Dit is een chemokine wat met name door bloedplaatjes wordt gepro-
duceert, vandaar de andere naam plaatjesfactor 4. Dit CXCL4 is ook ruim
verhoogd aanwezig in het plasma van patienten met systemische sclerose
vergeleken met gezonde controles. Ook hier is dit het meest uitgesproken
in de beginfase van de ziekte bij patienten met de diffuse vorm van systemi-
sche sclerose. Het is ook veel hoger aanwezig bij patienten met systemische
sclerose dan bijvoorbeeld bij patienten met systemische lupus erythemato-
sus. Wanneer je patienten met systemische sclerose onderverdeeld in een
groep met veel CXCL4 en een groep met weinig CXCL4 dan zie je in de
groep met veel CXCL4 dat patienten veel vaker longfibrose en pulmonale
hypertensie ontwikkelen. Verder onderzoek moet uitwijzen of een stijging
van CXCL4 voldoende markering is voor het starten van intensievere be-
handeling en daarmee het doen van vervolg CT scans en echografie van
hart overbodig kan maken.
Naast deze bevindingen laten we in hoofdstuk 2 zien dat CXCL4 ook
bijdraagt aan het mechanisme waardoor systemische sclerose ontstaat. Als
muizen CXCL4 krijgen toegediend via een pompje onder de huid ontstaat
daar fibrose. Ook endotheelcellen (de cellen van de vaatwand) en fibroblas-
ten (bindweefselcellen) laten wanneer zij gekweekt worden in een omge-
ving met CXCL4 afwijkingen zien die lijken op wat we zien in systemische
sclerose. Als we gezonde dendritische cellen kweken in een omgeving met
CXCL4 dan zijn zij daarna niet meer in staat om het enzym HO-1 verhoogd
tot expressie te brengen (hoofdstuk 7). Mogelijk is CXCL4 dus ook de oor-
zaak van dit defect in de ontspoorde dendritische cellen van patienten met
systemische sclerose.
s100a8
De pDC van patienten met systemische sclerose produceert niet alleen
CXCL4. In hoofdstuk 2 laten we zien dat deze ook S100A8 produceert. Dit
is een eiwit wat bekend staat om zijn belangrijke rol in alarmsistuaties, dan
wel stress. Het zorgt er kortgezegd ook voor dat het afweersysteem in een
staat van paraatheid en activiteit wordt gebracht. Nader onderzoek van het
plasma van patienten met systemische sclerose en gezonde controles toont
aan dat S100A8 ook verhoogd te vinden is in het plasma van patienten
(hoofdstuk 3). Hierbij hebben we het plasma onderzocht op alle aanwezige
eiwitmassa’s en gekeken naar de massa’s die verschillend zijn tussen ge-
zonde controle en patienten. Dit levert een lijst aan interessante eiwitten
waarvoor van de bijdrage en het nut uit verder onderzoek moet volgen.
Wanneer we ons focussen op S100A8 dan zien we dat dit verhoogd is in
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patienten met de gelimiteerde vorm van systemische sclerose en met name
in die patienten met longfibrose. Het zou interessant zijn als een stijging in
S100A8 de ontwikkeling van longfibrose in deze patientengroep zou mar-
keren. De toekomst zal dit uitwijzen.
type i interferon
Plasmacytoide dendritische cellen zijn eigenlijk met name bekend om de
productie van type I Interferon. Ook type I Interferon is belangrijk om het
afweersysteem te activeren. In patienten met systemische sclerose zien we
dat de verschillende cellen in het bloed duidelijk in aanraking zijn geweest
met type I Interferon. We meten dit op basis van de mate van expressie
van genen die door type I Interferon worden geactiveerd en noemen dit
de type I Interferon handtekening. Deze handtekening zien we ook al
duidelijk naar voren komen bij patienten met het fenomeen van Raynaud
en auto-antitoffen of nageriemafwijkingen passen bij systemische sclerose,
maar nog geen duidelijke ziekte. We hopen dat de aanwezigheid van de
type I Interferon handtekening in de toekomst het deel van de patienten
met alleen het fenomeen van Raynaud wat een hoog risico loopt op het
ontwikkelen van systemische sclerose kan markeren. Dit deel zouden we
dan intensiever kunnen vervolgen en op tijd starten met behandeling.
Samenvattend benadrukt dit proefschrift opnieuw het belang van het af-
weersysteem in de ontwikkeling van systemische sclerose. Door het afweer-
systeem goed te onderzoeken vinden we nieuwe aanknopingspunten voor
therapie. Verder geeft het inspiratie voor nieuwe parameters die een fase
van progressie van de ziekte kunnen markeren of zelfs die groep patienten
met een hoog risico op ziekte of orgaanbetrokkenheid kunnen aanwijzen. In
de dagelijkse klinische praktijk is het een uitdaging om het goede moment
voor het starten van intensievere therapie (met bijbehorend meer bijwer-
kingen) te kiezen en alle hulp om dat moment te markeren is meer dan
welkom. Ik hoop hieraan een nuttige bijdrage te hebben geleverd.
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D A N K W O O R D
Als eerste wil ik alle patiënten met systemische sclerose bedanken voor hun
bereidheid elke keer weer mee te doen aan onderzoek. Zonder jullie inzet is
het onmogelijk om verder te komen. Jullie bereidheid om mee te doen aan
onderzoek, ondanks vermoeidheid en moeilijk bloed kunnen laten prikken,
vind ik indrukwekkend. Het heeft mij mede gemotiveerd dit boek te schri-
jven.
Prof. Dr. Radstake, beste Tim, in 2008 in Boston begon ons gezamenli-
jke avontuur. Ons beider enthousiasme maakt een hoop mogelijk, met de
monsterexperimenten als illustrerend resultaat. Je hebt me altijd alle ruimte
gegeven om me te ontwikkelen. Je open houding voor ideeën en discussies
in alle richtingen maakten het voor mij een plezier om met je samen te
werken. Ik ben onder de indruk van de ontwikkelingen, die je de jaren
dat we samen hebben gewerkt, hebt doorgemaakt. Ik hoop daar ook in de
toekomst nog wat van mee te maken. Maar bovenal hoop ik dat we met
enige regelmaat onder het genot van een drankje in jouw tuin kunnen geni-
eten en de ontstane vriendschap kunnen onderhouden.
Prof. Dr. van den Berg, beste Wim, grote dank gaat uit naar jouw inzet
om ook dokters in het lab te faciliteren. Ik heb me vanaf de eerste dag
welkom gevoeld op lab Reuma en er drie jaar met groot plezier gewerkt. Je
kritische blik en jarenlange ervaring brachten elke keer nieuwe inzichten in
mijn lopend onderzoek. Hartelijk dank.
Dr. Vonk, beste Madelon, jouw kennis van het ziektebeeld systemische
sclerose is indrukwekkend en voor mij erg behulpzaam geweest om elke
keer weer het relevante patiëntenperspectief te vinden. In een drukke en
hectische periode vond je telkens tijd om mij zo nodig een stapje verder te
helpen, dit heb ik erg gewaardeerd. Het heeft me ook geïnspireerd, want
inderdaad als het tegen zit moet je soms gewoon even extra gas geven.
Dr Wagener, beste Frank, jij gaf een mij een voorbeeld hoe je groot weten-
schappelijk enthousiasme kan combineren met dagelijkse gezelligheid. Je
grote kennis van heme-oxygenase en wondgenezing gaf een heel nieuwe
visie op de mechanismes in systemische sclerose. Dit besprekend onder het
genot van een lekkere lunch bij Valdin of een goed glas wijn maakt een be-
spreking met jou tot een klein feestje: ik zal het missen. En daarbij de hulp
en bereidheid van Bas, bedankt!
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Lieve Renoud, wat een feest dat je vandaag naast me staat. Een vriend-
schap die begon met feest (introductietijd 2001) en door de jaren heen veel
feesten heeft gekend. Dat mag vandaag ook even gevierd! Je bent een dier-
bare vriend met wie ik met veel plezier heb samengewerkt gedurende de
jaren promotie. Met onze gezamenlijke brede interesse, regelbehoefte en
af en toe behoefte aan relativeren met een biertje hebben we elkaar wel
gevonden. Ik hoop nog lang van jou, Monica en je zoon Hugo te mogen
meegenieten.
Dear Marta, after spending all that time together in the lab you now stand
next to me when I am defending my thesis. Doing experiments together
while singing a beautiful song, listening to good music or discussing the
things of life that really matter, I truly miss it in my current working life. I
feel blessed having you as a close friend: millie gracie!
Jasper, samen naar Boston als start van onze wetenschappelijke carrière.
Vijf maanden samen naar het werk fietsen (en voor gek worden uitgemaakt
door de Amerikanen), samen werken en samen eten. Het was een mooie
tijd. Ik hoop dat we in de toekomst als reumatologen onze krachten nog
eens zullen bundelen. De fijne kneepjes van de celkweek en dendritische
celstimulaties heb ik mogen leren van Mark Wenink en Richard Huibens.
Dank voor de goede start. Richard, als Mister Bead, leerde je mij de won-
dere wereld van Luminex en flow cytometrie. Maar meer dan dat hield je
altijd kritische blik en uitgebreide wetenschappelijke interesse me bij het
dagelijkse werk scherp. Beste Kim, samen begonnen we aan het werk als
promovendus en samen trotseerden we vele frustraties. Ik ben blij dat we
het nu ook ongeveer tegelijk kunnen afsluiten. Je bent een buitengewoon
slimme collega en ik hoop dat voor jouw een mooie onderzoekscarriere in
het verschiet ligt. Mede-promovendi van ‘the mouse side’; Jeroen, Rik, Ben,
Arjan, Dennis, Bas, Wouter, Lilyanne, Eline, Martijn, het was gezellig om
met jullie de jaren van promotieonderzoek door te brengen. De jaarlijkse
evenementen als het kerstspel en de wedstrijden in U-tjes versieren, maken
werken op lab reuma tot een feest. Aan creativiteit sowieso geen gebrek,
waarbij ik met name erg heb genoten van het samenwerken aan stukjes met
Esmeralda, Miranda, Arjen, Rik en Richard (voor de attributen). Dank voor
de gezellige jaren.
Een van de leuke dingen van basaal onderzoeker en dokter zijn is dat
je van beide werelden de leuke dingen kan meepikken. De prettige samen-
werking met iedereen in de kliniek maakte de wandeling naar het gebouw
Interne eerder een uitje dan een moetje. Bij deze dank aan alle secretaresses,
reumaverpleegkundigen en reumatologen. Hanneke Knaapen en Annelies
van Ede, bedankt voor jullie bereidheid om altijd weer patiënten te vragen
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mee te werken aan onderzoek. Ik snap nu pas hoeveel tijd dat kost. Yvonne
en Kavish, het samen runnen van de artroscopie unit was een uitdaging,
maar met jullie eigenlijk ook een gezellige woensdagmiddag.
For only half a year I had the joy of working in Utrecht where the group
Radstake turned into such an international group that I decided to write
this part in English. When I was there, times were mainly changing and all
those changes took a lot of energy. At our last dinner I was very impressed
to hear how you all managed and wished I was there to enjoy it with you.
Special thanks go to Marzia, Alsya and Annelies for continuing a lot of
work and especially for all the patience on waiting for me to answer on
mails.
All the work performed and written down in this thesis would not have
been possible without strong collborations. Prof Lafyatis, who taught me
the first things on systemic sclerosis as a disease; welcomed us in Boston;
and gave us a lot of opportunities. The collabaroration with Marjan Versnel
and Zana Brikc in Rotterdam on the type I Interferon signature resulted in
a nice chapter. Furthermore I enjoyed visiting another Dutch lab and see-
ing different approaches. Last but not least the fruitfull and very pleasant
collaboration with Milan. Thanks for sending Marta over. Lorenzo Berreta,
millie gracie, for your hospitality but mainly for introducing me into the
Milan apperetivo. I hope we will meet often in the future and share time
accompagnied by good food and wine.
Beste Mariek, Mascha en Remco, bij jullie leerde ik meer over de wondere
wereld van de genetica. Van pipetteren met een P10 tot een multichannel
en van snp’s tot GT repeats, het was een uitdaging. Bedankt dat jullie altijd
tijd voor mij wilden maken en er altijd een plekje was om te werken.
Na bijna vier jaar onderzoek doen, ineens met volle vaart terug in de klin-
iek, dat was niet niks. Maar als je dan aan het werk gaat in zo’n prettige
omgeving als het Slingeland ziekenhuis, wordt het ineens een stuk leuker.
Ik heb ontzettend veel geleerd in een snel tempo en dat komt toch vooral
door met een kleine groep intensief samen te werken. Erik, Aart, Alexandra,
Job, Inge, Richard, Cees, Nail en Foeke bedankt voor jullie tijd en begeleid-
ing. Marnix, Rune, Helle-Brit, Marysia, Lieve, Kavish, Christine, Bibi, Joline,
Marjolein, Teske, Louise, Doreen, Marwi, Anke en Delia, bedankt voor de
gezellige samenwerking en ook de etentjes, carpool-uitblaasmomenten en
de zo mogelijk ijsjes om 16:00 uur.
Lieve Anne-Els en Saskia, bedankt voor jullie onvoorwaardelijke vriend-
schap. Anne-Els, al vanaf de eerste dagen van de middelbare school sta je
al bijna dagelijks aan mijn zijde en heb je altijd het geduld opgebracht om
even op me te wachten. Nu je ook promotieonderzoek aan het doen bent
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hebben we weer een nieuwe fase om te delen, en met plezier. Lieve Sas, al
heeft het krijgen van kinderen en het hebben van drukke banen de frequen-
tie van ons contact niet altijd goed gedaan, de kwaliteit van de vriendschap
blijft geweldig. Ik ga er nu weer meer tijd voor maken om daar ook van te
genieten.
Lieve Fellows en Fellies, Jelle, Paul, Lobke, Dick, Roy, Marloes en Roline,
een vriendschap die in de coschappen en na een fantastisch roadtrip naar
Italie ontstaat moet wel een vriendschap voor het leven zijn en dat is zo.
Als blijkt dat iedereen dan ook nog zo’n geweldige partner kiest dan staat
dat garant voor mooie avonden en heerlijke vakanties. Echter Fellows, we
moeten wel duidelijk houden waar de kern ligt en volgende keer gewoon
weer eens winnen bij de competitie met de Fellies. Bedankt guys voor jullie
vriendschap, geduld en steun.
Bij al dat harde werken is een moment om even lekker te keetuh meer dan
welkom. En al sinds de middelbare school staan jullie garant voor heel veel
lachspiertraining. Lieve Iris, Marjolein, Anne-Els en Renate, dank voor jullie
geduld met mijn veel te volle agenda en laten we het keetuh nog jarenlang
volhouden.
Dames’01, na jaren samen studeren, en de MFVN besturen is het nu de
tijd van samen promoveren, werken en kinderen krijgen. Bedankt voor de
gezelligheid, tips en oprechte interesse.
Lieve Tjarda, bedankt voor je vriendschap al 28 jaar. Ik hoop dat we nog
vele jaren mooie gesprekken kunnen hebben en leuke dingen samen kun-
nen doen.
Als je gezegend bent met zo’n grote familie dan is het onmogelijk om
iedereen persoonlijk te bedanken. Toch wil ik er een paar mensen uitlichten.
Als eerste natuurlijk Oma Roos. Met uw positieve instelling en onderne-
mendheid maakt u al 90 jaar het leven in volle gezondheid mee, dit mag
een voorbeeld zijn voor vele en zeker voor mij. En natuurlijk een speciaal
dank aan Ome Renee die grote delen van dit boek kritisch op de kwaliteit
van het gebruikte Engels heeft beoordeeld. Lieber Dieter, ich freue mich
dass du heute dabei bist. Es ist richtig schön um auch in Deutscher Opa zu
haben und damit die schöne Sachen des Lebens zu teilen. Ich geniesse die
schöne Stunden die wir zusammen verbringen immer.
Lieve Sander en Lotte, Moos, Anna en Saartje, medebewoners van Huize
Hupsakeetje, samen leven is een bijzondere en heel waardevolle ervaring.
Samen kinderen zien opgroeien maakt het extra speciaal. Bedankt voor deze
mooie jaren. Lotte, bedankt voor het ontwerpen van de kaft, je hebt er oog
voor.
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Lieve schoonfamilie Geurts, vanaf het eerste moment dat Wim me van
het station in Wehl ophaalde voel ik me welkom in jullie familie. Bedankt
voor jullie openheid, steun en waardering. Ik hoop dat we samen nog vele
jaren kunnen genieten van de almaar uitbreidende familie.
Lieve Corry en Jan, pap en mamma, dit boek is voor een groot deel jullie
verdienste. Jullie onvoorwaardelijke liefde en steun maakt al jaren dat ik
meer kan doen dan ik me kan wensen. Jullie ongekende flexibiliteit en pos-
itiviteit is een voorbeeld wat ik met plezier ter harte neem. Ik hoop dat we
nog vele jaren samen kunnen genieten. Ons volgende, deels gezamenlijke,
avontuur in Londen komt er al weer aan, ik zie er naar uit. Lieve Brigitte,
Rick en Ruudje, al worden jullie soms moe van al onze gedrevenheid, we
voelen ons toch gesteund. Bedankt voor jullie relativering en liefde.
Lieve Roos en Mirthe, jullie zijn het mooiste wat me is overkomen in
de jaren van promotieonderzoek en daarbuiten. Jullie plaatsen alles in het
juiste perspectief. Ik ben ontzettend trots op jullie en heb heel veel zin in
alle jaren samen die nog komen gaan.
Lieve Dirk, alles wat ik hier opschrijf om te proberen uit te drukken wat
jij voor mij betekent valt in het niet bij hoe het werkelijk is. Zonder jouw
steun en actieve bijdrage was dit boekje er nooit geweest. Je bent de meest
indrukwekkende persoon die ik ken en ik geniet er elke dag van je zo goed
te mogen kennen. Het leven is al een feest en met jou is het leven een feest
van liefde! Ik hou oneindig veel van je.
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